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ABSTRACT
A critical mechanism in immune homeostasis is the ability to stop an
ongoing inflammatory response once the inciting agent has been destroyed or
neutralized. Failure to do so can lead to autoimmune disease. One mechanism
the

immune

system

utilizes

to

self

regulate

is

the

secretion

of

immunosuppressive cytokines. For example, the cytokine interleukin-10 (IL10) is
a potent suppressor of numerous key immune cell populations. Among the cells
+

+

that secrete IL10 are several subsets of the CD4 T cell family. As CD4 T cells
are commonly found within diseased tissue in the setting of autoimmune disease,
+

medications capable of inducing IL10 expression in local CD4 T populations
would be of great therapeutic interest. The small molecule G-1, an agonist
directed against the membrane-bound estrogen receptor GPER, is known to
attenuate the multiple sclerosis-like animal model EAE. However, its effects on

vi

CD4

+

T cell populations were previously unknown. Using cultures of purified

+

CD4 T cells, we show that G-1 can elicit ERK-dependent expression of IL10. G1 treated cultures secreted 3-fold more IL10, with no change in the
proinflammatory cytokines IL17A, TNFα, and IFNγ. Analysis of Foxp3 and RORγt
+

expression demonstrated increased percentages of IL10 cells in both the TH17
+

+

+

(RORγt ) and Foxp3 RORγt hybrid T cell compartments. We also show that, in
mice, in vivo treatment with G-1 leads to increased IL10 secretion from
+

splenocytes. These results demonstrate that G-1 acts directly on CD4 T cells,
and to our knowledge provide the first example of a synthetic small molecule
capable of eliciting IL10 expression in TH17 or hybrid T cell populations. While G1 treatment was not effective in a murine model of colitis, investigations of its
effects in other T cell-based disease models are warranted.
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Glossary & Abbreviations
Ab

Antibody

AhR

Aryl hydrocarbon receptor

Antigen

The component of an invading pathogen, foreign moiety, host cell, or
other immunogenic material that elicits an adaptive immune response.

Biome

The full complement of all biological species, in total or for a given group.

CD

Crohnʼs disease

Classical ERs

The two estrogen receptors that fall into the category of ligand-activated
nuclear transcription factors, namely ERα and ERβ.

DSS

Dextran sulfate sodium

EAE

Experimental autoimmune encephalomyelitis

Epitope

The portion of an antigen that forms the 3 dimensional structure
recognized by mediators of the adaptive immune system, such as the T
cell receptor or antibodies.

Ex vivo

Experimentation on living tissue that has been removed from a living
multicellular organism and manipulated outside of it, for example
collecting cells from a mouse and culturing them in a dish.

GALT

Gut-associated lymphoid tissue

GPCR

G protein-coupled receptor

IBD

Inflammatory bowel disease

ICS

Intracellular cytokine staining

IEC

Intestinal epithelial cell

IEL

Intraepithelial lymphocyte

Uterine imbibition

The uptake of water into the uterus, leading an increase in uterine size
and wieght

IHC

Immunnohistochemistry

In vitro

Experimentation on samples or systems that have been established or
developed in a laboratory, and are completely independent of any
multicellular organism. For example experiments with tissue culture cell
lines.

xii

In vivo

Experimentation through the manipulation of the conditions within an
living multicellular organism. For example systemic treatment of a mouse
with a drug.

IPEX

Immune dysfunction,
(syndrome)

locus

genetically relevant segment of DNA, often describing a gene of interest.

LPS

Lipopolysaccharide

Lymphopenic

The state of having below normal levels of circulating lymphocytes, or in
the case of RAGKO mice a complete lack of lymphocytes.

MHC

Major histocompatibility complex

MS

Multiple Sclerosis

Mucosal immunity

The mucosal immune system is defined as all components on the innate
and adaptive immune systems that play a role in immunity within
mucosal tissue and its draining lymph nodes.

ORF

Open Reading Frame

Parenchyma

The physiologically functional tissue of an organ. Compare with stroma.

PBMC

Peripheral blood mononuclear cell

PCR

Polymerase chain reaction

RA

Rheumatoid arthritis

RBC

Red blood cell

qRT-PCR

quantitative real-time PCR

RT-PCR

reverse transcription PCR

Stroma

The supportive connective tissue that helps provide a structural
framework to a cell, tissue, or organ.

Systemic immunity

The systemic immune system is defined as all components on the innate
and adaptive immune systems that play a role in immunity within internal
tissues and their draining lymph nodes, as well as the spleen, excluding
systems that are involved in mucosal immunity.

Taxa

(Plural of taxon) A group of one or more organisms that have been
determined to be part of a group, usually based on phylogenetic
relationships.

TCMC

T cell-mediated colitis

TCR

T cell receptor

Polyendocrinopathy,

xiii

Enteropathy,

X-linked

TNBS

2,3,4-trinitrobenzene sulfonic acid

UC

Ulcerative colitis

US

United States of America
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Preface
Figure 1 : The "Father of Medicine"
This image of Hippocrates was taken from an article in
Environmental Health News, a publication of the School of Public
Health at the University of Washington in Seattle.

It was the great Greek physician Hippocrates (ca. 460 –
ca. 370 BC), known in the western world as the “Father
of Medicine”, who laid the foundation upon which
western medicine and medical science now rests. His
great contribution came with his rejection of divine forces
and the supernatural as the basis of human illness. His
philosophies in medicine are still an integral part of
modern allopathic medicine, embedded in the principles outlined by the
Hippocratic Oath. Since itʼs inception, many have contributed to the evolution of
biomedical science, including Aristotle (384 – 322 BC) and Claudius Galenus (c.
129 – 199 AD), the Syrian physician Ibn al-Nafis (1213-1288), who was the first
to correctly describe pulmonary and coronary circulation, as well as aeration of
the blood within the lung, and Andres Visalius (1514-1564), the author of de
humani corporis fabrica libri septem (on the fabric of the human body in seven
books), perhaps the worlds first widespread text on human anatomy. The
production of this work was made possible by the advances in artistry and
printing that evolved during Europeʼs Renaissance period. For all of these great
scientists and philosophers, their knowledge and intellect were only valuable in
that a medium of expressing their ideas was at hand, and the freedom for
independent thought was accepted. For them, the development of art and
science went hand in hand.
In 1838, Germans Matthias Schleiden and Theodor Schwann postulated the “Cell
Theory”, stating that organisms are made up of individual units that they called
“cells”. Breakthroughs in the 19th century also included the work of Frenchman
Claude Bernard, whose concept of the milieu interieur (internal environment)
would later to be described using the more familiar term “homeostasis” by the
American physiologist Walter Cannon. Others, including Koch, Watson, Crick,
Franklin, and Pauling set the stage stem cells, tumor vaccines, the human
genome project, and the age of molecular medicine, indeed ushering in a modern
Renessaince in medical science. As in the days of Hippocrates and Viaslius, we
rely on increasing robust methods of expression to convey exponentially complex
scientific concepts. As I move forward in my career, I hope never to lose sight of
the place art, creativity, and expression have in the pursuit of knowledge for the
common good, and the endeavor of scientific investigation.
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Chapter 1 : Introduction

Section 1.1 : Why do we need an immune system?
The beauty and diversity of Earths many inhabitants have been forged
through eons of evolutionary competition. In my mind it is a marvel that bags of
chemicals (cells), seemingly infinitely complex in and of themselves, can come
together in numbers into the trillions to form the finely tuned systemic
relationships that define animals, plants, and insects. No event was more critical
in our evolution than the advent of multicellularity, wherein groups of cells
developed specific skill sets that were advantageous to the group rather than the
cell itself. In essence, cells began to act collectively rather than individually,
eventually to become co-dependent on the existence of each other, growing into
a state of permanent symbiosis. However, this critical step came with a
competitive cost. Bacteria and other microorganisms largely rely on rapid
proliferation and genetic diversity of evade challenges from competitors and
propagate survival of their species. This simple and effective strategy is not
feasible for larger organisms, such as humans. Our complex structure provided
the form and function within which consciousness could arise, allowing us to
ponder questions about ourselves and world around us. However, this gift came
at a competitive cost. We humans must live for years in order to reach sexual
maturity before we can produce progeny and propagate our species. Thus we

1

must have ways to effectively defend ourselves from invading pathogens and
tumorigenic transformations over long periods of time to ensure the survival of
our species. The immune system provides a key component of that defense,
fighting off invading pathogens from the surrounding biosphere and aberrant
neoplastic growth from within. However, to truly appreciate our dependence on
this astonishing system, one must understand not only the why of itʼs existence,
but the immense difficulty of itʼs task.
In essence, we are a bag of cells; to be more precise, a well hydrated bag
of cells rich in nutrients and with a tightly regulated thermostat. These
characteristics make us the ideal incubator for countless bacteria, yeast,
helminthes, fungi, and other microscopic species whose existence is defined by
the endless search for opportunities to replicate and divide. We must be able to
detect, respond to, contain, and destroy all these potential pathogens. Given the
biodiversity of these groups, this is not a trivial matter. Letʼs take bacteria as the
example. A study from 2002 estimated that in a single gram of soil contains
between 6400 and 38,000 distinct bacterial taxa, and their estimates show a ton
of soil could contain up to 6 million (Curtis et al., 2002). While the actual number
of distinct bacteria on Earth is unknown, and is currently impractical to measure
or even estimate in any objective way (Ward, 2002), the overarching point
remains the same; there is an immense amount of biodiversity within the
microscopic biome, and our survival depends on the ability to chemically detect
and respond to the endless array of molecules expressed on the surface of these
invaders, or secreted by them. Additionally, many of these microorganisms have
2

evolved to take advantage of unique niches that our bodies provide, and their
high proliferation rate and lower DNA replication fidelity precipitates genetic drift,
meaning their pool of potential antigens can change over short periods of time.
Addressing these immense challenges is the charge of our immune system. This
next section will discuss how this amazing feat is accomplished.

Section 1.2 : Overview of the immune system
A complete perspective of the immune system requires an appreciation of
concepts based in the macroscopic world to those best understood through
conceptualization of protein interactions. A brief discussion of basic immunology
will be followed by a more detailed discussion of the principles directly pertinent
to the work presented.

Barrier functions and commensal flora
The most prominent feature of the immune system, at least to the naked
eye, is the skin. The skin is the largest organ in the human body and forms a
protective coating that constitutes our first line of defense against the harmful
pathogens of our surrounding environment. It serves as a fundamental barrier
between our body and what lies outside of it, while also playing a key role in
water retention. These properties make it a critical component of our host
defense (immune) system and systemic homeostasis. Without this protective
coating, our entire external surface would be a battlefield pitting our internal
3

defenses against fervent assaults from opportunistic pathogens. Such a contest
is not stacked in our favor. To point, consider the case of burn victims in the
clinic. Despite rapid debridement of devitalized tissue, constant monitoring, sterile
techniques in a controlled environment, and our modern arsenal of antibiotics,
infection is responsible for 75% of deaths in patients who have sustained burns
+

over 40 % of their body (Church et al., 2006). Without skin, we would be
constantly exposed to such infectious challenges across the surface of our body.
Of course, not all interactions with the external world are protected by skin.
There are numerous tissues whose physiological function is subject to highly
specialized cell populations in contact with the environmental interface, making a
thick layer of skin unequivocally incompatible with their purpose. Take the
example of the lungs, where gas exchange brings fresh oxygen into our system
and noxious gases like carbon dioxide are excreted. This process depends on
the exquisitely thin layer separating the capillary lumen from that of the lung
alveoli, placing RBCs in close proximity to the inspired air and its bounty of
oxygen. Other examples include the genitourinary tract, the eyes, and the
gastrointestinal tract from the oral cavity and nostrils to the anus. These sites
have three common ties; (a) they are all found within an internal body cavity, (b)
they are all involved in the process of absorption and/or secretion, and (c) they
are lined with epithelial cells. Collectively, these sites are referred to as the
mucosa.
Mucosal immunology is a complex topic. This entire document could be
taken up with discussion of its many attributes and context specific properties.
4

Instead, I will elaborate on one section of this field that closely relates to this
work, namely the unique plots that unfold along the lining of our gastrointestinal
tract. The details of specific immune cell populations are addressed later.
The setting of the mucosa presents a unique problem as direct contact to
the environment means constant challenge with foreign antigen. Thus the
mucosal immune system must approach its task with a discerning eye, avoiding
deleterious inflammatory reactions against harmless agents while managing to
respond to and control infectious ones. Within the intestinal tract, the gutassociated lymphoid tissue (GALT), intraepithelial lymphocytes (IELs), cells of
the lamina propria, and other players in intestinal immunity must dampen
responses to nutrients bound for absorption while preventing colonization of
pathogens. Failure of this system can have devastating consequences, as is the
case of Celiac disease where immune responses to gluten - a constituent of
grains such as wheat and barley - leads to; (a) inflammation within the walls of
the small intestine, (b) damaged villi (small finger-like projections that line the
intestines), (c) malabsorption, (d) seizures, (e) infertility, and/or (f) cancer (Sollid,
2000). This condition afflicts 1 in 133 people here in the US, and is commonly
found in Europe as well (Fasano et al., 2003). Conversely, improper control of
intestinal flora can assist in the development of inflammatory bowel disease (IBD)
(Marteau et al., 2004). Thus a delicate balance must be maintained between
action and inaction against foreign antigens.
Luckily, we donʼt go it alone: efforts to prevent colonization of pathogenic
microbes is augmented by a complex ecosystem of resident symbiotic bacteria
5

known as the commensal flora (Hooper et al., 2002). While much less in known
about the colonization by other microbes such as archea and fungi, it is
estimated that the human colon contains on the order of 1014 bacteria, 10 times
the number of human cells in the body (Hooper et al., 2002). These commensal
microbiota are extremely diverse, with an estimated 500-1000 distinct bacterial
species present (Eckburg et al., 2005). They play an active role in host defense
through the displacement of pathogens, augmented barrier function through
fortification of the gut lining, and competition for nutrients (O'Hara and Shanahan,
2006; Salzman et al., 2007). They also serve metabolic functions through the
production of key cofactors like vitamin K and folate (O'Hara and Shanahan,
2006), and are thought to be important in host development as animals raised in
germ-free environments fail to thrive (Wostmann, 1981). Indeed, OʼHara and
Shanahan have gone so far as to refer to our commensal microbiota as the
“forgotten organ” (O'Hara and Shanahan, 2006). It is increasingly clear that the
commensal flora play a key role in mucosal immunity within the intestinal tract.
There are, or course, host-derived mechanisms in place to mediate gut
immune homeostasis as well. The small and large intestine are lined by intestinal
epithelial cells (IECs). IECs are critical to establishing a barrier between the
colonized gut lumen and the underlying parenchyma. Like all epithelial cells they
are bound together by tight junctions, a fluid impermeable seal of tightly-bound
proteins and lipids that circumvent the lateral walls of the cell and fuse itʼs
membrane with that of neighboring cells. They form the decisive component of
the epithelial barrier. For example, disruption of tight junctions using a modified
6

bacterial product dextran sulfate sodium (DSS) permits gut flora access to the
underlying lamina propria and itʼs rich stable of immune mediators. The result is
an inflammatory condition in the gut wall that closely mimics IBD (Sollid and
Johansen, 2008). IECs also play an active role in host defense. Recruitment of
neutrophils and clearance of Clostridium rodentium infection in mice is dependent
on lymphotoxin beta receptor signaling in IECs, likely attributable to IEC
production of the chemotactic factors CXCL1 and CXCL2 (Wang et al., 2010). In
addition, IECs can activate the adaptive immune system through presentation of
antigen on MHC class II molecules (Bland, 1988), a function usually reserved for
professional antigen presenting cells (APCs) such as macrophages and dendritic
cells (see below). Paneth cells, which secrete bactericidal products like lysozyme
and α-defensins, and Goblet cells, which secrete at thick mucous layer that lines
the gut, also play a role in mucosal immunity. Collectively, this mucinous lining,
itʼs stock of bactericidal peptides, the commensal flora, and the tight network of
IECs generate a formidable barrier to invading pathogens within the gut.
While our barrier systems serve us well, even a simple everyday activity
like brushing our teeth can compromise their integrity, granting dangerous
microbiota access to our underlying tissue. I use the term “systemic immune
system” to refer to the collection of cell and protein based systems that monitor
our internal environment with the sole purpose of detecting and eliminating
harmful challenges from foreign invaders and neoplastic growth within our own
tissue.
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Leukocytes
The cohort of cells responsible for the amalgamated defensive posture of
both mucosal and systemic immunity are collectively referred to as white blood
cells or leukocytes (leukocyte comes from the Greek words “leuko” or white and
“kytappo” or cell). Derived from hematopoietic stem cells within the bone marrow,
they utilize the circulatory system to populate tissues throughout the body.
Leukocytes exhibit dramatic plasticity in localization and function, being heavily
influenced by diverse sets of gene products within the leukocytes themselves and
from the surrounding environment. Thus each tissue has a unique complement of
immune mediators tailored to the pathogens likely to be encountered.
Some leukocytes fall into the category of granulocyte, characterized by the
presence of large granules within their cytoplasm which carry an abundance of
immune mediators and/or bactericidal chemicals. Upon stimulation, granulocytes
release their contents into the local milieu leading to inflammation and destruction
of pathogens. Leukocytes also play an important role in the clearance of debris
through the process of phagocytosis. The class of leukocyte most directly
pertinent to this work are the lymphocytes. These cells are unique in the they
undergo somatic cell gene rearrangement collectively referred to as V(D)J
recombination. V(D)J recombination is dependent on the recombination activated
genes 1 and 2 (RAG1/2), and loss of either allele completely disrupts lymphocyte
development. This recombination event generates a vast complement of unique
binding pockets on lymphocyte antigen recognition receptors from a single set of
genes, which include the B cell receptor (BCR) and T cell receptor (TCR). This
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allows lymphocytes to detect and react to millions of different epitopes and mold
their response to unique pathogens. The different types of lymphocyte include:

T lymphocytes, which will be discussed below. These cells complete their
development in the thymus, where they undergo V(D)J recombination to
generate a unique TCR. Each T cell expresses a single TCR, and is
referred to as a clone. Note that there can be multiple copies of a single
clone as the result of “clonal expansion”.
B lymphocytes, which complete their develop in the bone marrow. Like T
cells, they undergo RAG-dependent somatic gene rearrangement, in this
case to develop the vast array of BCRs (which are in essence membranebound antibodies) and antibodies. Antigen recognition by BCR stimulates
B cells to mature and produce secreted antibodies (BCR without the
membrane anchoring region). Antibodies can neutralize surface receptors
to prevent infection and opsonize invading pathogens so they can be
recognized by phagocytic cells or destroyed by the complement cascade.
In addition to V(D)J recombination, B cells also undergo the process of
somatic hypermutation to generate further diversity. Like T cells, each B
cell expresses a single type of BCR/antibody, and is referred to as a clone.
B cells are reviewed here (Kurosaki et al., 2009)
NKT cells, which utilize a restricted repertoire of TCRs to recognize
glycolipids bound to the CD1d molecule presented on APCs. CD1d is
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structurally similar to MHC Class I (see Figure 2). NKT cells are reviewed
here (Godfrey et al., 2004).

Other cells types include the monocytes and macrophages, dendritic
cells, neutrophils, eosinophils, basophils, and mast cells, some of which are
discussed below. A detailed discussion of these cell types are beyond the scope
of this work and will not be included. A general description of these populations
can be found on wikipedia (www.wikipedia.com).

Innate and adaptive immunity
The systemic immune system is a complex network of specialized cells
and soluble mediators which act in a coordinated fashion to fend off pathogenic
insults and clear foreign antigen. Incredibly, this scheme has evolved to tailor its
response to the type of pathogen it is challenged with and its route of entry.
Unlike most tissues which have a defined structure and organization, the immune
system is dynamic and constantly evolving. It is divided into two main branches
that have distinct properties and kinetics; the innate immune system and the
adaptive immune system. Many of the topics discussed above – namely barrier
function, mucous production, bactericidal peptides, and neutrophil recruitment –
fall into the category of innate immunity, while lymphocyte-mediated antigenspecific immune responses, immunological memory, and the principles
underlying vaccination are all dependent on the adaptive immune system. While
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typically discussed as two distinct systems, it is important to realize that these
systems are not insulated for each other; quite the contrary in fact. Some of the
many ways that they communicate and affect each other are highlighted below.
A hallmark of innate immunity is the ability to rapidly respond to an
infection. Tissue-resident leukocytes like macrophages and dendritic cells (DCs)
constitutively express different combinations of pattern recognition receptors
(PRRs), which recognize pathogen associated molecular patterns (PAMPs)
commonly expressed by invading microbes. Numerous different PRR families
exist (Takeuchi and Akira, 2010). PAMPs include bacterial carbohydrates like
lipopolysaccharide (LPS), nucleic acid structures like viral double stranded RNA,
bacterial peptides such as flagellin, and many other microbial-specific products.
The constitutive expression of the toll-like receptors (TLRs) and other PRRs
allows cells of the innate immune system to rapidly respond to pathogens by
destruction of infected cells, phagocytosis of infectious particles, and the release
of antimicrobial peptides. Activation of innate immunity also drives tissue
inflammation which leads to the hematological recruitment of other phagocytic
populations like neutrophils and monocytes (which turn into macrophages upon
entering the tissue). Other soluble mediators, including the complement cascade,
also play a role in detecting, neutralizing, and destroying invading pathogens and
eliciting inflammation. The critical distinction from the adaptive immune system
described below is that the PRRs and other proteins of the innate immune
system are encoded in the germline and do not change over time
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In contrast to the innate immune system, the development of an adaptive
immune response takes days to weeks to mature. As described above,
phagocytic cells ingest foreign material and debris from dying cells, or are
infected themselves, leading to the destruction of infectious particles. However,
some of these phagocytic leukocytes then migrate to secondary lymphoid organs
(such as lymph nodes) where they play a role in adaptive immunity. These
professional antigen presenting cells (APCs – ex: dendritic cells or macrophages)
are programmed to process protein-based antigens and load them onto major
histocompatibility type II (MHC class II) molecules for presentation of helper T
cell populations. Helper T cell are important in all branches of the adaptive
immune system. Similarly, virtually any infected tissue or cell can process and
present antigen on the ubiquitously expressed MHC class I molecule, leading to
the activation of cytotoxic T cells. Cytotoxic T cells are critical mediators of
cellular (adaptive) immunity while antibody-mediated immunity is collectively
referred to as humoral (adaptive) immunity. TCR recognition of an MHC-antigen
complex initiates clonal expansion of that cell. Note that antigen recognition by
the BCR is independent of MHC, and B cells can in fact act as APCs for T cells.
The end goal of these actions is the expansion of lymphocytes tailored to the
specific challenge at hand. In addition, the adaptive immune system retains
clones generated from previous exposures in the form of memory T cells and B
cells. This “immunological memory” allows for a more immediate and robust
response to re-infection with the same agent, and forms the basis of vaccination.
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Thus the hallmark of adaptive immunity is that itʼs complement of molecules and
cells changes over time, reflective of itʼs experience with past infections.

T lymphocytes
The majority of the work in this document centers on T cell biology, thus a
more detailed discussion of their activity, function, and significance in human
disease in warranted. T cells can be broken into three main classes (Figure 2).
+

The first are the CD8 cells, or cytotoxic T cell population. These cells recognize
antigens presented on the ubiquitously expressed MHC class I molecules,
responding by killing the presenting cell as part of the cell-mediated immune
system. They are activated by soluble mediators like IFNγ, and play a role in the
clearance of intracellular infections and tumor rejection (Schepers et al., 2005).
The second class of T cell are the NKT cells, which where briefly described
above. While not discussed in detail, NKT cells have been linked to numerous
disease processed including diabetes and cancer (Godfrey et al., 2004).
+

Finally, the third class of T cell comprise the family of CD4 T lymphocytes
(or helper T cells), which respond to antigen-MHC class II complexes. The CD4
molecule recognizes and binds to MHC class II, and is critical for stable
interaction of the TCR-MHC-antigen complex. It is important to note that other
cells types have also been shown to express CD4, for example the NKT cells
described above and even macrophages, but these cells lack to the TCR co+

receptor CD3 and are not part of the helper T cell family. CD4 T lymphocytes
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are central to the coordination of immune responses. Upon antigen recognition
they express potent surface markers and secreting an array of chemokines and
cytokines. Their actions lead to recruitment and activation of numerous cells
types from both the innate and adaptive immune system, including neutrophils,
+

macrophages, B cells, and cytotoxic T cells. CD4 T cells are divided two main
groups; effector T cells, which play a role in enhancing immune reactions, and
regulatory T cells (TREGs), which suppress immune reactions. They are briefly
outlined in Figure 3. CD4

+

T cells develop in the thymus and emerge as a

population of naïve T cells, meaning they have yet to be exposed to antigen and
take on one of the characteristic phenotypes described below. Antigen
recognition initiates a cascade of signaling events that drive differentiation into
one of several distinct T helper populations, each of which is designed to initiate
a unique type of immune reaction (see Figure 3). Helper T cell differentiation is
determined by integration of a complex array of signals provided by the local
environment, mostly in the form of surface proteins on neighboring cells and
secreted signaling molecules like cytokines. This will be discussed in more detail
below. For the sake of simplicity, several poorly described lineages are not
included in Figure 3. Follicular T cells express that transcription factor RORγt,
and may develop in a similar fashion to TH17 cells. They are found in the B cell
zones of lymph nodes, where they assist in affinity maturation and plasma cell
development (Fazilleau et al., 2009). Helper T cells expressing IL9 and IL22 have
also been described and given the classification TH9 and TH22 cells, respectively.
Whether these represent truly unique lineages of are merely subsets of more
14

established CD4

+

lineages remains unclear (Murphy and Stockinger, 2010).
+

There is one other population of CD4 T cell which bear mentioning, namley γδ T
cells. This population of cells is found largely within the mucosal immune system
of the gut as part of the intraepithelial lymphocyte population. The TCR in vast
majority of T cell populations (including all helper/cytotoxic T cells) is a
heterodimer containing one copy each of the α and β TCR subunits or chains.
Conversely, γδ T cells expresses a TCR comprised of one γ and one δ subunit.
Similarly to the α and β chains, the γ/δ loci undergo V(D)J recombination and in
many respects these cells behave like other members of the adaptive immune
system. However, unlike their αβ TCR counterparts, the γδ T cells play a role in
the recognition of lipid antigens, recognize antigen independently of the MHC
complexes, and have a restricted repertories of TCRs, thus they exhibit innate
properties as well. While not discussed in detail, they have been reviewed in
(Xiong and Raulet, 2007).
The topic of cytokine function in relation to T cell development,
differentiation, and function is too vast to discuss further in this proposal, but has
been reviewed (Sanchez-Munoz et al., 2008). The pertinent details regarding
+

CD4 T cells will be discussed in detail below and throughout this thesis.
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Figure 2 : Introduction: The major classes of T cell.
Adopted from: Adams JU (2005) The Scientist 19(14): 15

+

Section 1.3 : Development of CD4 T lymphocytes
Helper T cells and the Mossman/Coffman paradigm (TH1 & TH2 cells)
+

CD4 helper T lymphocytes orchestrate adaptive immune responses to
invading pathogens, and are critical to the pathogenesis of numerous disease
processes, including autoimmunity and cancer. They are an attractive drug target
due to their central role in immunity, and their implication in a wide variety of
diseases. The original paradigm described by Coffman and Mossman divided
CD4

+

helper T lymphocytes into the T-helper-1 (TH1) and TH2 populations

(Mosmann and Coffman, 1989), delineated by their secretion of distinct cytokines
and expression of characteristic transcription factors. TH1 cells express the
transcription factor T-bet, secrete IFNγ, and are implicated in cell-mediated
immunity (Szabo et al., 2003), for example by enhancing the activity of CD8

+

cells and the recruitment of macrophages. The induction of TH1 cells requires
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interleukin-12 (IL12), and signaling through Signal Transducer and Activator of
Transcription (STAT)-1 and STAT4. In contrast, TH2 cells express the
transcription factor GATA3, which is induced by IL4-mediated activation of
STAT6 (Zhu et al., 2006). They secrete the cytokines IL4, IL5, and IL13, which
play an important role in humoral immunity by driving B cell maturation and
antibody class switching. There are also heavily implicated in atopic immune
responses (Paul and Zhu, 2010). See Figure 3. These two pathways are
generally thought to be mutually exclusive, as IFNγ blocks TH2 differentiation
while IL4 blocks TH1 differentiation and promotes the generation of TH2
populations (Zhu et al., 2006).

Figure 3 : Introduction: Lineages of CD4+ T cell.
Adopted from: Jetten AM (2009) Nucelar Receptor Signaling 7: e003
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TH17 cells
Up until about 2000, the TH1-TH2 paradigm seemed largely sufficient to
+

account for most of the activities attributed to CD4 T cell populations, and much
of their proinflammatory capacity was thought to reflect the activity of the TH1 arm
of the pair (McGeachy and Cua, 2008). It was shown that genetic disruption of
the IL12 p40 subunit prevented disease in experimental autoimmune
encephalomyelitis (EAE), an animal model of Multiple Sclerosis (MS), leading to
the theory that TH1 cells were important in the development of autoimmune
diseases (Brok et al., 2002). However, evidence from other animal studies slowly
built the case that another population must underlie the chronic inflammation
associated with these diseases. As early as 1990 it was known that injection of
the TH1-associated cytokines IL12 and IFNγ actually blocked rodent models of
acute neurological inflammation (Gran et al., 2004; Voorthuis et al., 1990).
Moreover, genetic deletion of IL12 receptor β (IL12Rβ) resulted in increased
disease severity in several models of autoimmune disease (Zhang et al., 2003),
further suggesting that the TH1 populations played a role in controlling
inflammation rather than precipitating it. Other interesting results, for example the
finding that loss of T-bet, but not STAT1, prevented the development of EAE
(Bettelli et al., 2004), further confounded the story.
In 2000, it was shown the IL12 p40 subunit was in fact a common subunit
of both the TH1-polarizing cytokine IL12 and the newly identified cytokine IL23
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(Oppmann et al., 2000). Studies in mice genetically deficient for the IL23-specific
subunit p19 (which have intact IL12) demonstrated that loss of IL23 was
associated with protection from autoimmune inflammation, not IL12 (Cua et al.,
2003). Moreover, p19-deficient mice were protected despite the presence of
neuropeptide-specific T cells expressing IFNγ. Conversely, mice lacking the IL12specific subunit p35 exhibited a rapidly-progressive form of EAE, despite low
+

numbers of IFNγ cells (Cua et al., 2003; Gran et al., 2002). Thus it was clear
that the TH1-polarizing cytokine IL12 and the major TH1-associated cytokine
product IFNγ were not critical to T cell-mediated chronic inflammation, and may in
fact suppress the disease. The search was on for another T cell mediator of
chronic inflammation.
TH17 effector cells were first identified as a distinct helper T cell lineage in
2005 (Langrish et al., 2005) when it was shown that IL17A producing T cell
exhibit a distinct transcriptional profile from TH1 cells (Langrish et al., 2005), and
that IL17A producing effector T cells express a characteristic transcription factor,
namely RORγt (Harrington et al., 2005; Ivanov et al., 2006). This classification
was shown to fit well into the Coffman-Mossmann paradigm of mutually exclusive
lineage

development.

Moreover,

work

from

two

independent

groups

demonstrated that both the TH1-specific and TH2-specific (Harrington et al., 2005;
Park et al., 2005) transcriptional regulators inhibit TH17 differentiation, further
solidifying their status as a unique and independent effector T cell population.
TH17 cells produce pro-inflammatory cytokines including IL17A/F. IL17A
mediates

numerous

inflammatory

responses,
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including

secretion

of

proinflammatory cytokines and chemokines from epithelial and endothelial cells
(Stockinger et al., 2007) neutrophil mobilization (Aujla et al., 2007), and many of
the pathological sequelae that result from chronic inflammation. IL17 and itʼs
many functions have been reviewed elsewhere (Ouyang et al., 2008).
Most work to date has centered on the peripheral induction of TH17 cells
from naïve precursors, but there is evidence that they can develop in the thymus
as well (Marks et al., 2009). In mice, peripheral differentiation of TH17 cells from
antigen-activated naive T cells depends on the presence of TGFβ and IL6
(Veldhoen et al., 2006; Veldhoen and Stockinger, 2006), while in humans
peripheral induction of TH17 cells depends on TGFβ paired with either IL-21 or IL+

+

23. Murine TH17 express CCR6, while human cells are CCR4 CCR6 . Other
proteins such as IRF1 (Kano et al., 2008), IRF4 (Brustle et al., 2007; Chen et al.,
2008), RORα (Yang et al., 2008), and IL23 (Volpe et al., 2008) are also involved
in the development of TH17 cells (Iwakura and Ishigame, 2006), while the Aryl
hydrocarbon receptor (AhR) seems critical to their production of the cytokine IL22
(Ramirez et al., 2010). The differentiation of TH17 cells has been reviewed
(McGeachy and Cua, 2008). IL23 in particular is important to function and
stability of TH17 cells. In 2003, IL23 was shown to drive production of IL17A from
activated T cells (Aggarwal et al., 2003), while il23a

-/-

mice have few IL17A
+

producing cells (Murphy et al., 2003). IL23 was later shown to induce an IL17A

T cell populations capable of driving autoimmune inflammation (Langrish et al.,
2005). These studies have led to the theory that IL23 plays a role in stabilizing
the TH17 phenotype (McGeachy and Cua, 2007). In 2007, Daniel Cuaʼs group
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showed that TH17 cells differentiated in culture with TGFβ and IL6 were actually
protective in an animal model of experimental encephalomyelitis, while those
treated with IL23 induced robust disease (McGeachy et al., 2007). Interestingly,
the cells differentiated with TGFβ and IL6 still expressed high levels of IL17A/F,
RORγt, RORα, IL21, and CCR6, suggesting that none of these factors were
important in IL23-mediated neuroinflammation. What the authors did show was
that IL10 was a critical factor in the bystander suppressive effects of the TGFβ
and IL6 differentiated cells. Thus the critical mediators of TH17 cells
proinflammatory phenotype are not clearly defined, at least in certain settings.
A concrete definition of what a TH17 cell is has been complicated by the
fact that many cell types produce the cytokine IL17A. Indeed γδ T cells (which
express the γδTCR rather than the conventional αβ TCR) are the main producers
of IL17A within the CD4+ compartment, at least in naïve animals (Stark et al.,
2005). Other populations which have been shown to express CD4 (but not CD3)
like NKT cells (Lee et al., 2008; Michel et al., 2007; Rachitskaya et al., 2008) and
lymphoid tissue inducer (LTi)-like cells also produce IL17A (Takatori et al., 2009).
Additionally, CD8+ T cells (He et al., 2006; Shin et al., 1998), alveolar
macrophages (Song et al., 2008), mast cells (Hueber et al., 2010; Mrabet-Dahbi
et al., 2009) and neutrophils (Li et al., 2010) have also been shown to produce
IL17A under certain conditions. These findings, and some of the other findings
discussed above led OʼConner et al (O'Connor et al., 2010) to characterize TH17
cells as, “CD4

+

effector T cells positive for the αβ (TCR), which have high

expression of the transcription factors RORα and RORγt, low expression of the
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transcription factors T-bet and GATA-3, and high surface expression of the
chemokine receptor CCR6; produce IL-17A, IL-17F, and IL-22; have surface
expression of the IL-23 receptor; and can produce the chemokine CCL20.” While
this is without question a clear and exhaustive definition, one wonders what a cell
expressing CD4, αβTCR, RORγt, the TCR co-receptor CD3, and IL17A would
then be called. For this work, we chose to go with a simpler definition; all cells
expressing CD3, CD4, RORγt, and IL17A will be referred to as TH17 cells.
As discussed above, TH17 cells are critical to the pathogenesis of
numerous autoimmune diseases (McGeachy and Cua, 2007; Pernis, 2009;
Stockinger, 2007), and numerous lines of evidence support their classification as
a proinflammatory population. However, like the data discussed above for TH1
cells, TH17 cells also appears to exhibit both pro- and anti- inflammatory effects.
This has led the hypothesis that some of the TH17-associated mediators may
provide protection against inflammation-induced tissue destruction in a
“microenvironment-specific” fashion (O'Connor et al., 2010). For example,
studies with the TNBS-induced colitis model has clearly demonstrated that
IL17RKO mice are protected from disease (Zhang et al., 2006), while several
studies have shown that inflammatory bowel disease (IBD) is associated with
increased levels of IL17A expression (Iwakura and Ishigame, 2006). In contrast,
in studies with the DSS-based model of acute colitis, in vivo neutralization of
IL17A was shown to enhance disease severity, while addition of recombinant
IL17A reversed this effect (Ogawa et al., 2004). This study was followed by data
out of Richard Flavell's lab who used the T cell-mediated colitis model to
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demonstrate transfer of IL17KO T cells in precipitates to a more severe disease
course than transfer of wild-type T cells, suggesting T cell-derived IL17A acts to
dampen disease (O'Connor et al., 2009). Other suppressive effects in the setting
of atherosclerosis have also been described (Taleb et al., 2010). Clearly, IL17A
can exhibit anti-inflammatory activity.
In addition to the microenvironment hypothesis mentioned above, one
possible explanation for these findings may be that IL17A and IL17F have distinct
roles in regulating inflammation, and as both IL17A and IL17F rely on the
IL17RA/C heterodimer for their signaling, observations made following disruption
of the IL17R may reflect the activity of IL17F rather than IL17A. IL17R signaling is
reviewed here (Gaffen, 2009). Thus studies in which IL17RA was deleted, or
where soluble receptor are used to neutralize IL17, have the caveat that both
IL17A and IL17F signaling are being disrupted, and contextual differences
observed in IL17 immunobiology may reflect differences in the relative
importance of either IL17A or IL17F in that setting. Moreover, IL17A and IL17F
can coexist as heterodimers. Therefore systemic neutralization of IL17A may also
affect IL17F as well. However, there is also evidence that both IL17A and IL17F
have redundant effects in the setting of colitis (Leppkes et al., 2009). Additionally,
studies with EAE have shown opposing effects for both IL17A and IL17F, with
one group showing that IL17RA signaling is required for disease induction (Hu et
al., 2010), while studies from another group demonstrated neutralization of IL17A
in IL17FKO mice had only a minimal effect on disease induction and severity
(Haak et al., 2009). TH17 cells have also been linked to numerous other
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diseases, including cancer, where it appears that TH17 cells enhance tumor
rejection (Kryczek et al., 2007; Martin-Orozco et al., 2009; Muranski et al., 2008;
Zou and Restifo, 2010). Thus despite the preponderance of evidence that TH17
cells are proinflammatory, there appears to be a great deal of variability in the
properties of these cells, and much more work needs to be done to clarify their
role in chronic inflammation.

Regulatory T cells (TREG cells)
Description of the distinct effector T cell lineages neatly reflected their
unique contributions to a developing immune response. However, this paradigm
did not appear to offer a clear mechanism for controlling and regulating the
inflammation that resulted from their actions. This led to the hypothesis that some
form of regulatory T cell must also exist. Early experiments by Fiona Powrie and
colleagues with murine colitis models clearly demonstrated that select
populations of CD4

+

T cell exhibited potent immunosuppressive properties,

including the ability to limit chronic inflammatory responses driven by more
pathogenic T cell populations (Powrie et al., 1993a). Yet it was unclear whether
these suppressive T cells were a subset of the one of the TH lineages, or a
unique population not yet described. Indeed, TH1 and TH2 cells were known to
produce IL10 (Del Prete et al., 1993), a potent immunosuppressive cytokine
(Moore et al., 2001). In addition, several experiments had shown that two key
TH2 cytokines, IL4 and IL10, can act together to inhibit cell-mediated immunity
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(Powrie and Coffman, 1993; Powrie et al., 1993b, c). The first marker for
regulatory T cells was the high affinity IL2 receptor subunit CD25 (Sakaguchi et
al., 1995). However, while effective at identifying TREG cells in the naïve setting,
this molecule is upregulated upon activation of many T cell populations, and was
clearly not specific to regulatory T cells (Fontenot et al., 2005b).
A major breakthrough in delineating the characteristics of regulatory T
(TREG) cells emerged when it was shown that a forkhead box transcription factor,
Foxp3, was critical to their function (Hori et al., 2003). The identification of a
TREG-specific transcription factor established these cells as a unique T cell
lineage. Further studies in mice have shown that Foxp3 can be induced during
thymic development in response to strong self-antigen recognition (Fontenot et
al., 2005b), leading to so called “natural” Foxp3

+

TREGs (nTREG). Foxp3

expression can also be driven peripherally by TGFβ signaling within naïve T cell
populations (Chen et al., 2003; Marie et al., 2005), generating “inducible” TREGs
(iTREG). Several lines of evidence demonstrate that Foxp3 is the critical factor in
the development of a regulatory phenotype. Foxp3

+

TREG cells suppress

numerous animal models of autoimmune disease (Yuan et al., 2007), and a
mutation in Foxp3 was found to be the genetic basis for the fatal
lymphoproliferative disorder observed in scurfy mice, which is characterized by
fulminate TH1-type inflammation within numerous tissues (Clark et al., 1999). In
+

addition, ectopic expression of Foxp3 in CD4 T cells confers a TREG phenotype
(Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003), while sustained
expression of Foxp3 was found to be critical to the suppressive function in
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nTREGs (Williams and Rudensky, 2007). These findings translated to humans as
mutations in Foxp3 were identified in over 50% of immune dysfunction,
polyendocrinopathy, enteropathy (IPEX) syndrome patients (van der Vliet and
Nieuwenhuis, 2007). However, the role of Foxp3 in humans appears to differ
+

from observations made in mice. Several groups have identified Foxp3 T cells
populations that lack regulatory activity (Allan et al., 2007; Gavin et al., 2006;
+

Morgan et al., 2005; Wang et al., 2007). And while treatment of murine CD4 T
cells with TGFβ precipitates a regulatory phenotype, the same has not been
observed in humans (Tran et al., 2007), despite the induction of Foxp3.
Interestingly, ectopic expression of Foxp3 using a lentiviral vector system does
confer a regulatory phenotype on human naïve T cells and memory T cells,
suggesting that stable expression of Foxp3 may be the critical determinant of its
function (Allan et al., 2008). None-the-less, there is evidence that the regulatory T
cell transcriptional profile has elements regulated by- and independent of- Foxp3
(Hill et al., 2007). A 2010 report has shown that the transcription factor Helios is
specifically upregulated in human nTREGs, and functions in the stabilization of
Foxp3 expression (Getnet et al., 2010), while suppression of Helios abrogated
their regulatory function (Getnet, 2010). More work is needed to clarify whether
Foxp3 functions differently in humans and mice, and the implications of Helios in
this paradigm.
TREGs suppress immune reactions by numerous mechanisms. The
simplest method is the secretion of inhibitory cytokines, including TGFβ, IL10,
and the recently identified cytokine IL35 (Collison et al., 2007). This is reviewed
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here (Vignali et al., 2008). These soluble mediators can act to suppress
proinflammatory populations in the local environment and drive the generation of
other

anti-inflammatory

TREG

cells.

For

example,

IL10

reduces

the

proinflammatory activity of numerous immune populations (Maynard and Weaver,
2008), can suppress autoimmune disease (Lavasani et al., 2010), and is
important to immune homeostasis within the mucosa (Rubtsov et al., 2008), in
addition to acting in a feed-forward mechanism by driving itʼs own expression in
other TREG cells (Maynard and Weaver, 2008).
TREG cells also utilize cytolysis in regulating inflammatory reactions.
Human iTREGs have been shown to exhibit target cell killing in a granzyme A and
perforin dependent mechanism (Grossman et al., 2004). Similar findings were
observed in mice as TREG cells from granzyme B-deficient mice had reduced
regulatory activity ex vivo (Gondek et al., 2005) and in vivo (Cao et al., 2007).
This correlated with data showing up-regulation of granzyme B in murine TREG
cells (Herman et al., 2004; McHugh et al., 2002).
A third mechanism employed by regulatory T cells involves suppression by
metabolic disruption. This categorical description is best exemplified by the
production of adenosine nucleosides. TREGs have been shown to express the 5ʼ
ribonucleotide

phosphohydrolase

CD73,

which

can

convert

adenosine

monophosphate to adenosine. Co-expression of CD73 with CD39 leads to locally
produced adenosine, which binds to the adenosine receptor 2A (A2AR) and
inhibits effector T cell function (Borsellino et al., 2007; Deaglio et al., 2007; Kobie
+

et al., 2006). Interestingly, A2AR activation on CD4 populations also enhances
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the generation of iTREG cells at the expense of TH17 cells via down-regulation of
IL6 and up-regulation of TGFβ expression (Zarek et al., 2008). Another study has
demonstrated TREG-mediated mitigation of inflammation by direct transfer of
cyclic adenosine monophosphate (cAMP) into effector T cells via gap junctions
(Bopp et al., 2007). Furthermore, inhibition of cAMP degradation has been shown
to augment T cell regulatory function (Bopp et al., 2009). A more controversial
mechanism of TREG-induced metabolic disruption is IL2-depletion-induced
apoptosis within effector populations (Vignali et al., 2008), which is postulated to
depend on TREG expression of the high affinity IL2 receptor CD25 (discussed
above).
Finally, regulatory T cells mediate suppression by directly targeting the
maturation and function of dendritic cell populations. TREGs express lymphocyte
activation gene 3 (LAG3) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) which
bind to MHC class II (Workman and Vignali, 2003) and CD80/86 (Cederbom et
al., 2000; Oderup et al., 2006), respectively, on DCs. This leads to a reduction in
their ability to activate effector populations. TREGs can also drive DCs to produce
indoleamine 2,3-dioxygenase (IDO), a potent pro-apoptotic factor in T cells. This
appears to occur in a CTLA-4-dependent fashion (Fallarino et al., 2003).
Moreover, intravital studies have demonstrated stable interaction between DCs
+

and Foxp3 TREGs in vivo (Tadokoro et al., 2006; Tang et al., 2006), while CTLA4 is critical to regulatory T cell control of colitis (Read et al., 2000). IL10 and
cAMP also appear to play a role in nTREG-induced suppression of DC function
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(Fassbender et al., 2010). Thus regulatory T cells regulate T cell-mediated
immunity through a number of direct and indirect mechanisms.
There has been some debate as to whether nTREGs rely on secreted
factors for their suppressive function. Several studies have attempted to assess
the importance of IL10 and/or TGFβ signaling in TREG-mediated regulatory activity
using culture-based T cell suppression assays (Piccirillo et al., 2002), and found
that loss of either pathway did not affect the suppressive function of the cells in
question. However, more recent evidence suggests that this may be due to the
dominant nature of contact-mediated inhibitory mechanisms in this setting. For
example, neutralization of IL10 has been shown to affect TREG function in culture
when TREGs and effectors are separated using a transwell assay system (Collison
et al., 2009). This line of thinking fits well with in vivo data that demonstrate TREGproduced IL10 is important in both immune homeostasis (Rubtsov et al., 2008)
and regulatory activity in the setting of T cell-mediated colitis (Asseman et al.,
1999; Asseman et al., 2003; Uhlig et al., 2006) and EAE (Mann et al., 2007). The
role of TGFβ appears to be a bit more convoluted. Inhibition of TGFβ by
neutralizing antibody or soluble receptor had little effect on TREG function ex vivo,
while T cells that cannot respond to TGFβ were as susceptible to suppression as
those from wild type animals (Piccirillo et al., 2002). These data suggest that
TGFβ is not important in the regulatory activity of TREGs. However, ex vivo data
from the Strober group showed that surface-bound TGFβ was required for
optimal regulatory activity of nTREGs (Nakamura et al., 2001). A similar finding
was reported in vivo, in the setting of the type-1 diabetes using the NOD mouse
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model (Green et al., 2003). Additionally, effector T cells that lack a functional
TGFβ receptor (TGFβR) could not be controlled by co-transfer of TREG cells in the
T cell-mediated colitis model (Fahlen et al., 2005), suggesting that the action of
TGFβ is critical to TREG-mediated suppression of effector populations in this
setting. Therefore, it appears that TREG-produced TGFβ is important in the in vivo
context, perhaps in a surface bound form that mediates direct interaction with
cells expressing the TGFβR.
Clearly TREGs are important in many pathological settings, including
autoimmunity, cancer, and other diseases characterized by chronic inflammation.
In the case of autoimmunity and chronic inflammation TREG cells act
unambiguously to prevent pathological inflammation and tissue destruction that
would otherwise harm the host. This is reviewed here (Vignali et al., 2008), and
much of the relevant data was discussed above. Conversely, several studies
have shown that TREG cells are recruited in the setting of cancer and certain
infections to prevent protective immune responses, thus contributing to the
development of human disease. For example, blockade of the IL10 receptor led
to viral clearance in mice chronically infected with lymphocytic choriomeningitis
virus (LCMV) (Brooks et al., 2006; Ejrnaes et al., 2006). However, other data
from murine models of Toxoplasma and Plasmodium infection clearly show that
loss of IL10 is associated with a lethal inflammatory response (Gazzinelli et al.,
1996) or enhancement of infection (Li et al., 1999), without major changes in
pathogen load. Thus IL10 can undermine sterilizing immune responses in the
case of some infections, while being protective to the host in others. The data in
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cancer are far more clear. Experiments with the B16 melanoma model have
+

shown that Foxp3 cells help tumors escape from immune surveillance by lysing
antigen-carrying DCs in tumor draining lymph nodes (TDLNs). This effect
occurred in a perforin-dependent manner (Boissonnas et al., 2010). Furthermore,
TREGs have also been shown to secrete granzyme B and perforin within the tumor
+

microenvironment, leading to the lysis of tumor-responsive NKT and CD8 T cells
(Cao et al., 2007). Moreover, tumors have been shown to drive the differentiation
+

of Foxp3 TREG cells. Further analysis demonstrated that these tumor-associated
TREGs prevented tumor rejection in an IL10-dependent manner (Bergmann et al.,
+

-

2007). In another study, tumor-produced TGFβ converted CD4 CD25 cells into
+

suppressive CD4 CD25

+

populations (Liu et al., 2007). Thus, part of the

mechanism that tumors use to evade immune surveillance is the induction and
recruitment of regulatory T cell populations, making them target of interest in
cancer therapy.

The TREG - TH17 axis and T cell-targeted therapy
There is an intriguing link between iTREG cells and TH17 cells, both of
which depend on TGFβ signaling for their differentiation (Bettelli et al., 2006; Lee
et al., 2009a). Foxp3 can inhibit RORγt function and the TH17 phenotype (Zhou et
al., 2008), likely through a coordinated interaction with the transcription factor
Runx1 (Zhang et al., 2008). Foxp3 has also been shown to block the transcription
activity of another TH17 associated transcription factor, RORα (Du et al., 2008).
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Conversely, IL6 signaling blocks the chromatin binding activity of Foxp3 and
promotes TH17 differentiation (Samanta et al., 2008; Sauer et al., 2008; Zhang et
al., 2008; Zhou et al., 2007). In addition, TH17 cell secrete the cytokine IL21,
which like IL6 and IL23, activates STAT3 and promotes TH17 differentiation at the
expense of iTREG induction (Wei et al., 2007). Autocrine activity of IL21 may
account for the surprising result that re-stimulation of differentiated TH17 cells
with exogenous TGFβ alone maintains expression of both IL17A and IL17F (Lee
et al., 2009b).
The choice between iTREG cells and TH17 cells can have profound
pathological implications. For example, as discussed above, TREGs actively
participate in tumor escape from immune surveillance (Boissonnas et al., 2010;
Kryczek et al., 2007; Sharma et al., 2009), while TH17 cells enhance tumor
rejection (Kryczek et al., 2007; Martin-Orozco et al., 2009; Muranski et al., 2008;
Zou and Restifo, 2010). One can imagine dampening the function of regulatory T
cell populations within the tumor bed or in the TDLNs to enhance anti-tumor
immunity. Conversely, work out of Nicholas Restifoʼs group at the NIH has
demonstrated that TH17-polarized cells exhibit enhanced tumoricidal activity after
adoptive transfer in B16 melanoma mice (Muranski et al., 2008; Zou and Restifo,
2010), at least in part through the induction of cytotoxic T cells (Martin-Orozco et
al., 2009). Thus a drug designed to shift tumor-associated regulatory T cells
toward the TH17 end of the spectrum might serve to diminish the pro-tumor
activity of resident TREG cells while at the same time driving TH17-mediated antitumor activity within the same population.
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This intimate interplay between critical factors in TREG and TH17
development, along with the dual reliance on TGFβ signaling for their
differentiation, has led to the conceptualization of the TREG-TH17 axis. From a
therapeutics perspective, the identification of drugs that promote pro- or antiinflammatory responses by influencing differentiation along this axis has gained
momentum as examples of T cell plasticity continue to be characterized
(Bluestone et al., 2009). Interestingly, the TREG and TH17 populations appear to
be particularly prone to late developmental plasticity (Lee et al., 2009a). These
results suggest it may be possible to treat disease by shifting the balance along
the TREG-TH17 axis in situ during ongoing immune responses, either to attenuate
inflammation in the setting of autoimmune disease, or to enhance immunity to aid
in pathogen clearance or tumor rejection. The developmental plasticity between
the TH17 and TREG populations is reviewed here (Lee et al., 2009a).
To that end, targeting non-cytokine signaling pathways may be a viable
option. There are several factors that appear of preferentially polarize cells
towards either the iTREG or TH17 phenotype. For example, ATP (Atarashi et al.,
2008), shinogosine-1-phosphate (Liao et al., 2007) and vitamin D (Colin et al.,
2010) can modulate TH17 development, while APC-derived indolamine 2,3dioxygenase (Sharma et al., 2009) and retinoic acid (Mucida et al., 2007) can
promote TREG populations. Targeting such pathways has the potential advantage
of avoiding the severe side-effect profiles that have plagued cytokine-targeted
therapies.
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Figure 4 : Introduction: The TREG-TH17 axis.
Adopted from: Tato CM& Cua DJ (2008) Nat Immunol. 9:1323-25

-

+

Other regulatory T cells (Hybrid T cells and Foxp3 IL10 cells)
It is now known that all helper T cell lineages can express IL10 (Figure 5),
+

-

and there is clear evidence that both Foxp3 and Foxp3 T cell populations can
exhibit regulatory activity through the production of IL10 (Maynard et al., 2007).
There is also evidence that IL10 can actually stabilize Foxp3 expression in vivo
(Murai et al., 2009). While the types and classifications of the various TREG
populations is a dynamic process, and often varies by investigator, it is clear that
at least some regulatory T cell populations do not express Foxp3. One such
population are the type-1 regulatory T (Tr1) cells, which were originally described
as be IL10–induced TREG cells that express IL10 (Roncarolo et al., 2006).
-

+

However, it is now clear that Foxp3 IL10 regulatory T cells can be generated
without exogenous IL10 (Maynard et al., 2007). While clear categorical
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+

descriptions of IL10 producing iTREGs are still lacking, the importance CD4 T cell
produced IL10 in regulating immune responses is not in question (Maynard and
Weaver, 2008), including in the setting of human inflammatory bowel disease
(Amre et al., 2009; Glocker et al., 2009).
The induction of IL10 within each of the distinct effector lineages is thought
to be important in limiting ongoing inflammatory reactions locally. The implicit
function of this negative feedback loop has led to the characterization of IL10

+

effector populations as “autoregulatory T cells”. Work with cultured T cells clearly
shows that ERK signaling is necessary for the induction of IL10 in TH1 and TH2
cells, and contributes to IL10 expression in TH17 populations, with no detectable
difference when p38 signaling is blocked (Saraiva et al., 2009). Furthermore,
IL10 production in TH1 cells requires IL12-signaling through STAT4, whereas TH2
cells are dependent on IL4-signaling through STAT6, and IL10 production in TH17
cells requires signaling through STAT3 (Stumhofer et al., 2007). IL27 is also
capable of inducing IL10 in all three lineages (Fitzgerald et al., 2007; Stumhofer
et al., 2007). Moreover, TGFβ blocks IL10 expression in CD4

+

T cells

differentiating in culture (Saraiva et al., 2009), while efficient induction of IL10
secretion from TH17-polarized cells requires both TGFβ and an activator of
STAT3 such as IL6 (McGeachy et al., 2007), IL21 (Spolski et al., 2009), or IL27
(Stumhofer et al., 2007). The ability to incite localized IL10 production suggests
that one mechanism to therapeutically treat the chronic inflammatory reactions
associated with autoimmune disease would be to induce IL10 expression within
the effector populations (ex: TH17 cells) contributing to the pathological
35

inflammation. Indeed, IL10 has been explored as a therapeutic option in many
disease settings (O'Garra et al., 2008).
Finally, several reports have characterized “hybrid” T cell populations
where Foxp3 is expressed in various effector T cell populations (Barnes and
Powrie, 2009). The thought is that induction of one of the canonical effector T cell
transcriptions factors (T-bet, GATA-3, or RORγt) in conjunction with Foxp3 allows
lineage-specific trafficking factors to be expressed in cells that are programmed
to function in a regulatory fashion. This induces trafficking of TREGs in the
circulation to sites of ongoing inflammation. Such a response is not
+

unprecedented as T-bet-induced CXCR3 expression in Foxp3 cells has been
shown to be important in targeting TREGs to sites of TH1-type inflammation and
limiting tissue damage (Koch et al., 2009).
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+

Figure 5 : Introduction: IL10 production in CD4 T cell lineages.
Adopted from: Maynard CL & CT Weaver (2008) Immunol Rev 226: 229-33

Section 1.4 : Estrogen
The other major topic relevant to this work centers on estrogen signaling
and the role of the G protein coupled receptor GPER, thus a brief discussion of
estrogen biology is presented.

Estrogens physiological effects
Estrogens belong to the family of lipid soluble steroid hormones. There are
numerous forms of estrogen, including estrone (E1), estradiol (E2), estriol (E3),
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and the estrogen sulfates (Pasqualini et al., 1989). In mammals, the form
associated with the highest activity is 17β-estradiol (hereafter referred to as E2)
(Prossnitz et al., 2008). E2 is shown in Figure 7 below. Estrogen is most
prominently associated with women of reproductive age, who generally have
much higher circulating levels that prepubescent females, postmenopausal
women, and males. However, it is important to note that estrogens play a critical
role in numerous physiological processes ranging from reproductive biology and
bone metabolism (Dupont et al., 2000) to cardiovascular and lipid homeostasis
(Baker et al., 2003). Moreover, although the major site of female estrogen
production is in the ovary; adipose tissue, the testis, and the central nervous
system (among others) are also capable of producing estrogen (Simpson et al.,
1993), and estrogen receptor deficiency is associated with female and male
infertility (Akingbemi, 2005). Indeed many cell types express the enzyme
aromatase which converts testosterone to estrogen (Simpson et al., 1993), and
extraovarian synthesis has been described (Baquedano et al., 2007). Thus,
estrogens are important in many settings, and in both sexes.
Estrogens have also been linked to numerous human diseases. There is a
long history linking estrogen to breast cancer in women (Beatson, 1898; Moore et
al., 1967). There are also environmental contaminants that can mimic estrogen
and

activate

estrogen

(xenoestrogens),

plant

receptors.
products,

These

include

(phytoestrogens),

synthetic
and

compounds

fungal

products

(mycoestrogens) (Prossnitz and Maggiolini, 2009). Thus understanding estrogen
signaling is critical in many areas of human exposure and disease.
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ERα and ERβ
The classic estrogen receptors ERα (Jensen and DeSombre, 1973) and
ERβ (Kuiper et al., 1996) contain DNA binding domains that recognize EREs
(estrogen response elements) on target genes where they act as ligand-activated
nuclear

transcription

factors.

Upon

estrogen

binding,

they

undergo

conformational changes that allow coordination of a complex transcriptional
profile through a multitude of protein-protein interactions with numerous enhancer
and regulatory elements (Marino et al., 2006). In additional to the transcriptional
events that result from activation of ERα and ERβ, estrogen responses are
known to include several rapid signaling events more commonly associated with
surface receptors such as receptor tyrosine kinases and G protein coupled
receptors (GPCRs). Examples include calcium mobilization and transactivation of
mitogen-activated protein (MAP) kinase cascades. While the majority of the work
on the classical estrogen receptors has focused on their ability to regulate
transcription, there is evidence that they can elicit some of the rapid signaling
responses associated with estrogen binding (Edwards, 2005). In reality, the
designation as rapid or “non-genomic” signaling versus “genomic” transcription
based signaling is largely arbitrary as each plays a substantial role in the
outcomes associated with the other. In general, these are collectively referred to
as estrogen signaling in this manuscript.
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GPER (GPR30)
At the start of the decade, dogma in the estrogen field stated that the
classical ERʼs (ERα and ERβ) accounted for all estrogen signaling events.
However, evidence in the literature demonstrating estrogenic effects in ERα/β
double knockout mice suggested that other estrogen receptors may exist (Das et
al., 2000; Shughrue et al., 2002). In 2000, it was demonstrated that the orphan G
protein-coupled receptor GPR30 could mediate estrogen-dependent ERK
activation in SKBr3 cells (which lack ERα and ERβ) (Filardo et al., 2000). These
findings were extended in 2005, when our group along with the team led by
Filardo and Thomas published work demonstrating estrogen binding to GPR30 in
cells lacking both ERα and ERβ (Revankar et al., 2005; Thomas et al., 2005). In
these studies, it was shown that E2 activation of GPER led to calcium
mobilization and activation of PI3 kinase. Since these initials reports, GPR30
(renamed GPER) has been linked to several estrogen-mediated events. A
current model of estrogen signaling is included below as Figure 6.
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Figure 6 : Introduction: Current model of estrogen signaling.
Adopted from: Prossnitz et al (2008) Annu Rev Physiol 70:165-90

The physiological functions of GPER remain largely unknown (Prossnitz
and Barton, 2009b), partly due to the fact that many reports prior to 2005 utilized
drugs that have yet uncharacterized functions in GPER signaling, and because
there is evidence of synergistic effects between ERα and GPER (Albanito et al.,
2007). However, some links have been identified. It appears that GPER plays a
role in estrogen-mediated secretion from pancreatic beta cells (Nadal et al.,
2011), while genetic disruption of GPER in female mice leads to altered bone
growth and blood pressure, with older mice exhibiting hyperglycemia and
impaired glucose tolerance (Martensson et al., 2008). Moreover male GPERKO
mice exhibit increased bone mass, bone mineralization, and overall weight (Ford
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et al., 2010). Links to several other human pathologies have also been
established, including pain disorders (Dun et al., 2009; Hazell et al., 2009;
Liverman et al., 2009; Lu et al., 2009) and cardiovascular disease (Bopassa et
al., 2010; Filice et al., 2009; Jessup et al., 2010; Meyer and Barton, 2009; Weil et
al., 2010; Yang and Reckelhoff, 2010). In terms of cancer, a multitude of reports
suggest that GPER can serve as a prognostic marker in gynecological cancers
(Filardo et al., 2006; Filardo et al., 2008; Giess et al., 2010; Liu et al., 2009;
Prossnitz and Barton, 2009a; Smith et al., 2007; Tu et al., 2009) and alter cancer
cell proliferation (Arias-Pulido et al., 2010; Ariazi et al., 2010; Chan et al., 2010;
Dong et al., 2010; Maggiolini et al., 2004). Links to Tamoxifen resistance in
breast cancer have also been established (Ignatov et al., 2010).
Several fundamental questions regarding GPERs function remain. Indeed,
the status of GPER as an estrogen receptor is not without controversy (Langer et
al., 2010; Otto et al., 2009). Some have speculated that GPER drives expression
of a little known ERα splice variant, termed ER36, which lacks much of the 5ʼ
transactivation domain and contains a unique 3ʼ exon. These authors have
hypothesized that it is this receptor which binds estrogen when GPER is
expressed (Kang et al., 2010). However, bioinformatics analysis of protein and
DNA sequences from the published C57BL/6 mouse genome (NCBI) shows
there is no homologous 3ʼ exon within 1Mb of the murine GPER locus (data not
shown) that would match the reported ER36 exon. In addition, we and others
have been unable to replicate the findings with ER36 described above (personal
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communication). Thus it appears that ER36 is unlikely to account for the
observed effects of GPER. The subcellular localization is also a point of question,
with some group (ours included) seeing it localized to the endoplasmic reticulum
(Revankar et al., 2007), and others localizing it to the plasma membrane (Filardo
et al., 2007; Sanden et al., 2010). Work is ongoing to resolve the exact
mechanism and setting for GPER-mediated estrogen signaling.
Given the importance of estrogen in breast cancer and other human health
conditions, and given the success in targeting G protein-coupled receptors
pharmacologically, our lab has developed a series of small molecules that
specifically target GPER. This class of compounds currently includes the GPERdirected agonist, G-1 (Bologa et al., 2006), and the antagonists G15 (Dennis et
al., 2009) and G36 (unpublished). These membrane-permeable small molecules
are highly specific for GPER. G-1 in particular shows minimal binding to classical
estrogen receptors (Arterburn et al., 2009) and has been tested against 25 other
GPCRs (Blasko et al., 2009). Like the estrogens (Muller et al., 1979), the G
compounds are uncharged, hydrophilic compounds that freely migrate across cell
membranes via passive diffusion, and are therefore attractive candidates for
rapid incorporation into the pharmaceutical pipeline. In addition, the growing
evidence that GPER plays a more subtle role in the majority of estrogens most
prominent physiological effects suggest that the G compounds may be
associated with a more attractive side-effect profile. See structures in Figure 7.
These compounds were used throughout this study.
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Figure 7 : Introduction: The G compounds and E2

Section 1.5 : Estrogen and the immune system
It has long been recognized that women exhibit a much higher prevalence
of numerous autoimmune diseases (Whitacre et al., 1999), with several lines of
evidence linking this observation to estrogen signaling. For example, the PRIMS
study showed that patients with multiple sclerosis (MS) experience a decrease in
relapses over the course of their pregnancy, most notably in the third trimester,
with a subset of women exhibiting a period of increased symptoms immediately
post-partum (Vukusic et al., 2004). These studies translate to animal models as
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estrogen has been shown to protect animals from experimental autoimmune
encephalomyelitis (EAE), a widely accepted animal model of multiple sclerosis
(Ito et al., 2001; McClain et al., 2007; Offner and Polanczyk, 2006; Polanczyk et
al., 2004a; Polanczyk et al., 2004b; Polanczyk et al., 2005). Analysis of cells from
the draining lymph nodes of EAE mice showed that estrogen can increase Foxp3
expression (Polanczyk et al., 2005). Other important immunoregulatory
molecules have been linked to estrogen as well. Increased expression of the
+

surface receptor programmed death (PD) -1 was observed on Foxp3 cells in
estrogen treated EAE mice, and PD-1 has been linked to estrogen-mediated
suppression of this model (Polanczyk et al., 2007; Wang et al., 2009a). Yet a
recent study showed that estrogen-mediated protection from EAE was not
dependent on Foxp3 expression (Subramanian et al., 2010). Thus it appears that
multiple mechanisms are responsible for estrogens protective effects in EAE.
Moreover, estrogens effects do not appear to be limited to the setting of
neurological

inflammation

as

studies

of

patients

with

systemic

lupus

erythematosus (SLE) (Clowse, 2007) and Rheumatoid arthritis (RA) (Da Silva
and Spector, 1992) have also linked these diseases to estrogen.
The evolutionary logic behind estrogen-mediated immune regulation may
stem from the need to suppress responses to paternal epitopes. Experiments
using allogeneic rejection models of pregnancy have demonstrated that TREG
populations are important in tolerance to foreign epitopes in utero (Schumacher
et al., 2007). Another reason that estrogen may impart an effect on the immune
system is the role of leukocytes in the remodeling processed during and post
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delivery (Read et al., 2007). Studies with cervical biopsies from post term women
undergoing prostaglandin-induced parturition showed that women who didnʼt
respond to therapy showed reduced leukocyte influx, including reduced numbers
+

of IL8 cells, as compared to women who did respond to therapy or who gave
birth at term. However, no differences in estrogen receptor expression were
observed (Dubicke et al., 2008). Interestingly, IL8 can be produced by TH17 cells
(Stockinger et al., 2007). Moreover, work with animal models has shown that
delivery of oral ethinyl estradiol protects animals from the development of EAE
while inducing IL10 secretion (Yates et al., 2010).
While it is clear that estrogen imparts a direct effect on immune
physiology, many questions remain. The majority of work to date has focused on
pathways within the TH1 and TH2 subpopulations, yielding variable results
(Pernis, 2007). However, efforts to delineate the role for specific estrogen
receptors have uncovered a few interesting insights. Estrogen-mediated
+

induction of Foxp3 within the CD4 T cell compartment was lost in ERαKO mice
(Polanczyk et al., 2003), and both ERα and ERβ have been linked to estrogens
protective effects in this model (Polanczyk et al., 2004a). Further insights
emerged when it was shown that G-1 can suppress EAE induced by direct
immunization with peptide from either myelin oligodendrocyte glycoprotein
(MOG) (Wang et al., 2009a) or myelin proteolipid protein (PLP) (Blasko et al.,
2009). This latter study also used an adoptive transfer protocol where pathogenic
cells from the draining LN (DLN) of PLP peptide-treated mice were harvested and
expanded ex vivo prior to injection into naïve hosts, who subsequently developed
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severe disease (Blasko et al., 2009). They were able to show that co-culture of
DLN cells with G-1 during ex vivo conditioning reduced disease severity without
the need for direct treatment to recipient mice. This effect was associated with
reduced production of IL17A and IFNγ from CNS lymphocytes, as well as
reduced levels of IL23 and CCL2 (a critical factor for macrophage recruitment to
the CNS in EAE) within the tissue itself. Despite the similarities in disease
outcome, these two studies focused on two distinct immune populations. In one
study, G-1 induced suppression of EAE was associated with increased PD-1
+

+

expression on Foxp3 T cells with no change in the number of Foxp3 cells
overall, while the protective effects of G-1 were largely absent in PD-1KO mice.
In addition, the protective effects of estrogen were significantly (but not
-/-

completely) attenuated in GPER

mice. This suggested that estrogen-mediated

suppression of EAE may be partially due to GPER-mediated induction of PD-1
+

expression on Foxp3 TREGs (Wang et al., 2009a). Conversely, in the second
study, G-1 treatment inhibited polyI:C-induced TNFα and IL6 production as well
as LPS-induced IL12(p40) and CCL5 production from primary human
macrophages. They went on to show that ectopic expression of GPER in the
human promyelocytic cell line HL60 allowed for G-1 induced calcium mobilization,
and that G-1 treatment reduced macrophage recruitment to the CNS of EAE
mice. Such observations suggest that G-1 may affect the macrophage population
to suppress EAE. These two conclusions are not mutually exclusive (Blasko et
al., 2009), but they bring up a common theme within the literature exploring

47

estrogens effects within the immune system; these interactions are complex and
multifaceted.
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Chapter 2 : The hypothesis

Section 2.1 : Preliminary findings and figures
The overarching theories that guided our preliminary work are summarized
in the following list;
1. Estrogen is a known modulator of the immune system and T cells.
2. GPER is a novel estrogen receptor.
3. GPER is a G protein-coupled receptor.
4. G protein-coupled receptors have been successfully targeted with
small molecules for therapeutic benefit.
5. We have developed a small molecule agonist for GPER, G-1, and
two small molecule antagonists, G15 and G36.
6. G-1 has already been shown to attenuate an animal model of
mutiple sclerosis.
+

7. CD4 T cell are central mediators of many immune diseases.
+

8. Small molecules that could modulate CD4 T cell populations would
be of immense therapeutic interest, both for systemic treatment and
for alteration of T cells ex vivo for tumor vaccines and other
adoptive therapies.
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Given these starting concepts, we set out to investigate whether our
+

GPER-directed agonist G-1 could alter CD4 T cell function by acting directly on
the T cells. Specific action within the T cell populations was delineated by using
cultures of purified, primary murine T cells stimulated ex vivo.

+

GPER affects cytokine secretion from CD4 T cells
+

To begin, CD4 splenocytes were collected using positive selection on a
magnetic bead-based cell purification system (AutoMACS) from the spleens and
lymph nodes of 7-11 week old C57BL/6 male mice. Purified cells were cultured in
96-well plates and stimulated with antibodies directed to CD3ε and CD28, which
mimics APC-driven T cell activation, along with various combinations of the
GPER-directed compounds G-1 and G36. Samples of medium were collected at
day 3 or day 5 post stimulation and screened for IL2, IL4, IL5, IL10, IL12, IL17A,
TNFα, and IFNγ production by Luminex Multiplex assay (Invitrogen). We
observed no trends for IL2, IL4, IL5, IL12, IFNγ and TNFα (data not shown) in the
G-1 treated cultures, although this was possibly due to autocrine/paracrine
uptake of these cytokines. Interestingly, G-1 treatment did induce the production
of the cytokines IL17A on day 3, and IL10 on day 5. These effects could be
inhibited by G36. (Figure 8). Combined, these findings suggest that GPERsignaling could enhance production of IL17A and IL10. As 10% of these cultures
+

consisted of cells other than CD4 T cells (data not shown), it was possible that
our observations were due to effect on other non-T cell populations. Additionally,
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+

the CD4 population contained both memory and naïve lineages, thus even if our
+

findings were the result of direct activity within the CD4 T cell population, these
data do not distinguish whether the effect was due to G-1 altering T cell
differentiation or rather a reflection of alterations in memory T cell cytokine
secretion. Thus our next question was whether G-1 could modulate T cell
differentiation.

+

G-1 modulates TGFβ-induced differentiation of naive CD4 T cells
To determine if GPER has an effect on the differentiation of naive T cell
+

populations, CD4 CD62L

hi

naive T cells were purified by fluorescence-activated

cells sorting (FACS) from the spleens and lymph nodes of 7-11 week old
C57BL/6 male mice. Purified cells were stimulated in culture for 5 days with antiCD3ε and anti-CD28 antibody (Ab) supplemented with TGFβ (10ng/mL) in the
presence and absence of G-1. No additonal treatments were added after day 0.
The decision to add TGFβ was based on the fact that;

(A) it is a common factor in the differentation of both TH17 and iTREG cells,
forming a critical cog in the TREG-TH17 axis (Figure 3). This is interesting
given our data show that G-1 can drive secretion of IL17A (the canonical
TH17 cytokine) and IL10 (a well known suppressive cytokine), and;
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(B) published work in human cancer cell lines had established that GPER
could inhibit TGFβ-induced cancer cell migration (Kleuser et al., 2008),
suggesting that GPER-mediated signaling could integrate with signals
from the TGFβ receptor.

The addition of IL2 to the culture medium served as the negative control,
as this cytokine blocks TH17 differentiation (Kryczek et al., 2007). Consistent
with our findings from Figure 8, the addition of G-1 lead to an increase in the
number of IL17

+

cells, as assessed by intracellular cytokine staining (ICS)

(Figure 9A). Interestingly, when the cells were re-stimulated with anti-CD3 Ab
following 5 days of culture, we observed drastically reduced IL17 and IFNγ
secretion from the cultures treated with G-1 (Figure 9B,C). These results
implicated a regulatory T cell population in the G-1 treated cultures. Given that
+

our results with enriched CD4 demonstrated increased secretion of IL10 at day
5, we wanted to determine if G-1 could drive IL10 production as well. However,
+

we were unable to detect IL10 cells in these cultures (data not shown), which is
consistent with a previous study from Anne OʼGarraʼs group which showed that
continuous treatment with TGFβ alone can block IL10 expression in cultured
+

CD4 T cells (Saraiva et al., 2009). It is important to note that removal of TGFβ or
addition of other factors after TGFβ treatment may lead to IL10 expression in
these cells, meaning this is not a stable inhibition of IL10 expression. Thus we
next sought to investigate IL10 and IL17A expression during CD4

+

differentiation in conditions that were ammenable to the production of IL10.
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T cell

+

+

+

G-1 enhances differentiation of a CD4 IL10 IL17 T cell population
+

As stated above, when G-1 was added to cultures of CD4 splenocytes,
there was a spike in IL17 production observed on day 3, which was subsequently
lost by day 5. The loss of IL17 production correlated with an increase IL10
production, although this trend never reached statistical significance (P = 0.11 by
studentʼs t-test, Figure 8). To determine whether G-1 can drive IL10 expression
during T cell differentiation, naïve CD4

+

T cells were collected, stimulated in

culture as described above, and stained for intracellular IL10 and IL17. In this
case, IL6 (20ng/mL) was added to the cultures along with TGFβ (5ng/mL). This
was based on the fact that a report out of Daniel Cuaʼs lab had shown that an
+

+

IL10 IL17 population of cells developed under these conditions, and that these
cells exhibited immunosuppresive activity in vivo (McGeachy et al., 2007).
Notably, these cells were shown to attenuate EAE, the same disease model used
in studies demonstrating G-1’s in vivo immunosuppressive properties (Blasko et
al., 2009; Wang et al., 2009a). It is also known that IL10 production within TH17
populations requires transactivation of STAT3 (Saraiva and O'Garra, 2010),
which can be elicited by treatment with several cytokines, including IL6
(Stumhofer et al., 2007). Thus these conditions presented the ideal opportunity to
investigate both IL10 and IL17A expression. Exposure to G-1 increased the
+

+

+

-

number of IL10 IL17 cells and IL10 IL17 cells (Figure 10), consistent with our
findings in Figures 8 and 9.
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Conclusions from preliminary studies
In summary, preliminary work suggested that G-1 drives expression of
+

IL10 and IL17A within differentiating CD4 T cells. We also noted an expansion
+

+

+

of the CD4 IL17 IL10 T cell population under TH17-polarizing conditions. These
cells have been previously shown to exhibit in vivo TREG activity. It is important to
again note that IL17A has been shown to exhibit immunosuppressive properties,
in addition to its role in proinflammatory processes (O'Connor et al., 2010). Thus
the induction of both IL10 and IL17A does not necessarily preclude G-1 from
therapeutic development.

Figure 8 : Preliminary data: G-1 drives IL17A and IL10 secretion from T cells.
+

CD4 splenocytes were collected by AutoMACS (Miltenyi) stimulated in culture with G-1 (Red) or
G-1 + G-36 (open boxes, gray area). Medium was collected 3 and 5 days later and analyzed for
IL10 and IL17 by Luminex Multiplex Assay. Summary of data from 3 independent experiments.
Statistical analysis done by studentʼs t-test. * = P < 0.05. Error bars = S.E.M.
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Figure 9 : Preliminary data: G-1 alters TGFβ-driven T cell differentiation.
+

hi

CD4 CD62L naïve T cells were stimulated with for 5 days in presence (black) or absence (white)
of TGFβ along with treatments indicated. Cultures were then stained for intracellular IL17A (A) or
were re-stimulated with antiCD3 Ab for evaluation of IFNγ (B) and IL17A (C) secretion by ELISA
assay. Summary of data from 3 experiments. Statistical analysis done by studentʼs t-test. *** = P
< 0.0005, ** = P = P < 0.005, * = P < 0.05. Error bars = S.E.M.

Figure 10 : Preliminary data: G-1 alters IL17A/IL10 expression in naive T cells.
+

hi

egfp

CD4 CD62L naive T cells from Foxp3
mice were collected by FACS and cultured for 4 days
with TGFβ + IL6, supplemented with either 100nM G-1 or DMSO, as indicated. Cells were then
stained for intracellular IL10 and IL17A, then analyzed by flow cytometry. Data from one of five
independent experiments shown. P values determined by studentʼs t-test. * = P < 0.05. Error bars
= S.D.
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Section 2.2 : Development of a hypothesis
Numerous studies have implicated the hormone estrogen in T cell function
and autoimmune pathogenesis (See Section 1.5). Yet to date, few studies have
definitively clarified the relationship between estrogen receptor signaling and T
cell physiology. The emerging evidence of GPER involvement in immune
regulation opens the door to new therapeutic targets for immune-related
diseases. Preliminary results with cultured CD4

+

T cells demonstrated that

selectively stimulating GPER leads to production of the suppressive cytokine
IL10 and the TH17-associated cytokine IL17A, including induction of an
+

+

IL10 IL17 T cell population. The ability to drive IL10 production from TH17 cells
is of therapeutic interest for two main reasons; this cytokine exhibits enormous
immunosuppressive

potential,

and

numerous

autoimmune

diseases

are

associated with a large number of TH17 cells (see Section 1.3). Interestingly,
previous reports have linked GPER to TGFβ signaling, a critical regulator of the
TREG-TH17 axis, while E2 is known to drive expression of the canonical TREG
transcription factor Foxp3. These results led to the following HYPOTHESIS:

The GPER-directed agonist G-1 drives differentiation of traditional and
hybrid regulatory T cells by direct action on CD4+ T cell populations,
including in the context of TH17 differentiation. (See Figure 11)
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Figure 11 : Diagram of hypothesis.

Section 2.3 : Aims of the study
In order to test the veracity of the hypothesis, the following Aims were
outlined, and the associated experiments were carried out:

Specific Aim 1 – To determine the effect of G-1 on the expression of key
regulatory T cell markers.
The ability of G-1 to induce development of regulatory T cell populations
was investigated in vivo and ex vivo. G-1 and physiological estrogen (E2) were
injected subcutaneously into various Foxp3egfp transgenic mice (Haribhai et al.,
2007) (Methods: Chapter 3) for in vivo studies of Foxp3, PD-1 and CTLA-4
+

expression. Similarly, CD4 naïve T cells were purified by fluorescence-activated
cell sorting (FACS) and stimulated in culture under various conditions to identify
G-1-mediated effects on Foxp3, RORγt, PD-1, and CTLA-4 expression by direct
action, or where assessed for suppressive function by T cell suppression assay.
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Specific Aim 2 – To delineate changes in T cell cytokine profiles following
treatment with G-1.
The ability of G-1 to modulate the expression of key cytokines within CD4

+

T cell populations was investigated following in vivo and ex vivo treatment. G-1 or
E2 was injected subcutaneously into either wildtype or GPERKO mice, after
which splenocytes were collected and stimulated ex vivo to analyze cytokine
+

production. In addition, CD4 naïve T cells were purified by FACS and stimulated
in the presence of G-1 under various conditions, including TH17-polarizing
conditions. Following culture, cells were either stained for intracellular cytokines,
transcription factors, or other moieties, or were re-stimulated and analyzed for
cytokine secretion. Signaling pathways were investigated by employing chemical
inhibitors, and proliferation was studied using fluorescent dyes.

Specific Aim 3 – To determine if G-1 treated T cells demonstrate
suppressive function in vivo in the setting of chronic inflammation.
The in vivo suppressive function of G-1 treated T cells was delineated
using a T cell-mediated model of colitis (TCMC; see Methods Chapter 3 and
Appendix E). We also investigated whether systemic treatment with G-1 could
inhibit disease induction. This paradigm was selected on the basis that Foxp3
(Murai et al., 2009; Uhlig et al., 2006), IL10 (Asseman et al., 2003; Coquerelle et
al., 2009; Uhlig et al., 2006), and IL17A (O'Connor et al., 2009) have been shown
to attenuate wasting disease and colonic inflammation in this model.
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Chapter 3 : Materials and Methods

Section 3.1 : Cell sorting with MoFlo and AutoMACS
T cells were obtained from single cell suspensions following homogenization of
spleens and lymph nodes by mechanical disruption and passage through a 70µm
nylon filter. Suspensions were stained with anti-CD4, antiCD62L, and anti-CD44
antibodies
+

(Biolegend).
lo

CD4 CD44 CD62L

hi

Enriched

populations

of

+

CD4 CD62L

hi

and

naïve T cells (See Appendix B) were collected by flow

cytometric cell sorting on MoFlo cell sorter (Cytomation) using the Sort Single
setting. Purity was regularly >96%. In most cases, experiments were repeated
with both types of sorted naïve T cell, and no differences were noted. Other
populations were collected in a similar fashion. See Appendix B for more details
on sorting logic and criteria.

+

Section 3.2 : Culture of CD4 T cells
All experiments and cell purification were carried out in RPMI 1640 medium
supplemented with fetal bovine serum (FBS), penicillin/streptomycin, Lglutamine, HEPES, sodium pyruvate, and 2-mercaptoethanol. Phenol red-free
buffers and charcoal-stripped FBS were used to minimize exposure to estrogens
or phyto/xenoestrogens that could have confounded our results (Berthois et al.,
1986). This medium was used for all T cell culture experiments (T cell media).
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Cells were stimulated in culture with soluble anti-CD3ε (1.0 µg/mL) and antiCD28 (2.5 µg/mL) antibodies (Biolegend), and supplemented with various
combinations of TGFβ (0.5-10.0ng/mL), IL6 (20ng/mL), and IL23 (20ng/mL) as
described (Biolegend and eBiosciences). Non-polarizing conditions (TH0)
contained no exogenous cytokines. TH17 conditions contained TGFβ + IL6 ±
IL23. Experiments were carried out using 96 well plates with 2x105 cells per well
(106 cells/mL). For experiments using GPER and MAPK inhibitors, freshly sorted
cells were incubated at 37°C (+5% CO2) for 60-90 minutes with 25µM PD98059
(MEK inhibitor), 250nM JNK II inhibitor, 100nM SB203580 (p38 inhibitor), or
500nM G15 or G36 (GPER antagonist (Dennis et al., 2009), provided by Dr.
Jeffrey Arterburn at New Mexico State University) where indicated, prior to
addition of stimulatory antibodies or cytokines. All compounds used in the study
were dissolved in DMSO. All cultures were incubated at 37°C (+5% CO2).

Section 3.3 : Staining cells for flow cytometry
Intracellular cytokine staining: Following 4 days in culture, cells were washed
with medium and “rested” for 60-90 min at 37°C (+5% CO2). Cultures were then
treated with PMA (50ng/mL) and ionomycin (500ng/mL) for 4-5 hours in the
presence of Brefeldin A (Biolegend) followed by fixation in Fixation Buffer
(Biolegend). Samples were then washed and stained for intracellular proteins in
Permeabilization Wash buffer (PWB – Biolegend) for 2 hours at room
temperature, and washed with excess PWB for 15 minutes at room temperature

60

prior to centrifugation and analysis. Immediately after staining, data were
collected on a FACScalibur (Becton Dickinson). Data analysis was performed
using FlowJo software (TreeStar). Antibodies for staining included anti-IL10allophycocyanin (APC), anti-IL10-phycoerythrin (PE), anti-IL17A-PE, and-IL17APerCP, and anti-IFNγ-APC all from Biolegend, as well as anti-RORγt-PE from
eBiosciences.

Staining of surface markers: Cells were collected and spun down, either from
single cell suspensions of homogenized tissue or from purified cultures of T cells
as indicated. Cells were resuspended in 100µl 50% PBS + 50% T cell media
(See Section 3.2 above) with appropriate antibodies diluted 1:100. Cells were
stained for 15-30 minutes at room temperature, after which 500µl of 50%PBS/T
cell media was added to dilute out the antibody, and incubated for an additional
2-5 minutes before being spun down. Cells were then either resuspended in PBS
or fixed with Fixation Buffer (Biolegend) and stored at 4°C for up to 2 weeks prior
to analysis by flow cytometry. For Annexin V and 7-AAD staining, cells were spun
down and resuspended in 100µl 1X Annexin V staining buffer (BD Pharmingen),
to which 5µl of Annexin-V-PE and 7-AAD were added. Staining was followed as
described above for other surface markers, only Annexin staining buffer was
used to wash off excess antibody/stain.

Proliferation studies (eFluor670): For analysis of proliferation, freshly sorted T
cells were stained with 2.5µM eFluor670 according to the manufacturerʼs
61

protocols (eBiosciences). Cells were then cultured, stained, and analyzed as
indicated above. Geometric mean fluorescence intensity (GMFI) of eFluor670
was determined using FlowJo software (TreeStar), and un-stimulated controls
were used to differentiate between proliferating and non-proliferating cells.

Section 3.4 : Flow cytometry
The data were collected on a FACScalibur (Becton Dickinson). Data analysis was
performed using FlowJo software (TreeStar). All equipment was provided by the
Shared Flow Cytometry Resource at UNM.

Section 3.5 : ELISA and Luminex multiplex assays
Following 4 days in culture, cells were washed with cold medium to remove any
cytokines in solution, resuspended in fresh medium, and counted. Cell were then
plated in a 96 well plate with 2x105 cells per well (106 cells/mL), allowed to
incubate for 60-90 min at 37°C (+5% CO2), and re-stimulated with soluble antiCD3ε (2.5 µg/mL) antibody. Following the indicated incubation times hours,
culture medium was collected and spun down to remove any residual cells. The
concentration of IL6, IL10, IL17A, IFNγ, and TNFα in the cell-free culture medium
was analyzed using custom bead arrays from Millipore, and quantified on a
Luminex 100 system with the Luminex XY plate handling platform. Assays were
performed according to the manufacturers protocols. Duplicate wells were
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assayed for each sample, and data are representative of the average median
value for each sample. Analysis was performed using IS 2.3 software (Luminex).

Section 3.6 : Immunofluorescence and cryosectioning
Samples were fixed in PBS + 4% paraformaldehyde + 10% sucrose, then
embedded in OCT for cryosectioning on a cryostat. 7-10µm sections were used.
Sections were then mounted on slides and immursed in VectaShield with DAPI,
and analyzed on a Zeiss Meta Confocal microscope provided by the UNM
Microscopy Facility.

Section 3.7 : Western blots
Protein samples for western blot were collected in RIPA buffer and incubated on
ice for 30 minutes. Samples were stored at -20°C prior to use. 15 µg or protein
was loaded onto a acrylamide gels, and run using standard western blot
protocols.

Section 3.8 : (q)RT-PCR
Cells were homogenized with QIAshredder tubes (Qiagen) and RNA was
extracted using the RNeasy mini kit (Qiagen) following manufacturer instructions.
RNA was then quantitated using a Nanodrop spectrophotometer (Thermo
Scientific). Reverse transcription was performed in a 20ul reaction volume using
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100ng of RNA and Applied Biosystems High Capacity cDNA Reverse
Transcription kit with RNase inhibitor (Applied Biosystems). Samples were then
prepared for quantitative PCR using Applied Biosystems SYBR Green Master
Mix.

Reactions were carried out in 20ul reaction volume containing 10ul 2X

SYBR Green master mix, 0.5uM forward and reverse primer, and 2ul (10ng)
cDNA template. Quantitative PCR was performed on Applied Biosystems 7500
Fast Real-time PCR system and standard conditions consisting of 50°C for 2 min
followed by 40 cycles of 95° for 15 sec, 60° for 1 min. GAPDH was used as a
loading control for all samples. 7500 Fast software was used for data collection.
Data was analyzed using the standard ΔΔCT method.

Section 3.9 : T cell-mediated colitis model
A TH1-type model of IBD can be elicited by intraperitoneal injection of 4x105
+

hi

CD4 CD45RB

naïve T cells into Rag1KO mice (Ostanin et al., 2009). For
hi

these experiments, CD45RB
lo

CD45RB

+

were defined as the top 40% of CD4 cells, and

included the bottom 15% of CD4

+

cells. Disease progression was

followed by monitoring the weight of the mice.

Histological sections and

intracellular cytokine staining were used to evaluate disease severity. See
Appendix E for examples of data from one of these experiments.
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Section 3.10 : Mice
Male (7-11 weeks old) wildtype and Foxp3egfp mice were used for this study for
collection of purified T cell populations by AutoMACS or FACS. Rag1KO mice
were used as the recipient mice for T cell-mediated colitis experiments. All mice
were on the C57BL/6 genetic background and were purchased from Jackson
Laboratory. Animals were subsequently housed, bred, and cared for according to
the institutional guidelines in the Animal Resource Facility at the University of
New Mexico, and studies were carried out in accordance with the guidelines of
the Institutional Animal Care and Use Committee (IACUC) under approved
protocols. Foxp3-IRES-GFP (Foxp3egfp) transgenic mice, which contain egfp
under the control of an IRES inserted downstream of the foxp3 coding region,
have been previously described (Haribhai et al., 2007).

Section 3.11 : G compounds and estrogen
Our lab has developed a series of small molecules that specifically target
GPER, including an agonist, G-1 (Bologa et al., 2006), and an antagonist G-15
(Dennis et al., 2009). Extensive studies will need to be conducted to determine
the potential side effects and off-target activity of the G compounds if they are to
move into pharmaceutical production. However, some studies have begun to
address these concerns. In 2009, a study demonstrating that G-1 could protect
mice against disease in the multiple sclerosis (MS) model experimental
autoimmune encephalomyelitis (EAE) reported G-1 had a greater than 1000-fold
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selectivity for GPER relative to 27 other endocrine receptors, with minimal
binding observed at a concentration of 10µM (Blasko et al., 2009). In another
study from that same year, G-1 was able to protect mice from EAE without
exhibiting many of the physiological side effects associated with estrogen
treatment, including increased uterine weight, decreased femur length, and
induction of progesterone (Wang et al., 2009a). They observed that G-1
decreased serum corticosteroid levels to a similar degree as estrogen treatment.
However, GPER plays a smaller role in the majority of classical estrogenmediated physiological responses as compared to its more well known
counterpart ERα (Prossnitz and Barton, 2009b).

Section 3.12 : Administration of compounds in vivo.
Injections: A vehicle consisting of 90% emulsion solution (PBS + 0.9% Tween20 + 0.9% BSA) and 10% ethanol was used. For delivery of compounds, E2 or
G-1 was dissolved in ethanol and added at appropriate concentrations such that
100µl per animal per injection was used. The compound was added to each
injection as part of the 10% ethanol found in the vehicle, thus it was diluted such
that less than 10µl per animal per injection was required. Injections were done in
the afternoon, and to limit stress from the long series of injections inherent to this
study, animals were sedated using isofluorane (provided by ARF) prior to
injection. Compound was delivered subcutaneously on the dorsum adjacent to
the hind limb, and the side of injection was alternated every two days.
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Pellets: For the delivery of compounds over extended periods of time, compound
was packaged into cholesterol-based pellets (Innovative Research of America)
and implanted sub-dermally in the posterior flank via incision immediately cranial
to the hind limb. The pellets were implanted one week (7 days) prior to the
animals being used in any experiment. The pellets are designed by the
manufacturer to release compound over 60 days, and for control animals pellets
devoid of compound were used.

Section 3.13 : Statistical analysis
Exclusion of data points: Any point that was determined to be greater than or
equal to 2.5 standard deviations away from the mean of a set was excluded from
the set. Standard deviation was calculated prior to removal of the data point in
question.

Calculations: Statistics were calculated using Prism 5 for Mac OS X software
(GraphPad), and some values were verified using the online studentʼs t-test tool
found

at

the

following

website:

http://www.physics.csbsju.edu/stats/t-

test_bulk_form.html. This site is provided Saint Benedict & Saint Johnʼs
University. Observations were considered statistically significant if they were
associated with a P value of less than or equal to 0.05.
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Chapter 4 : Foxp3 induction

Section 4.1 : Preface
In this first data chapter, we investigate the ability of G-1 to affect naïve T
cell differentiation, and establish it as a T cell modulating drug compound. Our
preliminary data suggest that G-1 may modulate expression and secretion of the
critical suppressive cytokine IL10, which is known to be produced by a multitude
of regulatory and effector T cell populations. Additionally, we saw that G-1 drove
IL17A expression, suggesting that it may modulate TH17 differentiation. This is
interesting considering G-1ʼs ability to suppress disease induction in an animal
model of experimental encephalomyelitis, which is heavily linked to the TH17
population. A brief review of pertinent background is presented first.

Section 4.2 : Introduction
The immune system is faced with the complex task of responding to
natures endless array of pathogenic microorganisms, many of which exhibit high
mutations rates. To meet this challenge, the adaptive immune system uses
somatic cell gene rearrangement during lymphocyte development to generate
vast repertories of unique antigen recognition receptors, including the T cell
+

recpetor (TCR). In the case of CD4 T cells, TCR activation leads to clonal
expansion and differentiation into one of three main lineages; TH1, TH2, or TH17
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cells. These divergent populations coordinate distinct immune responses through
the expression of unique mediators and signaling molecules. While effective at
itʼs purpose, this approach is marked with an inherent risk of autoimmunity
through the generation of self-reactive clones, or cells responsive to common
environmental contaminants that pose no risk to the host. In order to mitigate this
danger, the immune system has evolved a series of approaches aimed at
eliminating and/or limiting self-reactive antigen receptors and the cells bearing
them, as well as mechanisms to limit the extent of inflammation in situ. One such
mechanism is the induction of regulatory T cell populations.
+

CD4 regulatory T (TREG) cells are an eclectic population which play a
critical role in this system. The most well defined class of TREG cells express the
transcription factor Foxp3 (Fontenot et al., 2003; Hori et al., 2003; Khattri et al.,
2003). This protein is critical to immune homeostasis as loss of Foxp3 function in
both humans and mice precipitates a fatal multi-organ autoimmune condition
marked by the inability to control T cell responses (Clark et al., 1999; PateyMariaud de Serre et al., 2008). Experimentally, Foxp3

+

TREG cells suppress

numerous animal models of autoimmune disease (Yuan et al., 2007).
Conversely, excessive TREG activity has been shown to inhibit protective antitumor immune responses (Boissonnas et al., 2010; Zou, 2006) and immunity
+

against infection (Belkaid and Tarbell, 2009). Thus Foxp3 cells are a critical
point of control in many disease settings. Foxp3 expression can be elicited during
thymic development in T cell receptor (TCR) dependent fashion (Nunes-Cabaco
et al., 2010), leading to “natural” or nTREG cells. Additionally, conventional T cells
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in the periphery can be driven towards a suppressive phenotype during the
course of an antigenic immune response when stimulated in the presence of
TGFβ (Chen et al., 2003), IL2 (Fontenot et al., 2005a), IL10 (Murai et al., 2009),
IL35(Kochetkova et al., 2010), and/or retinoic acid (Elias et al., 2008), or when
antigen recognition occurs in the absence of appropriate costimulatory ligands
like CD80 and CD86 (Gottschalk et al., 2010). This leads to numerous types of
inducible regulatory T (iTREG) cell (Vignali et al., 2008), many of which express
Foxp3.
It has long been recognized that women exhibit a much higher prevalence
of numerous autoimmune diseases (Whitacre et al., 1999), with several lines of
evidence linking this observation to estrogen signaling. Recent work has
identified the G protein coupled receptor GPER as an estrogen binding receptor,
making it a third estrogen receptor identified, along with the two ligand-activated
nuclear transcription factors ERα and ERβ. This shift in paradigm is of great
interest to those seeking to target or exploit estrogens many functions for
therapeutic benefit. In light of this our group has developed a series GPERtargeted small molecules, including an agonist, G-1 (Bologa et al., 2006). In
binding assays, G-1 shows >1000-fold selectivity for GPER relative to 27 other
known endocrine receptors (including the classical estrogen receptors) (Blasko et
al., 2009), with minimal off-target binding detected at 10µM. Two reports have
shown that G-1 can suppress EAE induced with either MOG (Wang et al., 2009a)
or PLP (Blasko et al., 2009) peptide. One group found that G-1-mediated
protection was dependent on up-regulation of PD-1 within the Foxp3 population
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(Wang et al., 2009a), while the second reported that the effect was associated
with changes in the cytokine profile of macrophages (Blasko et al., 2009). Neither
group did comprehensive studies to investigate potential direct effects of G-1 on
T cell populations. These facts made G-1 an interesting compound to investigate
+

for immunomodulatory properties in the context of CD4 T cell biology.
In our preliminary work we showed that G-1 could drive production of the
TH17 associated cytokine IL17A, as well as the potent suppressive cytokine IL10
from CD4

+

T cells stimulated polyclonally in culture. Thus we wanted to
+

determine if G-1 might affect the expression of any of the CD4 lineage specific
transcription factors, namely T-bet (TH1), GATA-3 (TH2), RORγt (TH17), and
Foxp3 (TREG). Here we show that G-1 can induce Foxp3 expression in cultured
+

CD4 T cells, and enhances the suppressive function of TH17-polarizied T cells.
Given G-1 has several properties that make it attractive for rapid incorporation
into the pharmaceutical pipeline, these initial findings demonstrate that G-1 and
the other G compounds warrant further investigation for their T cell regulatory
properties, and the utility of targeting GPER in immunopathologies should be
further delineated.

Section 4.3 : Results
GPER expression in T cells
It has been reported that human regulatory T cells (Blasko et al., 2009)
and murine splenocytes (Isensee et al., 2009) express GPER. However, no

71

reports investigating GPER expression in murine CD4

+

T cells have been

published to date. To begin our studies, we sought to determine if GPER is
+

expressed within various CD4 T cell populations from C57BL/6 mice. Hence
+

+

+

lo

hi

-

CD4 Foxp3 TREGs and CD4 CD44 CD62L Foxp3 naïve T cells were sorted
by FACS from Foxp3-IRES-EGFP knockin transgenic mice (Haribhai et al.,
2007). Expression of GPER mRNA was determined by endpoint RT-PCR (Figure
12A), with GPERKO and ERαKO splenocytes serving as controls. We detected
GPER expression in both cell types. To verify that the message was being
expressed into protein, we attempted western blots with two distinct rabbit
antisera raised against short peptide sequences of GPER, one from mouse and
one from human GPER (Details are found in Appendix A). Unfortunately we were
unable to clearly corroborate protein expression of GPER as the antibodies
appeared to crossreact with a roughly 40-45 kDa protein in splenocytes from
GPERKO mice (see Figure 36E in Appendix A). As GPER has a molecular
weight of approximately 42kDa, this non-specific binding made it impossible to
adequately resolve GPER expression by western blot. Experiments using
cryosectioning of tissue and cytospinning of purified T cells were also unclear as
GPERKO cells and tissues also exhibited robust staining. Thus protein
expression of GPER could not be verified.

72

+

G-1 increases Foxp3 expression in CD4 T cells
We next turned our attention to assessing the impact of G-1 on expression
of the lineage-specific transcription factors responsible for programming the
various helper T cell sub-sets. Our preliminary data demonstrated that G-1
treatment could increase production of both IL10 and IL17A from T cells,
suggesting it may have an impact on the number of TH17 cells, and hence the
expression of RORγt (Figure 8). It is also known that estrogen can elicit IFNγ
expression (Karpuzoglu et al., 2006), and can decrease IRF1 expression, which
in theory would alleviate IFNγ-mediated suppression of IL4 (Lengi et al., 2006).
As GPER appears to act in concert with the classical estrogen receptors in some
settings (Albanito et al., 2007), it is possible that G-1 may alter the TH1-TH2 axis
that is largely regulated by IFNγ and IL4, and thus the expression of T-bet and
GATA3 (See Section 1.4). To determine if G-1 could affect the expression of the
+

canonical transcription factors by direct action on CD4 T cells, naïve T cells
were collected by FACS and stimulated ex vivo with antiCD3 and antiCD28
antibodies under TH0 conditions (meaning without the addition of exogenous
cytokines or neutralizing antibodies), either with 10nM E2, 100nM G-1, or
equivalent concentrations of DMSO. Samples were collected after 4 days in
culture and analyzed for mRNA expression of T-bet, GATA3, RORγt, and Foxp3
by qRT-PCR. As can be seen in Figure 12B, no major effects with E2 were
observed. Conversely, G-1 led to an increase in the expression of Foxp3, with no
change in the expression of the three effector T cell transcription factors noted.
The difference between treatment with estrogen and the GPER-specific agonist
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G-1 likely reflects the impact of activating the classical estrogen receptors, which
may counterbalance activation of GPER when cells are stimulated with E2.
These data suggested that G-1 could act on T cell populations to drive Foxp3
mRNA expression.
This result was interesting given the previous findings from the Offner
group, who showed that estrogen could expand the Foxp3 population in vivo
(Polanczyk et al., 2005), but G-1-mediated suppression of EAE was associated
with an increase in the expression of PD-1 on Foxp3

+

cells, rather than an

+

increase in the number of Foxp3 cells themselves (Wang et al., 2009a). To
determine if we could recapitulate our finding in vivo, male naïve Foxp3egfp mice
were treated for 7 seven consecutive days with either G-1, E2, or vehicle via
subcutaneous injection. Following treatment, mice were sacrificed and the
+

spleens were analyzed for the expression of CD4 and GFP (Foxp3) (Figure
+

13A,B). We noted a small but significant increase in the number of Foxp3 cells
+

within the CD4 compartment. The increase was similar to the increase observed
for E2-treated mice. Given the importance of PD-1 in G-1-mediated EAE
suppression, we also sought to describe any changes in the expression of PD-1.
To our surprise we were unable to detect any change in the surface expression
+

of PD-1 (Figure 13C,D) on either the total CD4 T cell population or the Foxp3

+

sub-set following treatment with G-1. It is important to note that these two results,
namely the data presented here and the data from the Offner lab, are not
necessarily incongruous. Our data were collected in naïve male mice, and we
looked specifically at the populations within the spleen, while the Offner group
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collected data from the draining lymph nodes as well as the spleen of female
EAE mice. These two settings may results in differential effects of G-1 signaling,
leading to related but distinct outcomes. Future work will be needed to address
this hypothesis.

G-1-mediated induction of Foxp3 in TH17 polarizing conditions
We hypothesized that the difference in Foxp3 and PD-1 expression in
splenocytes of naïve mice versus cells in the setting of EAE following systemic
G-1 treatment reflected the presence of TH17-polarizing conditions in the EAE
mice. This would not be unexpected as it is known that IL6, one of the cytokine
implicated in TH17 development, can inhibit Foxp3 expression (Samanta et al.,
2008). If there is a high concentration of IL6 during the preclinical stages of EAE
development it is possible that this would mask the effects of G-1 in terms of
Foxp3 induction, even without the development of overt disease. It is also
possible that the immunoprivileged environment of the CNS lacks certain key
signals that are required for G-1-mediated induction of Foxp3, although the fact
that we observed that G-1 could elicit Foxp3 expression ex vivo without the
addition of any exogenous mediators indicate this is explanation is less likely. To
determine if any of the local mediators important in TH17-like inflammation were
necessary for G-1-mediated increases in Foxp3, naïve T cells were collected by
FACS from Foxp3egfp mice and stimulated in culture as before, in the presence of
either G-1 or DMSO. In this case, cultures were supplemented with various
combinations of the key TH17-polarizing cytokines TGFβ, IL6, and IL23.
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Following 4 days in culture, cells were analyzed for the expression of GFP
(Foxp3), PD-1 and CTLA-4 by flow cytometry. Consistent with our findings in
Figure 12, we observed that G-1 treatment precipitated an increase in the
+

number of Foxp3 cells in cultures which lacked exogenous cytokines (Figure
14). We also observed that G-1 led to an increase in the number of cells
expressing Foxp3 in cultures supplemented with IL6 and IL6 + TGFβ.
Interestingly no effect was observed in cultures supplemented with TGFβ alone.
However, given the large number of cells expressing Foxp3 in these cultures
(>50%), it is possible that there are few cells remaining capable of expressing
Foxp3. Thus the loss of G-1-mediated Foxp3 induction in cultures treated with
TGFβ alone may reflect the lack of uncommitted cells capable of switching on
Foxp3 rather than any relevant alterations in signal integration related to G-1ʼs
activity. Finally, we also observed a trend towards increased numbers of Foxp3

+

cells in G-1-treated cultures supplemented with IL23, although this trend never
reached statistical significance (Figure 14).
We next sought to determine if we could observe any changes in the
expression of the inhibitory molecules PD-1 and CTLA-4 following ex vivo G-1
treatment of purified T cells cultures. Like PD-1, CTLA-4 inhibits T cell activation
and is upregulated on TREG populations. It has also been implicated in the
pathogenesis of animal models of colitis (Coquerelle et al., 2009). As before, we
utilized naïve T cell cultures purified by FACS and cultured with various
combinations of TH17-polarizing cytokines TGFβ, IL6, and IL23, in addition to
adding either G-1 or DMSO. Analysis of the entire culture showed that under TH0
76

conditions, G-1 treatment led to a modest increase in the expression of PD-1 and
CTLA-4 (Figure 15). A similar pattern was noted in cultures supplemented with
IL6, while cultures treated with TGFβ alone also demonstrated increased CTLA-4
(Figure 15). However, all observable differences were extremely small, equating
to a roughly 25% change in the expression, or less. Similarly, when we looked
+

specifically at the Foxp3 population, changes were seen exclusively in the nonpolarizing conditions (Figure 16). Again, increases in both PD-1 (Figure 16A,B)
and CTLA-4 (Figure 16C,D) were minimal, on the order of 20%.

G-1 induced Foxp3 expression occurs within hybrid T cells
The observation that G-1 can drive Foxp3 expression under TH17polarizing conditions raises the question of whether G-1 affects the expression of
the transcription factor RORγt. We didnʼt note any changes in RORγt expression
in Figure 12 under TH0 conditions, but it is possible that G-1 cannot elicit RORγt
without the addition of IL6 and TGFβ, especially given the importance of these
cytokines to activation of rorc locus. Additionally, the developing paradigm of
hybrid T cell populations, which appear to function by targeting to sites of lineage
specific inflammation, raise the question of whether G-1-mediated Foxp3
+

expression occurs within the RORγt . Therefore, naïve T cells were collected
from Foxp3egfp mice and cultured under TH17-polarizing conditions. After 4 days
in culture, cells were collected and stained for the intracellular moieties IL10,
IL17A, and RORγt, while GFP expression was again used as a surrogate for
Foxp3. Samples were then analyzed by flow cytometry. We did not observe any
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differences in RORγt expression between G-1 and DMSO treated cultures
(Figure 17). However, virtually all of the Foxp3 expressing cells fell into the
+

+

hybrid T cell category (Foxp3 RORγt ), thus G-1 treatment increased the number
of hybrid T cells in differentiating cultures of naïve T cells.

G-1 treated cells exhibit increased suppressive function ex vivo
Finally, we wanted to know if G-1 treated cells would still exhibit enhanced
suppressive function. Given that we were not observing any changes to the
expression of PD-1 or CTLA-4 when T cells were differentiated under TH17polarizing conditions (Figure 15,16), or following in vivo treatment with G-1
(Figure 13), but were able to observe increased Foxp3 expression (Figure
13,14), G-1-induced suppression would likely be through a distinct mechanism
+

from the up-regulation of PD-1 on Foxp3 cells reported in the suppression of the
TH17-mediated disease EAE. Thus naïve T cells were collected by FACS and
cultured with TGFβ + IL6 in the presence of either 100nM G-1 or DMSO.
Following 4 days of differentiation, cells were collected, washed, and used in a T
cell suppression assay with eFluor670 stained splenocytes as the responder
cells (see Chapter 3). These cultures were then stimulated with antiCD3ε
antibody for three days, and dilution of eFluor670 was determined by flow
cytometry. As can be seen in Figure 18, G-1 treated cells were able to inhibit
proliferation of the responder splenocytes more efficiently than the DMSO treated
controls, demonstrating that G-1 can enhance the suppressive function of TH17polarized T cells.
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Section 4.4 : Discussion
In this chapter, we have begun to delineate the effects of G-1 treatment on
+

the differentiation of CD4 T cell populations, and its impact on the polarization
towards different helper T cell lineages. We observed that treatment of naïve T
cells with G-1 under non-polarizing conditions (TH0 conditions) drives expression
of the canonical regulatory T cell transcription factor Foxp3, while not affecting
the expression of any of the established effector transcription factors T-bet,
GATA3, or RORγt, as determined by qPCR. Interestingly, E2 treatment did not
have the same affect, despite the evidence in the literature that it can expand the
+

Foxp3 population in vivo. Whether this is a product of the dose of E2 that we
chose to employ (10nM), or reflective of the fact that induction of Foxp3 is a
secondary effect of estrogens action within another immune population remains
unclear.
We now know that GPER is implicated in estrogen-induced immune
regulation, building on evidence for the role of ERα. One study by the Offner
group investigated the role of ERα in estrogen-induced Foxp3 expression in
CD4

+

T cells from the draining lymph nodes of EAE mice. They found that

estrogen did not increase Foxp3 expression in ERα

-/-

mice, which corroborated

previous findings that disruption of ERα was associated with a loss in E2mediated protection from EAE (Polanczyk et al., 2004a). However, these studies
only looked at Foxp3 expression by RT-PCR and western blot, which does not
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+

actually address that number of Foxp3 cells. Additionally, as mentioned in the
introduction there is compelling evidence that GPER and ERα can act in a
coordinated fashion such that loss of one moiety interferes with signaling from
the other. To further delineate the conditions in which G-1 could elicit Foxp3
expression, and ascertain as to whether increased Foxp3 mRNA reflected an
+

increase in the number of Foxp3 cells, we cultured naïve T cells from Foxp3egpf
knockin mice, which express GFP anytime the Foxp3 transcript is made. Flow
cytometric analysis of FACS purified naïve T cells stimulated in culture under TH0
conditions demonstrated that G-1 treatment led to an expansion of the number
+

Foxp3 cells, consistent with the qPCR data. These findings translated to the in
vivo setting as systemic delivery of G-1 in Foxp3egpf knockin mice drove
+

expansion of the CD4 Foxp3

+

population, without significant changes in the

+

relative percentages of CD4 cells (Figure 39, Appendix C).
In our preliminary data we noted an increase in IL17A secretion upon
+

treatment of CD4 cells with G-1. Hence, we also investigated the impact of G-1
on Foxp3 expression under TH17-polarizing conditions. Our data demonstrate
that G-1 can elicit Foxp3 expression in cultures treated with IL6 and IL6 + TGFβ.
Collectively, these data suggest; (a) that G-1-mediated Foxp3 expression
resulting from direct action on the T cell populations can occur in a variety of
inflammatory milieu, and (b) that differences in the observed in vivo effects of G-1
are not the result of variable levels of the TH17-polarizing cytokines TGFβ or IL6.
However, as we did see some instability in the induction of Foxp3 in IL23 treated
cultures (Figure 14), it is possible that stabilization of the TH17 lineage following
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prolonged exposure to IL23 (McGeachy et al., 2007; McGeachy et al., 2009;
McGeachy and Cua, 2007; Yen et al., 2006) may block G-1-mediated Foxp3
expression. This would indicate that G-1 is acting on polarized, but uncommitted,
TH17 cells to drive Foxp3 expression. This concept warrants further study.
Two previous reports demonstrated that G-1 can suppress disease in the
MS-like animal model EAE (Blasko et al., 2009; Wang et al., 2009a). In one
study, the authors found that G-1ʼs protective effects correlated with increased
PD-1 expression on Foxp3

+

TREG cells, and were dependent on intact PD-1

expression in the host animal as PD-1KO mice were not protected from disease
by G-1 (Wang et al., 2009a). However, these experiments were based on in vivo
administration of G-1, and analysis was based on experiments with cells from the
draining lymph nodes of diseased animals. Thus, it is not clear whether these
observation reflect a direct effect of G-1 driving PD-1 expression within the
Foxp3

+

population itself, or is the result of G-1 effects on another cell type,

perhaps leading to the induction of other mediators. We were unable to detect
any changes in PD-1 or CTLA-4 expression following in vivo treatment with G-1.
We were able to detect increased expression of both molecules in a few
conditions tested ex vivo, but these effects were much smaller than those
reported in the literature following in vivo G-1 treatment of EAE mice in which the
+

+

percent of Foxp3 PD-1 cells nearly doubled (Wang et al., 2009a). These effects
+

were also smaller than the 50% increase in the number of Foxp3 cells observed
in Figure 15. Additionally, no changes were detected under TH17-polarizing
conditions (TGFβ + IL6 ± IL23), suggesting that if this effect is valid it is likely the
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result of a distinct mechanism from that responsible for G-1-mediated Foxp3
expression.
We do not feel that these data represent a counterpoint to the findings of
Halina Offner and her colleagues. Rather, these results suggest that the effects
of G-1 are dependent on context, which makes sense given the variable effects
that many signaling pathways within the immune system can have, depending on
the setting in which they occur. As mentioned in the introduction, estrogens are
produced in reproductive organs, adipose tissue, and the central nervous system
(among others), and estrogen receptor deficiency is associated with both female
and male infertility (Akingbemi, 2005). We chose to use male mice in our studies
to eliminate the confounding effects of surgery (ovariectomy) and/or high levels
of endogenous estrogens found in female mice. However, an important caveat to
this approach is that the findings herein may not be recapitulated in female mice.
Thus some of the differences that we noted from other published work, namely
the induction of Foxp3 expression with only small changes to PD-1 expression,
may in fact represent a sexual dimorphism of GPER signaling. Moreover,
previous studies have focused on Foxp3 expression within the setting of EAE.
Thus it remains possible that a GPER signaling could also pay a role in estrogeninduced Foxp3 expression, in particular in settings outside of EAE. Studies with
other animals models of disease will be needed to address this hypothesis.
The data from the T cell suppression assay showed that G-1 induced
Foxp3 expression correlated with increased suppressive function ex vivo.
However, it should be noted that the results from this assay were highly variable,
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and further studies will be needed to determine the veracity of these results
(Figure 18 is only one example from four independent experiments, and
exhibited the most robust response we saw). Moving forward, it would be
instructive to test the effects of neutralizing PD-1 to compare results, so as to
verify that G-1-induced suppression is indeed independent of PD-1 signaling, as
suggested by our data showing the absence of changes to PD-1 expression in G1 treated cultures. Also, it was recently noted that GPER is required for
suppression of EAE by oral ethinyl estradiol (Yates et al., 2010). It is possible
that G-1 induced changes in T cell cytokine secretion are responsible for the ex
vivo suppressive activity, especially given our preliminary data which shows that
+

G-1 can elicit IL10 production from CD4 cells (Chapter 2). Interestingly, we also
noted an increase in IL17A production from G-1 treated cultures (See preliminary
data Figure 8-10). While classically thought of as a proinflammatory cytokine,
several reports have demonstrated that IL17A can serve in an anti-inflammatory
capacity in several setting, including in the induction of atherosclerosis (AitOufella et al., 2010; Taleb et al., 2009) and colitis (O'Connor et al., 2009).
Moreover, it appears that some of the in vivo suppressive activity associated with
+

IL17A production can be attributed to autocrine activity directly on the CD4 T
cell populations themselves, as the adoptive transfer of IL17A receptor knockout
T cells was associated with more severe disease in an animal model of colitis
(O'Connor et al., 2009). Thus increased IL10 or IL17A secretion could play a part
in G-1ʼs enhancement of T cell suppressive function. The work in Chapter 5 and
Chapter 6 attempt to build upon this idea.
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Section 4.5 : Conclusions
We provide evidence that the GPER-directed small molecule G-1 can elicit
Foxp3 expression within CD4

+

T cells, and expand the precentage of cells

expressing Foxp3 in vivo. We also noted no major changes in the expression
levels of the well-characterized inhibitory receptor PD-1 following in vivo or ex
+

+

+

vivo treatments of G-1 on the total CD4 populations or on CD4 Foxp3 TREGs.
Our results vary from previously published report that demonstrated G-1 can
increase the surface expression of PD-1 in Foxp3

+

regulatory T cells in the

setting of experimental encephalomyelitis, suggesting the G-1 exhibits contextspecific effects on immune populations. These data demonstrate that further
study of G-1s immunomodulatory properties are necessary to fully elucidate the
full scope of its therapeutic potential, including a detailed study of its effects of T
cell populations.
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Section 4.6 : Figures

Figure 12 : GPER expression in T cells, and G-1 induction of Foxp3 mRNA.
+

+

+

hi

lo

-

CD4 GFP natural regulatory T cells and CD4 CD62L CD44 GFP naive T cells were collected
egfp
by FACS from male Foxp3
mice and were; (A) analyzed for GPER and GAPDH expression by
RT-PCR, or (B) where cultured with antiCD3ε and antiCD28 antibody for 4 days then analyzed for
expression of the canonical CD4+ T cell transcription factors T-get, GATA3, RORγt, and Foxp3 by
qRT-PCR. (B) Summary of the means from 4 independent experiments. P values determined by
studentʼs t-test. Error bars = S.E.M. These data were collected by Kristin Owens.
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Figure 13 : In vivo treatment with G-1 increases Foxp3 expression, but not PD-1.
egfp

Seven to eleven week old male Foxp3
mice were injected with 17β-estradiol (E2 - 0.5µg/day) ,
G-1 (5µg/day) or vehicle for 7 consecutive days. One day following the last injection, single cell
suspensions were made from spleen. Cell were then stained for CD4, PD-1, and CTLA-4 and
+
analyzed by flow cytometry. (A) Individual dot plots showing GFP (Foxp3) expression in CD4 T
cells from the spleen of vehicle or G-1 treated mice, with each square representing one mouse.
Summary of all data collected from the spleen showing; (B) the percent of CD4+ cells expressing
+
+
+
Foxp3, (C) the percent of either CD4 or CD4 Foxp3 cells expressing PD-1, or (D) the GMFI of
+
+
+
PD-1 on CD4 Cells or CD4 Foxp3 cells. P values determined by studentʼs t-test. Error bars =
S.D.
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Figure 14 : G-1 treatment of naïve T cells increases Foxp3 expression.
+

hi

lo

egfp

CD4 CD62L CD44 naive T cells from Foxp3
mice were collected by FACS and cultured for 4
days in the conditions indicated. Individual wells were supplemented with either 100nM G-1
(Black bars) or DMSO (White bars). GFP (Foxp3) expression was assessed by flow cytometry.
(A) Representative plots and (B) summarized data from three to four independent experiments is
shown, with conditions for both panels indicated at the bottom of the figure. P values determined
by studentʼs t-test. *** = P < 0.0005, ** = P< 0.005, * = P < 0.05, N.S. = not significant. Error bars
= S.D.
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Figure 15 : G-1 treatment has minimal effect on PD-1/CTLA-4 expression.
+

hi

lo

egfp

CD4 CD62L CD44 naive T cells from Foxp3
mice were collected by FACS and cultured for 4
days in the conditions indicated. Individual wells were supplemented with either 100nM G-1 (black
bars) or DMSO (white bars). Cells were then stained for PD-1 and CTLA-4 then analyzed by flow
cytometry. Representative histograms from the total population are included for PD-1 (A) and
CTLA-4 (C), with the isotype control (shaded region in gray), DMSO treated cells (Gray line
without shading) and G-1 treated cells (Black line) shown. Data for geometric mean fluorescence
intensity (GMFI) for PD-1 expression (B) and CTLA-4 expression (D) are summarized from three
independent experiments. P values determined by studentʼs t-test. * = P < 0.05. N.S. = not
significant. Error bars = S.D.
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Figure 16 : G-1 has minimal effect on PD-1/CTLA-4 expression on TREG cells.
+

hi

lo

egfp

CD4 CD62L CD44 naive T cells from Foxp3
mice were collected by FACS and cultured for 4
days in the conditions indicated. Individual wells were supplemented with either 100nM G-1 (black
bars) or DMSO (white bars). Cells were then stained for PD-1 and CTLA-4 then analyzed by flow
cytometry. Representative histograms from the Foxp3+ population are included for PD-1 (A) and
CTLA-4 (C), with the isotype control (shaded region in gray), DMSO treated cells (Gray line
without shading) and G-1 treated cells (Black line) shown. Data for geometric mean fluorescence
intensity (GMFI) for PD-1 expression (B) and CTLA-4 expression (D) are summarized from three
independent experiments. P values determined by studentʼs t-test. * = P < 0.05. N.S. = not
significant. Error bars = S.D.
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Figure 17 : G-1 treatment of naïve T cells expands the hybrid population.
+

hi

egfp

CD4 CD62L naive T cells from Foxp3
mice were collected by FACS and cultured for 4 days
with TGFβ + IL6, supplemented with either 100nM G-1 or DMSO, as indicated. Cells were then
stained for RORγt and IL17A. (A) A representative histogram showing the gating for determining
hybrid T cells is. (B) Summary of data from five experiments showing the relative percent of
hybrid T cells in DMSO versus G-1 treated cultures. (C) Representative plots from one of two
independent experiments done in triplicate showing IL17A and Foxp3 staining. P values
determined by studentʼs t-test. Error bars = S.D.
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Figure 18 : G-1 treated T cells exhibit enhanced suppressive activity in vitro.
+

hi

egfp

CD4 CD62L naive T cells from Foxp3
mice were collected by FACS and cultured for 4 days
with TGFβ + IL6, supplemented with either 100nM G-1 or DMSO, as indicated. Cells were then
collected, washed, and used as regulatory T cell in an in vitro T cell suppression assay. For
responder cells, splenocytes from male wild-type C57BL/6 mice were collected and stained with
the proliferation dye eFluor670 (eBiosciences). Cells were mixed in the ratios indicated and
stimulated with antiCD3ε Ab. After 3 days in culture, samples were analyzed for dilution of
eFluor670 by flow cytometry. Example from one of four independent experiments. Statistics
determined by studentʼs t-test and 2-way ANOVA test. * = P < 0.05 (studentʼs t-test). N.S. = not
significant. Error bars = S.D.
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Chapter 5 : ERK-dependent IL10 induction

Section 5.1 : Preface
In this chapter, we investigate the role of GPER in altering cytokine
production from T cell populations (Aim 2). This builds on the data presented in
+

Chapter 4, wherein G-1 led to an increase in Foxp3 expression within CD4 T
cells. While Foxp3 expression imparts a suppressive phenotype on cells in which
it is expressed, other secreted factors, including cytokines and chemokines, are
also important in regulating immune reactions. Thus in order to build a more
comprehensive picture of G-1ʼs activity in T cell populations, we decided to
investigate the ability of G-1 to modulate the production of several key cytokines,
including IL10, IL17A, and IFNγ, under conditions that drive differentiation of the
TH17 lineage. The introduction starts with a short review of the various helper T
cell lineages, and the contextual framework from which they are characterized.
Some review of IL10 function, and estrogen and G-1 in immunity, follows.

Section 5.2 : Introduction
CD4+ helper T lymphocytes orchestrate adaptive immune responses to
invading pathogens, and are critical to the pathogenesis of numerous disease
processes, including autoimmunity and cancer. They are an attractive drug target
due to their central role in immunity, and their implication in a wide variety of
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diseases. There are several distinct lineages of CD4

+

helper T cell, each

specialized in enhancing specific branches of the immune system. The original
paradigm described by Coffman and Mossman divided CD4

+

helper T

lymphocytes into the T-helper-1 (TH1) and TH2 populations (Mosmann and
Coffman, 1989), with TH1 producing IFNγ and coordinating cellular immunity
responses and TH2 secreting humoral immunity mediators such as IL4, IL5, and
IL13. In 2005, the TH1-TH2 paradigm was expanded as the TH17 population
emerged as a third class of helper/effector T cell. TH17 cells are characterized by
expression of the transcription factor RORγt (Harrington et al., 2005; Ivanov et al.,
2006), and secrete pro-inflammatory cytokines including IL21 (Wei et al., 2007)
and IL17A/F. These cells are important to controlling infections by extracellular
pathogens, but also play a deleterious role in human health by contributing to the
pathogenesis of numerous autoimmune diseases (Torchinsky and Blander,
2010). In mice, TH17 differentiation depends on TGFβ and IL6 or IL21 within the
local milieu (Torchinsky and Blander, 2010), while IL23 signaling plays a critical
role in stabilizing the TH17 phenotype (McGeachy et al., 2009). Although TH1,
TH2, and TH17 effector T cells coordinate a robust and diverse arsenal of
adaptive immune responses necessary for the maintenance of human health,
mechanisms of restraint must limit effector responses to protect the host from
immune-mediated damage.
A major breakthrough in elucidating the mechanisms of adaptive immune
regulation emerged with the identification of an array of regulatory T cell (TREG)
populations. The best defined class of TREG cells express the forkhead
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transcription factor Foxp3 and suppress numerous animal models of autoimmune
disease (Vignali et al., 2008), whereas loss of Foxp3 function in humans and
mice precipitates a fatal multi-organ autoimmune condition marked by the
inability to control T cell responses (Clark et al., 1999; Patey-Mariaud de Serre et
al., 2008). TREGs function to dampen immune responses through a variety of
approaches, including contact-mediated inhibition, secretion of perforin and
granzyme A/B, sequestration of key growth factors such as IL2, and secretion of
suppressive cytokines including TGFβ, IL10, and IL35 (Vignali et al., 2008). IL10
in particular plays an important role in immune homeostasis, both in mice (Kuhn
et al., 1993) and humans (Glocker et al., 2009), suggesting it has several nonredundant roles in regulating inflammatory responses. Many cell types in addition
+

to Foxp3 cells (Saraiva and O'Garra, 2010) can produce IL10, most notably
+

several lineages of CD4 T cells (Saraiva et al., 2009), including TH1 (Del Prete
et al., 1993; Jankovic et al., 2007; Meyaard et al., 1996), TH2 (Del Prete et al.,
1993; Fiorentino et al., 1989), and TH17 (Fitzgerald et al., 2007; McGeachy et al.,
2007; Stumhofer et al., 2007) cells, as well as various types of regulatory T cells
(Maynard and Weaver, 2008). In a feed forward mechanism, IL10 can drive itʼs
own expression through the induction of an IL10-producing TREG population
termed Tr1 cells (Battaglia et al., 2006; Roncarolo et al., 2006). Conversely, IL10
+

can also be induced independently of IL10 signaling in both Foxp3 and Foxp3

-

TREG populations (Maynard et al., 2007). Studies using conditional knockout mice
have begun to identify specific roles for IL10 produced by distinct T cell
populations. For example, loss of IL10 production in Foxp3
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+

TREGs leads to

inflammation within the wall of the gut (Rubtsov et al., 2008). IL10 acts on antigen
presenting cells to downregulate expression of costimulatory molecules and
decrease their production of proinflammatory cytokines, in addition to acting on T
cell themselves (Moore et al., 2001). Given its potent anti-inflammatory effects,
various strategies are being explored to target IL10 for therapeutic intervention
(O'Garra et al., 2008).
Estrogen is a well-documented modulator of immune function in humans
and mice, capable of increasing the expression of Foxp3 (Polanczyk et al., 2005)
and IL10 (Yates et al., 2010). These effects translate to human disease wherein
multiple sclerosis (MS) patients experience a decrease in symptoms during
pregnancy (Confavreux et al., 1998), and to murine models of autoimmune
disease where estrogen inhibits development of experimental autoimmune
encephalomyelitis (EAE) (Wang et al., 2009a), an animal model of MS. Although
the effects of estrogen are presumed to be mediated by the classical estrogen
receptors, ERα and ERβ, recent studies have pointed to the newly described G
protein-coupled estrogen receptor GPR30/GPER as contributing to many of
these responses. We and others have recently shown that, like E2, the GPERselective agonist G-1 can attenuate EAE (Blasko et al., 2009; Wang et al.,
2009a). In the current work we show that G-1 can evoke IL10 expression and
secretion from CD4+ T cells differentiated under TH17-polarizing conditions. G-1mediated IL10 expression was blocked by the GPER-directed antagonist G15
(Dennis et al., 2009), and was dependent on ERK signaling, consistent with
known mechanisms of IL10 production within effector T cell populations (Saraiva
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and O'Garra, 2010). Analysis of IL17A, Foxp3 and RORγt expression
demonstrated that these responses occurred in cells expressing both IL17A and
+

+

RORγt, as well as in a population of Foxp3 RORγt hybrid T cells. G-1-mediated
IL10 expression was blocked by the GPER-directed two antagonists, G15
(Dennis et al., 2009) and the unpublished compound G36. However, the use of T
+/-

cells from GPER

-/-

and GPER

mice yielded unexpected results as G-1

appeared to have no effect on cells derived from heterozygous mice, while cells
from knockout mice appeared to exhibit a similar trend as was observed in wild
types. Taken together, our results demonstrate a novel immunomodulatory
property for G-1, and suggest that this small molecule may serve as a model
compound for a new class of T cell-targeted pharmaceuticals. In addition, these
data suggest that the family of GPER-directed small molecules may serve as
model compounds for a new class of T cell-targeted pharmaceuticals in the
treatment of autoimmune disease and cancer. However, more elegant studies
are going to be required to delineate the role of GPER and/or other cellular
targets in our observed G-1-mediated effects, as well as any effects of other G
compounds.

Section 5.3 : Results
+

G-1 elicits IL10 in CD4 cells under TH17 polarizing conditions
As in chapter 4, in order to investigate the direct effects of G-1 on CD4+ T
cells, we chose to utilize purified cultures of naïve T cells activated by polyclonal
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stimulation with antiCD3ε and antiCD28 antibody. This eliminated secondary
effects due to the activity of G-1 on APCs within the culture. Furthermore, primary
cells from male mice were used throughout the study to avoid potential
confounding effects of either; (a) varying estrogen levels in female mice, or (b)
the

inflammatory
+

lo

CD4 CD44 CD62L

effects
hi

of

ovariectomy.
+

We

have

also

shown

that

+

naïve T cell and CD4 Foxp3 TREG populations express

the G-1 target GPER (Section 4.3).
Given our preliminary findings wherein G-1 drove expression of IL10 and
IL17A, and given that G-1 can protect mice from EAE (Blasko et al., 2009; Wang
et al., 2009a) and the importance of the TH17 lineage to this model (Ivanov et al.,
2006), we began by determining the effects of G-1 on naïve T cell differentiation
under TH17-polarizing conditions (TGFβ/IL6 ± IL23). Thus, naïve T cells from 711 week old male C57BL/6 mice were collected by FACS and stimulated for 4
days ex vivo, supplemented with various combinations of TGFβ, IL6, and IL23.
Following 4 days of stimulation, cells were analyzed for expression of IFNγ,
IL17A, and IL10 by intracellular cytokine staining (ICS). Expression of IL10 was
present exclusively in cultures treated with IL6 (Figure 19A), consistent with
previous findings using ex vivo culture systems where treatment with TGFβ alone
blocks IL10 expression in differentiating CD4+ T cells (Saraiva et al., 2009), and
efficient induction of IL10 secretion from TH17-polarized cells requires both TGFβ
and IL6 (McGeachy et al., 2007). As expected, IL17A expression was dependent
on TH17-polarizing conditions [i.e. treatment with both TGFβ and IL6 (Figure
19A-C)], and was enhanced by the addition of IL23. G-1 treatment resulted in an
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increase in the number of IL10+ cells within TH17-polarized cultures (Figure
19B), as well as in the presence of IL23 (Figure 19C), which is known to be
important in stabilizing the phenotype of TH17 populations. G-1-mediated IL10
expression was not reflective of a general effect on cytokine production as no
+

increase in the number IL17A cells was observed in either condition (Figure
19B,C). In addition, G-1 had no effect on IFNγ expression in cultures stimulated
+

with CD3/28 alone (Figure 19D); however, few IFNγ cells were detected in the
other culture conditions tested (Figure19D, 20).
+

To determine whether the increased numbers of IL10 cells translated into
a specific increase in the secretion of IL10 from G-1 treated cultures, naïve T
cells were collected and stimulated as above, in the presence of TGFβ and IL6.
After 4 days of differentiation, DMSO and G-1 treated cells were collected,
washed with medium to remove any cytokines released over the course of
differentiation, and re-plated. Cells were then re-stimulated with anti-CD3ε Ab for
24 hours, after which culture medium was analyzed for the presence of newly
secreted IL6, IL10, IL17A, TNFα, and IFNγ by Luminex multiplex assay. Cells
differentiated in the presence of G-1 produced approximately three-fold more
IL10 that control cultures (Figure 21A), consistent with our observation that G-1
increased the number of IL10-producing cells. No difference in the secretion of
IL6, IL17A, TNFα, or IFNγ was detected (Figure 21B-E), again suggesting that
G-1 was specifically driving the production of the anti-inflammatory cytokine IL10,
and not proinflammatory mediators such as IL17A and IFNγ. Taken together,
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these data show that G-1 can specifically drive IL10 expression within and
+

secretion from CD4 T cell populations.

+

+

+

-

Induction of an IL10 IL17A and IL10 IL17A population by G-1
As G-1-induced IL10 expression was dependent on TH17-polarized
conditions, we sought to determine the relationship of G-1-induced IL10+ cells to
those expressing the characteristic TH17 cytokine IL17A. Thus, naïve T cells
were again collected by FACS and polyclonally stimulated in the presence of
TGFβ and IL6. Cells were cultured with increasing doses of G-1 and analyzed for
IL17A and IL10 by ICS (Figure 22). Our data reveal a dose-dependent increase
+

-

+

+

in the number of IL10 IL17A (Figure 22A, B) and IL10 IL17A cells (Figure
22A, C) within G-1-treated cultures. A similar trend was observed under IL23
polarizing conditions (Figure 19A and data not shown). In addition, G-1mediated IL10 expression was blocked by the recently described GPER
antagonist G15 (Dennis et al., 2009) or G36 (manuscript in preparation) (Figure
+

+

23). Furthermore, the induction of a population of IL10 IL17A cells suggests that
G-1 can elicit IL10 expression within cells that have differentiated to the TH17
lineage. Taken together, these data show that G-1 can elicit IL10 production
within the TH17 compartment, a response that is blocked by preincubation with
the GPER antagonists G15 and G36.
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ERK signaling is critical for G-1-mediated IL10 expression
IL10 production within TH populations has been shown to be dependent on
signaling through extracellular signal-regulated kinases (ERK1/2) (Saraiva et al.,
2009; Saraiva and O'Garra, 2010), one of three MAP kinase cascades, the
others comprising JUN N-terminal kinases (JNK1/2) and p38. GPER has been
shown to activate the ERK pathway, although predominantly in cancer cells
(Filardo et al., 2000). To test whether G-1-mediated induction of IL10 was
dependent on MAP kinase signaling, naïve T cells were treated with either
PD98059, an inhibitor of the ERK pathway, SB203580, an inhibitor of the p38
pathway, or the JNK II inhibitor, and stimulated under TH17-polarizing conditions
as before. Consistent with other published reports (Saraiva et al., 2009), we
found that inhibition of p38 had no effect on IL10 expression in TH17-polarized
cells. Similarly, JNK signaling appeared not to be required for G-1-mediated
induction of IL10 (Figure 24A). In contrast, there was no difference in the number
of IL10

+

cells observed between control and G-1-treated cultures when cells

were cultured with the ERK inhibitor PD98059 (Figure 24A-C), consistent with a
role for ERK signaling specifically in G-1-mediated IL10 induction. Of note,
+

+

PD98059 prevented expansion of both the IL10 IL17A

+

-

and the IL10 IL17A

populations (Figure 24C). These data demonstrate that G-1 mediates IL10
expression by increasing ERK signaling in CD4+ T cells.
The ERK pathway is known to be a potent activator of cell proliferation. To
determine if G-1-mediated increases in IL10 were the result of increased
proliferation of cells expressing IL10 rather than induction of IL10 de novo, naïve
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T cell were stained with the proliferation dye eFluor670 prior to stimulation in
culture. We were unable to detect any significant difference in the proportion of
dividing cells following G-1 treatment. The observation that G-1 treated cultures
demonstrated attenuated dilution of the eFluor dye as compared to the DMSO+

treated cultures (Figure 25) indicates that the increased number of IL10 cells
following G-1 treatment is not due an increase in cell proliferation, and in fact
show that proliferating cells are going through fewer divisions when treated with
G-1, perhaps due to the action of IL10. In addition, the dramatic increase in the
number of non-dividing cells expressing IL10 in some G-1 treated cultures (as
indicated in the upper right quadrant in Figure 25B) suggests that G-1 can
specifically drive expression of IL10 independent of cell division. Taken together,
these data show that G-1 stimulates de novo IL10 expression within
differentiating TH17 through direct action on T cells via an ERK-dependent
mechanism.

IL10-induction occurs within a hybrid T cell population
An emerging paradigm in T cell biology is the induction of “hybrid” T cell
populations that express one of the canonical effector T cell transcription factors
(for example T-bet from the TH1 lineage) as well as Foxp3 (Barnes and Powrie,
2009). These cells appear to play a role in the regulation of specific types of
inflammatory responses, where the expression of Foxp3 imparts a suppressive
phenotype, and the expression of the lineage-specific factor such as T-bet leads
to a repertoire of gene products (e.g. chemokine receptors) that allow for
101

targeting to sites of inflammation. Presumably, this provides a mechanism for the
recruitment of regulatory T cells to sites of ongoing inflammatory responses. To
investigate the expression of Foxp3 together with RORγt, naïve T cells were
collected from Foxp3egfp transgenic mice (Haribhai et al., 2007). Cells were
stimulated for 4 days in the presence of TGFβ and IL6 with or without G-1 added
to the culture. Following differentiation, IL10, IL17A, RORγt, and Foxp3 were
analyzed by ICS or detection of endogenous GFP expression by flow cytometry.
-

+

G-1 was equally effective at inducing IL10 production within Foxp3 RORγt TH17
+

+

cells as in Foxp3 RORγt hybrid T cells (Figure 26). The TH17 subset saw an
+

+

+

-

+

-

increase in both IL10 IL17A and IL10 IL17A cells, while only IL10 IL17A cells
were detected in the hybrid T cell population. In fact no IL17A+ cells were present
in the Foxp3+ population (Figure 26). These data demonstrate the ability of G-1
to induce IL10 within the recently described hybrid TH17 population in addition to
-

+

conventional (Foxp3 RORγt ) TH17 cells.

Splenocytes from GPER

-/-

mice produce less IL17A and IL10

To begin to determine if our results in discussed so far translated to the
-/-

setting of intact animals, GPER

mice were treated with E2 in vivo, and

splenocytes were collected for ex vivo analysis. As we were interested in looking
at cytokine production specifically from T cell populations, the splenocytes were
stimulated with antiCD3ε and antiCD28 antibodies, which, as mentioned
previously, activates T cells by mimicking antigen presentation. Cells were
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stimulated for 48 hours after which cell free culture medium was analyzed for a
series of cytokines by Luminex Multiplex assay (Figure 27 and Appendix D).
Several trends were observed, including drastic reductions in the production of
-/-

IL4, IL10, and IL17A from GPER

splenocytes. The reduction in IL4 is interesting

because of previous work demonstrating the E2 can elicit IL4 production,
possibly by alleviating IFNγ-induced suppression of the il4 locus (Lengi et al.,
2006). However, the fact the IL13 production from these same cells is not
affected by a lack of GPER suggests that GPER was not involved in TH2
differentiation. Of note, another TH2 cytokine, IL5, also appeared to be affected
by the loss of GPER (Appendix D). The loss of IL17A and IL10 production in
-/-

GPER

cells was also interesting as both cytokines are elicited by the

combination of IL6 and TGFβ signaling during TH17 differentiation (McGeachy et
al., 2007), and G-1 can attenuate the TH17-dependent disease model EAE
(Blasko et al., 2009; Wang et al., 2009a).
The fact that a loss of GPER expression can lead to decreased IL10 and
IL17A expression suggests that systemic treatment with the GPER-directed
agonist G-1 should be able to stimulate production of these cytokines following T
cell activation. Moreover, our results leading up to these in vivo studies show that
treatment of naïve T cells with G-1 in culture can lead to increased IL10
expression and secretion. To determine if these findings translated to in vivo G-1
treatment, wild-type mice were injected subcutaneously with G-1 for 7
consecutive days, after which they were sacrificed and splenocytes were
stimulated in culture with antiCD3ε and antiCD28 antibodies. Samples of
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supernatant were collected 24, 48, and 72 hours after stimulation and analyzed
for secreted IL6, IL10, IL17A, IFNγ, and TNFα by Luminex multiplex assay. No
trends were observed for any of the analytes following 24 hours of stimulation
(Figure 28). In agreement with our results with cultured naïve T cells, cells from
G-1 treated mice secreted increased levels of IL10 (Figure 28A). Notably, we
also observed that splenocytes from G-1-treated mice secreted increased levels
of IL17A (Figure 28B). This varied from our findings in Figure 19, wherein no
+

increase in the number of IL17A cells was observed, and Figure 21 were naïve
T cells cultured with G-1 produced similar levels of IL17A as compared cells
treated with DMSO. However, these data reflect our observations following E2
-/-

treatment in GPER

mice (Figure 27). Moreover, we were able to detect G-1-

mediated IL17A induction within naïve T cells under specific experimental
conditions. For example, stimulation of naïve T cells in culture with TGFβ alone
+

showed that G-1 could elicit a small increase in the number of IL17A

cells

(Figure 29A). These results are also in agreement with data described within our
preliminary data, where G-1 treatment

led to a sequential increase in IL17A
+

and IL10, respectively, in cultures of enriched CD4 T cells (see Chapter 2). A
portion of this same data is showing the trend of IL17A production from G-1
treated cells versus untreated cells has been re-graphed in Figure 29B. We also
+

noted that only IL17A secretion from enriched CD4 T cells is altered, not IL4 or
IFNγ (Figure 29C). The difference in the temporal dynamics of those results and
the data reported here following in vivo G-1 treatment are likely due to the
presence of numerous other immune populations within the unsorted splenocyte
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cultures, and may also reflect differences in systemic treatment with G-1 relative
to co-culture ex vivo. Therefore our observations that systemic G-1 enhances
TCR-mediated IL17A secretion likely reflects the variable nature of the in vivo
environment, or perhaps secondary effects resulting from activity on other
immune

populations.

In

addition,

IL17A

has

been

show

to

exhibit

immunosuppressive properties in several settings, including in the development
of atherosclerosis (Ait-Oufella et al., 2010; Taleb et al., 2009; Taleb et al., 2010)
and the induction of T cell mediated colitis (O'Connor et al., 2009). Moreover,
cells treated with TGFβ + IL6 have been shown to exhibit bystander suppressive
effects in EAE, despite producing higher levels of IL17A (McGeachy et al., 2007).
As there appeared to be no induction of IL17A when exogenous IL6 was added
to the culture, it is also possible that the setting of the CNS does not provide the
appropriate conditions required for G-1-mediated IL17A induction. Thus the
induction of IL17A is reconcilable to its ability to attenuate EAE, despite the
established importance of TH17 cells to EAE induction (Cua et al., 2003; Ivanov
et al., 2006; Langrish et al., 2005), and the fact that systemic neutralization of
IL17A/F attenuates clinical symptoms in this model (Hofstetter et al., 2005).
Conversely, splenocytes from G-1 treated mice produced decreased levels of
IFNγ relative to those that were treated with vehicle alone (Figure 28C),
suggesting that in addition to driving production of IL10 and IL17A, G-1 may act
systemically to reduce the levels of IFNγ. No changes in the secretion of TNFα
(Figure 28D) or IL6 (Figure 28E) were noted, in agreement with our findings
from Figure 21. Collectively, these data suggest that pharmacological stimulation
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of GPER in vivo leads to an increase in the production of the cytokines IL10 and
IL17A, and decreased production of the proinflammatory cytokine IFNγ following
T cell activation.

G-1 exhibits unexpected activity in GPER

-/-

cells

G-1 was originally described as an agonist directed towards GPER, and
we saw in previous findings from this chapter that the GPER-directed antagonists
G15 and G36 could block G-1-mediated IL10 expression (Figure 23). To
determine if our observations were in fact due to signaling through GPER, naïve
+/-

-/-

T cells were collected simultaneously from GPER

and GPER

mice, then

treated in culture as before. To our surprise, we observed no G-1-mediated
+/-

induction of IL10 expression in cells derived from GPER
+

+

mice. Conversely, G-1
+

treatment led to increased number of IL10 and IL10 IL17A cells within cultures
-/-

of GPER

T cells. This result repeated to varying degrees in three independent

experiments (Figure 30). As in Chapter 4, the reasons for this observation are
not clear, but it is possible that the role of GPER in thymic T cell development
contributes (Wang et al., 2008). Irrespective of the basis for this observation,
these data cast doubt over the actual target of G-1 in the data presented, despite
-/-

the correlation between the findings outline above with GPER

mice and
-/-

systemic G-1 treatment. Unfortunately, the question of G-1 treatment in GPER

mice was not addressed in these studies, but should be a priority for future work.
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Section 5.4 : Discussion
+

CD4 T cells play a critical role in the pathogenesis of many of the most
prominent diseases of the Western world, including cancer, autoimmunity, and
infectious disease. The cytokine IL10 is a potent suppressor of immune
responses, capable of acting on a multitude of cells types to dampen
inflammatory responses and limit host damage to infection and autoimmune
disease. In this chapter, we demonstrated that in vivo treatment with the GPERdirected agonist G-1 can drive IL10 production from splenocytes following T cell
activation. Furthermore, our findings with purified cultures of naïve T cells
+

suggests that these observations are due to the direct action of G-1 on CD4 T
cell populations themselves, as treatment with G-1 drove IL10 production from
TH17-polarized naïve T cell populations. We observed an increase in the number
of cells expressing IL10 within the G-1-treated cultures, as measured by ICS.
This response was not due to global changes in cytokine production as G-1 had
no effect on the expression of IL17A under TH17-polarizing conditions, or in the
induction of IFNγ in non-polarizing (TH0) conditions. Results from ICS translated
into increased cytokine secretion. G-1-treated cultures of purified T cells
produced three-fold more IL10 in response to re-stimulation compared to
controls, with no significant change in the secretion of proinflammatory cytokines
IL6, IL17A, TNFα, or IFNγ, demonstrating high selectivity for the mechanism of
immune regulation by G-1. Similarly, systemic administration of G-1 had no effect
of IL6 or TNFα secretion. Interestingly, we did note increased secretion of IL17A
following in vivo treatment with G-1, while also observing a decrease in the
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production of IFNγ. The difference in IL17A and IFNγ regulation following
systemic G-1 treatment as compared to our the results from purified T cell
cultures may reflect effects of G-1 on other immune populations following in vivo
treatment. Another possibility would be that G-1-mediated IL10 production is
elicited during the week long injections of G-1, leading to inactivation splenic
APCs and a decrease in the secretion of TH1-polarizing cytokines like IL12, and
thus lower IFNγ production. It is worth noting that in our preliminary data we
observed increases in both IL10 and IL17A production with G-1 treatment in
+

enriched cultures of CD4 T cells, and in some experiments with the purified
+

cultures of naïve T cells G-1 increased the number of IL17A cells. Thus it seems
+

as though G-1 can drive IL17A expression by acting directly on CD4 T cells in
some settings. Future studies will be required to clearly elucidate the contextual
framework required. Such studies may prove valuable in determining G-1ʼs
potential as a therapeutic, as IL17A can act in both a pro- and anti-inflammatory
capacity (O'Connor et al., 2010).
These results build upon previous studies that demonstrate G-1 can
influence immune responses under autoimmune conditions (Blasko et al., 2009;
Wang et al., 2009a; Wang et al., 2008). TH17 cells are implicated in the
pathogenesis of numerous autoimmune diseases and are localized in high
numbers to sites of autoimmune inflammation. Our data suggest that it may be
possible to induce IL10 in situ where large numbers of TH17 cells persist, through
systemic treatment with G-1. That this may be a feasible therapeutic approach is
suggested by experiments in which co-injection of IL10-producing cells
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differentiated in the presence of TGFβ and IL6, as was done here, inhibits the
development of EAE following adoptive transfer of neuropeptide-reactive TH17
cells (McGeachy et al., 2007). This effect was dependent on IL10 production
(McGeachy et al., 2007) and suggests that such cells can inhibit fully
differentiated pathogenic T cell populations through the secretion of IL10 in situ,
as would likely be required in the case of a viable therapeutic intervention based
on the findings of our study.
Our findings also suggest that GPER-mediated induction of IL10 may play
a role in estrogenʼs ability to suppress autoimmune diseases. Two previous
reports demonstrated that G-1 can suppress disease in the MS-like animal model
EAE (Blasko et al., 2009; Wang et al., 2009a). In one study, the authors also
observed increased IL10 production from G-1-treated splenocytes collected from
diseased animals as compared to placebo controls (Wang et al., 2009a). This
correlated well with our results in Figure 28, where we observed increased IL10
production following ex vivo stimulation of splenocytes derived from G-1 treated
mice. Interestingly, in our work we also noted increased IL17A and decreased
IFNγ secretion from G-1-treated splenocytes, which stands in contrast to the
findings in the report discussed above, where the opposite trend was detected in
the draining lymph nodes of EAE mice treated with G-1. They also noted an
increase in IL6, while no observable difference was detected in our experiments.
As was the case in Chapter 4, whether these differences are the result of
effects on other cell types or differential expression of other immune mediators
requires further investigation. The fact that our work was done in male mice and
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the previous report was done in female mice may also have contributed to
differences between our results and previous observations. It is also possible that
G-1 has divergent effects on T cells depending on the context in which it is
acting, and perhaps the inflammatory environment of the CNS provides the
appropriate context to precipitate G-1-mediated induction of PD-1. This would
explain the differences between our results following systemic G-1 treatment in
naïve mice, and the results reported by Wang et al. In contrast to their results
described above, we have not observed any changes in PD-1 expression on
+

Foxp3 T cells following in vivo administration of G-1 in naive animals or after ex
+

vivo treatment of cultured CD4 T cells (Section 4.3). It has also been recently
shown that estrogen can protect mice from EAE in a Foxp3-indpendent manner
(Subramanian et al., 2010). The authors noted an increase in IL10 production,
though it is not known what cells were responsible for this effect. Interestingly,
+

IL10 production in CD4 T cells can inhibit the development of EAE (Fitzgerald et
al., 2007), a disease whose pathogenesis is dependent on RORγt expression
(Ivanov et al., 2006). The fact that we demonstrated G-1 leads to an increase in
-

IL10 within Foxp3 RORγt

+

cells, and that IL10 induction occurs even in the

presence of IL23, suggest that one explanation for the results observed with the
EAE model above is the induction of IL10 through E2-mediated activation of
+

GPER in, and subsequent IL10 production from, RORγt cells specifically within
the CNS. This would be consistent with results discussed above, and other
studies that have shown; (a) E2 can increase IL10 production in vivo in a GPERdependent manner (Yates et al., 2010), and (b) the in vitro suppressive activity of
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TREG cells from PD-1KO mice was enhanced following in vivo treatment with E2,
without changing the expression levels of Foxp3 (Polanczyk et al., 2007). Further
+

studies using conditional knockouts of IL10 within the CD4 compartment will be
needed to definitively address these questions.
G-1 has been characterized as a selective agonist for the G proteincoupled estrogen receptor GPER (Bologa et al., 2006), a recently identified nonclassical member of the estrogen receptor family (Prossnitz et al., 2008).
Consistent with this mechanism of action, G-1-mediated IL10 expression was
inhibited by the addition of the GPER-directed antagonist G15 (Dennis et al.,
2009). Our results are also supported by observations that G-1-mediated
inhibition of EAE is dependent on GPER expression (Wang et al., 2009a).
Although small molecules can be subject to off-target activity, it is unlikely that
both G-1 and G15 would exhibit off-target profiles that mimic their established
activities towards GPER. Nevertheless, further investigation into the G-1 target(s)
-/-

in T cells is warranted. To begin to address this question, we employed GPER

mice to investigate whether G-1 was acting through GPER. Our finding that G-1+/-

mediated IL10 expression is lost in GPER

-/-

, only to return in GPER

cells, is

difficult to reconcile with an assertion that G-1 is acting exclusively through
GPER. Interestingly, investigation of some of our findings from Chapter 4 also
showed a similar trend (see Figure 39, Appendix C), in that systemic treatment
+

-/-

with G-1 led to an increase in the number of Foxp3 cells in GPER
+/-

no trend was observed in GPER

mice, while

mice. It is worth noting again that these mice

exhibit higher levels of apoptosis in double negative thymocytes at baseline, and
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lack the E2-mediated increase in this population following systemic estrogen
administration (Wang et al., 2008). However, even if one postulates that aberrant
+/-

thymic development or insufficient expression of GPER in the GPER

T cells

constitutes the basis for the loss of G-1 induced IL10 production in this
-/-

population, the observation that G-1 can drive IL10 expression in GPER

T cells

indicate that it is capable to eliciting a response in the complete absence of
GPER; suggesting that in this context G-1 is acting via off target activity. It would
-/-

be interesting to determine if G-1-mediated IL10 expression within GPER

cells

can be blocked by the GPER-directed antagonists. If G15 and G36 prove
-/-

incapable of blocking the G-1 effect in GPER cells, this would further support
the hypothesis that two distinct targets are indeed responsible for these effects in
-/-

wildtype versus GPER

cells. That finding may not be as statistically unlikely as

random chance would predict as other sex steroids such as androgens and
progestins also effect the immune system, receptors whose ligands are
chemically similar to G-1. This notion is further supported by the fact that GPER
gene expression is clearly involved in G-1-induced IL10 expression, based on the
+/-

observation that the effect is consistently lost in GPER

cells. It may be that in

the complete absence to GPER, a compensatory mechanism within the
developing thymocytes is induced which drives expression of another G-1
binding receptor that carries redundant function within the cell; for example one
might postulate the up-regulation of another sex steroid receptor. Why lower
expression of GPER would only impart an effect on the G-1-mediated induction of
IL10 and not the expression of the proposed secondary G-1-binding receptor
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may reflect differences the activities of G-1 and itʼs natural ligand, E2, which
would presumably be responsible for the second effect. Therefore, it will be worth
looking at the effect of E2 in IL10 induction within T cell populations. Moving
forward, future studies aimed at verifying GPER as the target of G-1 within the T
cell population should ideally employ inducible knockout strategies or retroviral
RNAi targeting of GPER to avoid the confounding effects of aberrant thymic T cell
-/-

development observed in GPER

mice.

Our results have begun to elucidate the mechanisms by which G-1
induces IL10 expression and production. Addition of the MEK1 inhibitor PD98059
blocked G-1-mediated IL10 induction, whereas addition of inhibitors of the p38
and JNK pathways had no effect. These findings are consistent with data
reported in the literature (Saraiva et al., 2009). Given that ERK signaling is
implicated in IL10 expression within TH1 and TH2 cells, it will be interesting to
determine whether G-1 can drive IL10 production under TH1 or TH2-polarizing
conditions. The lack of IL10 expression in unpolarized (TH0) cells is not
unexpected. IL10 production in TH1 cells requires IL12-signaling through STAT4,
whereas TH2 cells are dependent on IL4-signaling through STAT6, and IL10
production in TH17 cells requires signaling through STAT3 (Stumhofer et al.,
2007). Furthermore, IL27 is also capable of inducing IL10 in all three lineages
(Fitzgerald et al., 2007; Stumhofer et al., 2007). However, IL4, IL6, IL12, IL21,
and IL27 are produced by APCs and/or differentiated T cell populations; therefore
the cytokines necessary for IL10 production are likely limited in pure cultures of
naïve T cells that we employed. Additionally, our findings with TGFβ alone are
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consistent with previous findings using ex vivo culture systems that suggest
treatment with TGFβ blocks IL10 expression in differentiating CD4+ T cells
(Saraiva et al., 2009), and efficient induction of IL10 secretion from TH17polarized cells requires both TGFβ and an activator of STAT3 such as IL6
(McGeachy et al., 2007), IL21 (Spolski et al., 2009), or IL27 (Stumhofer et al.,
2007). We observed that G-1 was unable to induce IL10 production in
differentiating naïve T cell without the addition of both TGFβ and IL6 to the
culture medium, suggesting the G-1 cannot replace any of the critical signals
-/-

necessary to induce IL10 in TH17 cells. A study using T-bet STAT6

-/-

double

knockout mice suggests that the sole function of TGFβ in TH17 development is
blocking the differentiation of TH1 and TH2 cells (Das et al., 2009). Thus our
observation that G-1 treatment with IL6 alone does not consistently elicit IL10
+

production despite detectable levels of IL10 cells may reflect a dependence on
TH17 differentiation. Future studies will need to address this question. Given our
findings in Chapter 4, we also investigated whether G-1-mediated Foxp3
expression was dependent MAPK signaling. However, our findings indicate that
G-1 drives Foxp3 expression via a mechanisms independent of ERK, p38, or
JNK II signaling (Figure 41, Appendix D). This suggests that IL10 induction and
Foxp3 induction occur via distinct mechanisms.
Another interesting observation from this study was that G-1 was capable
of eliciting IL17A production under certain conditions. There is a longstanding
debate about how the apparent immunosuppressive activities of E2 can be
reconciled with the higher prevalence of autoimmune disease in women. It is
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possible that E2-mediated activation of GPER may drive increased IL17A
production under specific circumstances, and that this contributes to augmented
autoimmune pathogenesis in women. Future studies aimed at investigating this
possibility should be directed at delineating the specific conditions in which
GPER activation leads to IL17A, and perhaps IL17F, production. It would be
interesting to correlate these findings with studies investigating the expression of
ERα, ERβ, and GPER, which can vary over time. An explanation for the sexual
dimorphism in the prevalence of autoimmune disease may reside in identifying a
setting where GPER plays a predominant role in estrogen signaling, perhaps due
to downregulation of ERα and/or ERβ within specific cell populations, under
conditions were GPER activation leads to production of IL17A or even IL17F. If
these properties can be definitively described, there is also the possibility that G1 may serve a role in T-cell based tumor vaccine strategies. Evidence suggests
that polarization of tumor-specific T cells towards a TH17 phenotype prior to
adoptive transfer can enhance tumor eradication (Muranski et al., 2008). It is
possible that G-1 or a related compound may serve as a cost effective and safe
alternative to recombinant cytokines during T cell culture, or even as a systemic
adjuvant treatment to help stabilize the cells post adoptive transfer, especially
given the fact we saw increased IL17A production following in vivo G-1
treatments in the data presented here. Moreover, further delineating the role of
GPER

is

polarization

along

the

TREG-TH17

axis

may

uncover

other

pharmacological mechanisms, for example the use of G15, that can elicit
antitumor responses by driving conversion of TREG cells into TH17 populations, a
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strategy which was validated in principle with the use IDO-inhibitors in the B16
melanoma model (Sharma et al., 2009).
+

+

Finally, the IL10 IL17A

cells we identified appear to be part of the

autoregulatory pathway (Maynard and Weaver, 2008), as they express RORγt
+

but not Foxp3. In fact we detected virtually no IL17A cells within the Foxp3

+

population (Figure 6 and data not shown). While not completely unexpected
since Foxp3 can inhibit some of the transcriptional activity of RORγt (Zhou et al.,
+

+

2008), Foxp3 IL17A cells have previously been reported (Beriou et al., 2009).
+

+

Our observation that G-1 induces IL10 expression in Foxp3 RORγt hybrid T
cells suggests that in addition to generating IL10 production in populations
already localized at the site of inflammation, G-1 may also enhance the
suppressive function of TREG populations drawn in from the circulation. If IL10 can
be stably induced in hybrid T cell populations following in vivo G-1 treatment,
their suppressive activity may be enhanced as they are recruited to sites of
ongoing inflammation.
Numerous attempts have been made to harness the immunosuppressive
properties of IL10 for therapeutic benefit, many of which have been based on the
use of biologics (O'Garra et al., 2008). To our knowledge, this is the first evidence
that a synthetic small molecule can shift the balance along the TREG-TH17 axis in
favor of IL10 production, in this case by acting directly on T cell populations.
These data build on prior results demonstrating that dexamethasone and retinoic
acid can elicit IL10 from polyclonally stimulated naïve T cells when IL4, IL12 and
IFNγ are neutralized (Spolski et al., 2009). Also worth noting is the fact that it is
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becoming increasingly clear that GPER likely plays a smaller role in the majority
of classical estrogen responses, such as uterine imbibition, as compared to its
more well known counterpart ERα (Dennis et al., 2009). Thus G-1 may be
associated with a more tolerable side effect profile.

Section 5.5 : Conclusions
Our findings suggest that the membrane-permeable small molecule G-1
may serve as a novel T cell-targeted immunosuppressive agent through the
induction of IL10 in settings where large populations of TH17 cells exist, for
example in rheumatoid arthritis, inflammatory bowel disease, or psoriasis. G-1
may also prove useful for in vitro generation of IL10-producing cells for adoptive
immunotherapy. Future studies delineating the specific signaling mechanisms
and molecular targets of G-1 and other related compounds will be seminal to the
continued development of this new class of immunoregulatory estrogenic small
molecules. The selectivity of G-1 (Blasko et al., 2009; Bologa et al., 2006) and its
attractive pharmacological properties (Wang et al., 2009a) make this compound a
strong candidate for pharmaceutical development, paving the way for the
development of novel T-cell targeted immunotherapeutics.
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Section 5.6 : Figures

+

Figure 19 : The GPER agonist G-1 induces IL10 production from CD4 T cells.
+

lo

hi

CD4 CD44 CD62L naïve CD4+ T cells were collected by FACS and cultured for 4 days ex vivo
with various combinations of TGFβ, IL6, and IL23, and supplemented with 100nM G-1 or vehicle
(DMSO, control). Cells were subsequently stained for intracellular IFNγ, IL17A, and IL10, then
analyzed by flow cytometry. (A) Representative plots from the various conditions showing
intracellular IL17A and IL10. (B) Quantification of data from five to seven independent
experiments showing relative number of total IL10+ cells and total IL17A+ cells cultures treated
with TGFβ + IL6. (C) Quantification of data from four to seven independent experiments showing
relative number of total IL10+ cells and total IL17A+ cells cultures treated with TGFβ + IL6 + IL23.
(D) Quantification of the number of IFNγ+ cells in cultures stimulated with CD3/28 in nonpolarizing conditions (i.e. without the addition of any cytokines). P values determined by studentʼs
t-test; * p<0.05; *** p<0.0005. Error bars = S.E.M; NS: not significant.
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+

Figure 20 : G-1 does not alter the number of IFNγ cells.
+

lo

hi

CD4 CD44 CD62L naïve CD4+ T cells were collected by FACS and cultured for 4 days ex vivo
with various combinations of TGFβ, IL6, and IL23, and supplemented with 100nM G-1 or vehicle
(DMSO, control). Cells were subsequently stained for intracellular IFNγ, IL17A, and IL10, then
analyzed by flow cytometry. (A) Representative plots from the various conditions showing
intracellular IFNγ and IL10.
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Figure 21 : G-1 increases IL10 secretion from T cells, but not proinflammatory
cytokines.
+

hi

CD4 CD62L naïve CD4+ T cells were collected by FACS and cultured for 4 days ex vivo with
anti-CD3/28 + IL6 + TGFβ in the presence of 100nM G-1 (black bars) or DMSO (white bars).
Cells were washed on day 4 and re-stimulated with antiCD3/28 alone. Culture medium was
collected after 24 hours and analyzed for the presence of secreted (A) IL10, (B) IL17A, (C) IFNγ,
(D) TNFα, (E) and IL6 by Luminex multiplex assay. Data are the means from three independent
experiments done in triplicate. P values determined by studentʼs t-test. Errors bars = S.E.M.
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+

Figure 22 : G-1 induces IL10 expression in IL17A cells.
+

lo

hi

+

hi

CD4 CD44 CD62L or CD4 CD62L naïve CD4+ T cells were collected by FACS and cultured
for 4 days ex vivo with anti-CD3/28 + IL6 + TGFβ. Increasing doses of G-1 (1 – 500nM, black
bars) or equivalent amounts of vehicle (DMSO, white bars) were added. Cells were subsequently
stained for intracellular IL17A and IL10, and analyzed by flow cytometry. (A) Representative plots
from the various conditions showing intracellular IL17A and IL10. (B-C) Quantitation of data from
one of two independent experiments showing the percent of cells that are (B) IL10+IL17A- and
(C) IL10+IL17A+ for the given conditions. P values determined by studentʼs t-test. Errors bars =
S.D.
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Figure 23 : G-1-mediated IL10 production is blocked by GPER antagonists.
+

lo

hi

+

hi

CD4 CD44 CD62L or CD4 CD62L naïve CD4+ T cells were collected by FACS and cultured
for 4 days ex vivo with anti-CD3/28 + IL6 + TGFβ, and cultures were pretreated with the GPER
antagonist G15 or G36. Summary of data from two independent experiments showing that the
GPER-directed antagonists G15 and G36 can block G-1-mediated IL10 induction within CD4+ T
cells. P values determined by studentʼs t-test; * p<0.05; ** p<0.005. Error bars = S.E.M.
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Figure 24 : G-1-induced IL10 production is ERK dependent.
+

lo

hi

CD4 CD44 CD62L naive CD4+ T cells were collected by FACS and cultured for 4 days ex vivo
with anti-CD3/28 + IL6 + TGFβ in the presence of 100nM G-1 (black bars) or DMSO (white bars).
Cultures were supplemented with inhibitors of the ERK (PD98059), JNK (JNK II inhibitor), or p38
(SB203580) signaling cascades. Following culture, cells were collected and stained for
intracellular IL10 and IL17A, and analyzed by flow cytometry. (A) Graphs represent summary of
data from three independent experiments. (B) Representative plots from one of four independent
experiments with PD98059. (C) Summary of data from four PD98059 experiments analyzing
induction within populations expressing combinations of IL10 and IL17A. P values determined by
studentʼs t-test. * p<0.05; ** p<0.005; *** p<0.0005. Errors bars = S.E.M.

123

Figure 25 : G-1 effects are not dependent on proliferation.
+

hi

CD4 CD62L naive CD4+ T cells were collected by FACS and stained with the proliferation dye
eFluor670 (eBiosciences) prior to culture. Following differentiation for 4 days ex vivo in culture
with anti-CD3/28 + IL6 + TGFβ in the presence of 100nM G-1 (black bars) or DMSO (white bars),
cells were stained for intracellular IL10. (A) Percent of cells proliferating and the inverse of GMFI,
a measure of total proliferation. (B) Sample plots showing IL10 expression and eFluor670
staining. The upper right quadrant shows cells expressing IL10 without evidence of proliferation.
Data show one of two independent experiments. Error bars = S.D. NS = not significant.
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Figure 26 : G-1 induces IL10 production within the hybrid T cell population.
+

hi

egfp

CD4 CD62L naïve CD4+ T cells were collected by FACS from Foxp3
mice and cultured for 4
days in vitro with anti-CD3/28 + IL6 + TGFβ1 in the presence of 100nM G-1 (black bars) or DMSO
(white bars). Cells were collected and stained for intracelluar IL10, IL17A, and RORγt, and
analyzed by flow cytometry. Cells that were Foxp3+ RORγt+ were designated as hybrid T cells,
while those that were Foxp3- RORγt+ were designated as TH17 cells. (A) Gating logic to
determine hybrid T cell and TH17 populations. (B-D) Graphs represent summary of data from
three independent experiments showing the relative number of (B) IL10+IL17A-, (C)
IL10+IL17A+, and (D) IL10-IL17A+ populations. Error bars = S.E.M. * p<0.05; ** p<0.005; ***
p<0.0005. NS, not significant.
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Figure 27 : IL10 and IL17A secretion is reduced from GPERKO splenocytes.
Seven to eleven week old male wild-type or GPERKO C57BL/6 mice were injected with estrogen
(E2 – 500ng/day) or vehicle for 7 consecutive days. One day following the last injection,
splenocytes were collected and cultured in the presence of antiCD3ε (1.0 µg/mL) and antiCD28
(2.5 µg/mL) Ab. Culture medium was collected after 48 hours and analyzed for the presence of
secreted IL2, IL4, IL13, IL10, IL17A, and TNFα by Luminex multiplex assay.. Graphs are mean
data with three mice per group. Errors bars = S.E.M.
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Figure 28 : Cytokine secretion following in vivo treatment with G-1.
Seven to eleven week old male wild-type C57BL/6 mice were injected with G-1 (5µg/day) or
vehicle for 7 consecutive days. One day following the last injection, splenocytes were collected
and cultured in the presence of antiCD3ε (1.0 µg/mL) and antiCD28 (2.5 µg/mL) Ab. Culture
medium was collected after 24, 48, and 72 hours and analyzed for the presence of secreted IL6,
IL10, IL17A, IFNγ, and TNFα by Luminex multiplex assay. Graphs are mean data with three to
five mice per group. Errors bars = S.E.M. P values determined by studentʼs t-test, except where
2-way ANOVA is indicated. * = P ≤ 0.05, ** = P ≤ 0.01.
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+

Figure 29 : G-1 transiently induces IL17A from total CD4 cells in culture.
+

hi

(A) CD4 CD62L naïve CD4+ T cells were collected by FACS from C57BL/6 mice and cultured
for 4 days ex vivo with anti-CD3/28 antibody, both with (grey squares) and without (white
squares) TGFβ (10 ng/mL). Cultures were supplemented with rIL2 (100 U/mL), E2 (10nM), or G-1
(100nM) as indicated. Cells were collected and stained for intracelluar IL17A then analyzed by
+
flow cytometry. Summary of data from three independent experiments. (B) CD4 cells were
enriched by magnetic bead sorting (AutoMACS) and stimulated in culture with anti-CD3/28
supplemented with G-1 (100nM: black boxes with solid black line) or without (white boxes with
dashed grey line). Culture medium was collected following 3 days and 5 days of stimulation, then
analyzed for secreted IL17A by Luminex multiplex assay. Summary of data from 2 independent
+
experiments. (C) CD4 cells were enriched by magnetic bead sorting (AutoMACS) and cultures;
with media only (white bars), with anti-CD3/28 only (light grey bars), with anti-CD3/28 + 10nM E2
(dark grey bars), or with anti-CD3/28 + 100nM G-1 (Black bars). Culture medium was collected
after 3 days of stimulation and analyzed for IL4, IL17A, and IFNγ secretion by Luminex multiplex
assay. Example from one of two independent experiments. Errors bars = S.E.M. P values
comparing two points were determined by studentʼs t-test, P values comparing G-1 and vehicle
curves were determined by 2-way ANOVA as indicated. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤
0.005.
NOTE: Figure 29A is the same as Figure 9A in preliminary data.
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Figure 30 : G-1 induces IL10 expression in GPERKO cells, but not GPERhet cells.
+

hi

egfp

CD4 CD62L naïve CD4+ T cells were collected by FACS from GPERhet x Foxp3
or GPERKO
egfp
x Foxp3
mice and cultured for 4 days in vitro with anti-CD3/28 + IL6 + TGFβ in the presence of
100nM G-1 or DMSO. Cells were collected and stained for intracelluar IL10 and IL17A by flow
cytometry. The graph shows the ratio of a given population (indicated along the X-axis) observed
in G-1 treated cultures relative to cultures treated with DMSO alone. Naïve T cells from GPERhet
(clear, white boxes) and GPERKO mice (dark, red boxes) were collected and stimulated the same
day for a given experiment. Each box indicates the mean from one individual experiment done in
duplicate or triplicate, with three independent experiments shown.
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Chapter 6 : Data from the T cell-mediated colitis model

Section 6.1 : Preface
Perhaps the most attractive model to investigate the therapeutic potential
of G-1 is the T cell mediated colitis model. While the TH17 population has been
widely discussed for its proinflammatory attributes and its role in autoimmunity,
there is an emerging story which suggests these cells exhibit regulatory
properties in certain settings through the activity of IL17A, perhaps best
exemplified by the pleiotropic effects of IL17A in the setting of autoimmune colitis,
as discussed in the introduction (Section 1.3). Additionally, as has been
discussed previously, IL10 has been shown to play a role in immune
homeostasis at environmental interfaces, such as the gut, and is effective in
suppressing animal models of colitis. Therefore, in this chapter we investigated
G-1ʼs ability to function prophylactically and therapeutically in an animal model of
T cell-mediated colitis.

Section 6.2 : Introduction
Inflammatory bowel disease (IBD) is characterized by inflammation and
ulceration of the gastrointestinal mucosa (Podolsky, 2002), and numerous lines
of evidence have linked T cell to disease pathogenesis and prevention. The
+

importance of Foxp3 cells in mucosal immunity is highlighted by patients with
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immunodeficiency,

polyendocrinopathy,

and

enteropathy

X-linked

(IPEX)

syndrome, at least 50% of whom harbor a mutation in the Foxp3 gene (van der
Vliet and Nieuwenhuis, 2007). These patients present clinically with watery
diarrhea due to villous atrophy and severe intestinal inflammation (Patey-Mariaud
de Serre et al., 2008). Experimentally, TREGs suppress the colitis associated with
adoptive transfer of pathogenic T cells into lymphopenic hosts (Yuan et al.,
2007). Some of their suppressive function is mediated by the cytokine IL10,
which reduces the proinflammatory activity of numerous immune populations
(Maynard and Weaver, 2008). Furthermore, IL10 is essential to gut immune
homeostasis, because IL10KO mice exhibit spontaneous colitis (Etling et al.,
2007), and loss of IL10 production by Foxp3

+

TREGs leads to mucosal

inflammation (Rubtsov et al., 2008).
TH17 cells have also been linked to IBD (Harrington et al., 2005; Ivanov et
al., 2006). Given the established pro-inflammatory activity of IL17A/F, it is
attractive to hypothesize that T cell-mediated mucosal inflammation is
determined by the balance between Tregs and TH17 cells. In reality, the role of
TH17 cells in colitis has proven controversial. Patients with UC express high
levels of IL17 in the intestinal mucosa (Kobayashi et al., 2008), large numbers of
activated TH17 cells have been found in lesions from CD patients (Kleinschek et
al., 2009), IL23KO mice are protected from colitis (Yen et al., 2006), and two
studies have identified IL23R gene (Il23r) variants that protect against IBD
(Dubinsky et al., 2007; Duerr et al., 2006). However, there is evidence IL17A is
actually protective in both a T cell independent (Ogawa et al., 2004) and T cell
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dependent (O'Connor et al., 2009) model of IBD. Moreover, one of the major
contributing factors to IBD pathogenesis is compromised epithelial barrier
function along the GI tract. It is thought that loss of tight junction integrity between
the epithelial cells lining the gut lumen allows commensal flora access to immune
mediators within the mucosal wall where they elicit a robust inflammatory
response (Yu et al., 2004). Whether this is a precipitating event or simply
contributes to the chronic stages of IBD is still debated, though numerous animal
models provide clear evidence that transient disruption of barrier function can
induce colitis (Sollid and Johansen, 2008). TH17 cells can impact the gut wall
integrity thorough production of the cytokine IL22 (Ouyang and Valdez, 2008),
which acts on IECs to promote mucosal wound healing in a STAT3-dependent
manner (Pickert et al., 2009). Interestingly, recent work demonstrated that IL23
+

enhances colitis by blocking Foxp3 TREG activity (Izcue et al., 2008). IL23 also
drives production of the TH1-specific cytokine IFNγ in the GI mucosa (Hue et al.,
2006). This is important as there is clear evidence that TH1 responses can drive
colonic inflammation. Adoptive transfer of pathogenic T cells from IFNγKO mice
does not induce colitis (Ito and Fathman, 1997), and IFNγ neutralization
abrogates disease in this model (Powrie et al., 1994). These results appear to
translate to human disease as IL23-mediated IFNγ production has been
correlated with the chronic inflammation associated with CD (Kamada et al.,
2008), and elevated levels of IFNγ have been detected in the intestinal mucosa of
IBD patients (Breese et al., 1993). Thus, it may be that IL23-mediated TH1 are
responsible for the T cell component of IBD.
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As mentioned in Section 1.3, there is an intriguing link between the
+

developmental pathways for Foxp3 TREGs and TH17 cells. Like other settings
within the body, the decision between cell types depends on the other signals
present (Samanta et al., 2008; Sauer et al., 2008; Zhang et al., 2008). For
example, ATP from gut flora (Atarashi et al., 2008) or LPS in the presence of
apoptotic cells (Torchinsky et al., 2009) appears to aid TH17 development in the
colonic lamina propria.
In the previous chapters we showed that the GPER-directed agonist G-1
can drive Foxp3 and IL10 expression in polyclonally stimulated naïve T cells. We
chose to investigate whether these findings translated to the in vivo setting using
the T cell-mediated colitis model of IBD. The reason for selecting this model was
based on the fact that the adoptive transfer step allowed us to treat cells in
culture prior to injection into recipient mice and, if needed, we could control the
genotype of the donor T cells specifically without affecting the genotype of the
recipient animal. Moreover, IL17A and IL10 have both been shown to contribute
in TREG-mediated suppression of colonic inflammation in this model. To our
surprise, G-1 was unable to prevent the development of colitis following ex vivo
treatment of donor cells, or by sustained systemic treatment prior disease
induction. However, treatment of animals with clinically apparent wasting disease
with G-1 led to a rapid increase in the rate of disease progression, which
+

correlated with a decrease in the number of IL17A cells within the mucosal
immune system of the gut. These findings suggest that G-1-mediated regulation
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of T cell cytokine production may not be a viable treatment in the setting of colitis,
and other models will need to be explored.

Section 6.3 : Results
Prior to initiating these studies, we wanted to determine if we could detect
+

hi

IL10 induction within cells used to induce disease. Thus, CD4 CD45RB

cells

were collected by FACS and stimulated with antiCD3/28 Ab in the presence of
TGFβ and IL6, supplemented with DMSO or 100nM G-1. We detected an
+

increase in the number of IL10 cells within the G-1 treated cultures, which
+

hi

correlated with our findings in Chapter 5 for CD4 CD62L naïve T cells (data not
shown). Thus, we moved forward with our in vivo experiments.

Treatment of T cells with G-1 in culture does not alter colitis
To investigate the in vivo suppressive properties of G-1 treated naïve T
+

hi

cells, CD4 CD45RB

naïve T cells were collected and stimulated as before,

namely plus or minus G-1 in the presence of TGFβ and IL6. Following 4 days in
culture, DMSO or G-1 treated cells were injected into Rag1KO recipient mice to
test for any variability in the induction of colitis. Given the fact that T cells cultured
in the presence of TGFβ and IL6 exhibit reduced pathogenic potential in the
animal model EAE due to attenuated recruitment of proinflammatory leukocytes
and can confer bystander protection through the secretion of IL10 (McGeachy et
al., 2007), it was possible that the mice from both groups would fail to develop
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colitis. However, we observed a typical clinical course in mice treated ex vivo with
TGFβ and IL6 (Figure 31). We predicted that if G-1-mediated IL10 induction is
stable following transfer and expansion in vivo, then mice injected with G-1
treated cells should demonstrate a more indolent disease course and/or a
reduction in disease severity relative to the DMSO treated control cells. To our
surprise, G-1 treated cells were capable of driving disease onset and progression
with identical characteristics as the DMSO treated cells (Figure 31), despite the
known protective effects of IL10 in this model. There are two possible
interpretations of this data; either (a) G-1-mediated IL10 induction is not stable
following transfer into lymphopenic mice, or (b) the amount of IL10 secreted is
insufficient to confer bystander protective effects in this model.

Systemic treatment with G-1 does not inhibit colitis
To determine if the failure of G-1-treated cells was the result of changes in
effector phenotype following homeostatic proliferation, we chose to treat recipient
mice with systemic G-1 immediately after adoptive transfer of freshly sorted
+

hi

CD4 CD45RB pathogenic naïve T cells. This should expose the cells to G-1 up
to and following their in vivo expansion, and during their differentiation into
effector lineages in the gut lamina propria, where many cells undergo TH17
differentiation, likely due to an abundance TGFβ and IL6. Previous work has
demonstrated the ability of in vivo derived peptide-specific effector T cells from
the draining lymph nodes of EAE mice to respond to TGFβ and IL6 by the stable
production of IL10 (McGeachy et al., 2007), hence it was reasonable to
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hypothesize that systemic G-1 would expand IL10 production in vivo in the
setting of colitis, especially given G-1 is known to suppress EAE (Blasko et al.,
2009; Wang et al., 2009a) and induce IL10 expression in vivo (Yates et al., 2010)
and (Figure 28). In the first series of experiments G-1 was delivered using
custom-made 60 day-release cholesterol pellets (either 1.125 mg or 0.225 mg),
which have been previously used to effectively deliver both E2 and G-1 in the
treatment of EAE (Wang et al., 2009a). The pellets were implanted 7 days prior
to the adoptive transfer of T cells to ensure that wound had healed properly and
to give time for the drug to begin being released. While this time frame was
chosen based on previous experiences, it is important to note that we have no
tool for directly analyzing the presence of drug circulating in the animals, and
thus verify the effectiveness of this strategy. Animals implanted with G-1 pellets
demonstrated slightly reduced weights relative to the vehicle treated animals
(Figure 32), but a similar pattern was also noted in the non-diseased mice,
suggesting a small effect of G-1 treatment on weight. This is consistent with
previous data which showed increased body mass in male GPERKO mice (Ford
et al., 2010). However, these data suggest that in vivo G-1 treatment with
implanted pellets was not effective in preventing T cell-mediated colitis.
As we have no mechanism for tracking the release of G-1 from the pellets
it was possible that there was not sufficient G-1 circulating at a critical stage
following the adoptive transfer of the pathogenic T cell populations. One line of
evidence supporting this hypothesis was our observations that the G-1 pellets
never broke down, as compared to the sham control pellets which did on
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occasion (data not shown). To verify our findings from the pellet experiments,
mice were treated with 5 µg of G-1 via daily subcutaneous injection for the first 21
days following transfer of freshly sorted T cells. This would ensure daily delivery
of G-1 up until the typical onset of clinical symptoms, which usually present 3-4
weeks after ignition of disease. In agreement with our previous results, daily
delivery of G-1 had no effect on disease course (Figure 33), even when the mice
were followed for 9 weeks. This finding further demonstrates that G-1 cannot act
to prevent disease in the T cell-mediated colitis model.

G-1 acccelerates wasting disease when given therapeutically
These data show that that G-1 treatment cannot prevent the onset of
wasting disease in an adoptive transfer-based T cell-mediated colitis model of
IBD. However, one final possibility is that effective treatment with G-1 requires
ongoing T cell differentiation, and in particular the presence of TH17 polarizing
conditions, as we observed for the induction of IL10 in Chapter 5 (Figure 19). If
indeed there is an issue with the use of cholesterol pellets, perhaps specific to
the Rag1KO mice, and treatment with G-1 prior to the onset of clinical symptoms
was ineffective due to a lack of TH17 polarizing conditions, then it was possible
that treatment of animals with fulminate colitis with G-1 would finally uncover a
therapeutically viable activity of G-1 in this model. Along those lines, a cohort of
Rag1KO mice were injected with colitogenic T cells and allowed to progress to
the onset of clinical symptoms (Figure 34). Starting on day 35 post T cell
injection, mice were treated with 5 µg of G-1 via daily subcutaneous injection for
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7 consecutive days, matching the paradigm used in Chapter 5 to demonstrate G1-enhanced IL10 production from TCR activated splenocytes following systemic
G-1 treatment (Figure 28). To our surprise, administration of G-1 in this context
led to an immediate and significant increase in the development of wasting
disease (Figure 34), as compared to the vehicle controls.

G-1 has distinct effects on the mucosal & systemic immune system
To investigate what the underlying cause of this unexpected result might
be, animals were sacrificed upon completion of the experiment and spleens,
mesenteric lymph nodes (MLN), inguinal lymph nodes (ILN), and colonic lamina
propria cells were collected for analysis of surface markers and intracellular
cytokine expression (Figure 35). We were unable to detect any intracellular IL10
in any of the tissue samples (data not shown). As mentioned, IL17A is also
protective in this model and has been observed to be modulated by G-1 in vivo
(Figure 28), and in vitro (Figure 8, 9 10, 19, & 22). Thus, intracellular IL17A was
analyzed (Figure 35A). We saw that mice treated with G-1 had an increase in
+

+

the percentages of CD4 IL17A

cells in their ILNs, in agreement with our

previous findings (Figure 9, 10, and 22), although it is important to note that
unlike the majority of our ex vivo experiments these cells did not express IL10
(data not shown). Interestingly, when cells from the MLN were analyzed for IL17
expression, the opposite trend was observed, wherein G-1 treated mice had a
+

+

lower percentage IL17A cells within the CD4 compartment (Figure 35A). This
result reached statistical significance. A similar pattern was noted in the colonic
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lamina propria cells, although it never reached statistical significance. No
-

+

difference in CD4 IL17A

cells was noted in any setting (Figure 35A). Our

observation that augmentation of wasting disease in response to G-1 treatment
+

correlated with reduced percentages of IL17A cells within the mucosal immune
system is consistent is with a previous report using this same model which
showed IL17AKO and IL17A receptor KO T cells impart a more severe disease
course following adoptive transfer.
To determine if alterations in the expression of other proinflammatory
cytokines may also be implicated in G-1ʼs effects, cells from the various tissues
were stained for IFNγ (Figure 35B) and TNFα (Figure 35C). Staining for IFNγ
+

+

demonstrated that G-1 treated mice had lower percentages of CD4 IFNγ cells.
As there is strong evidence that IFNγ is important in promoting the development
of colitis (Ito and Fathman, 1997), these data suggest that alterations in IFNγ
expression are not responsible for G-1 effects. However, the decrease in
+

CD4 IFNγ

+

cells correlates well with our findings in Chapter 5 where we

observed a decrease in the secretion of IFNγ in response to ex vivo TCR
crosslinking from splenocytes exposed to G-1 in vivo (Figure 28). Staining for
TNFα yielded results that were a bit more varied. While we observed no effects
on TNFα secretion following systemic G-1 treatment in Chapter 5 (Figure 28),
+

+

here we noted that there were fewer TNFα cells in the CD4 T cell population
+

(CD3 CD4

+

cells) from the colonic lamina propria of G-1 treated mice.
+

-

-

Conversely, there were more TNFα cells in the CD3 CD4 population from the
MLN of G-1 treated mice (Figure 35C). Neither pattern reached statistical
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significance (P > 0.05). Collectively, these data show that modulation of IFNγ and
TNFα expression do not contribute to the G-1 effect observed in Figure 33.
Perhaps the most interesting observation from the entirety of this work
was our identification of distinct and opposite compartment-specific effects
following systemic administration of G-1 in the colitis model; specifically,
+

+

increased percentages of CD4 IL17A

cells in the systemic immune system

(ILN) of G-1 treated mice correlating with a decreased in the percentage of
+

+

IL17A cells among the CD4 population in the mucosal immune system (MLN)
of the same animals. One possible explanation for the altered response to G-1
treatment in the mucosa is that naive T cells within the mucosa and itʼs draining
lymph nodes exist in a unique resting state due to the constant challenge of the
commensal flora and the distinct milieu of immune mediators within the gut wall
(see Introduction). To determine if the apparent reversal of G-1ʼs effects within
the mucosal immune system was reflective of a unique property intrinsic to T
cells from this setting, naive T cells from the MLN were collected by FACS,
stimulated in culture with antiCD3/28 antibody in the presence of TGFβ + IL6,
and supplemented with either 100nM G-1 or DMSO. MLN-derived naïve T cells
responded to G-1 treatment with an increase in the number of IL10
+

+

and

+

IL10 IL17A cells (data not shown), similar to what was observed when cells
were collected from the spleen and other LN populations (Figure 19 and 22).
However, the effect was much weaker than what was observed in our previous
studies, and trend did not reach statistical significance. These data suggest that
compartment-specific differences in G-1ʼs effect on IL17
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+

T cell number may

reflect inherent differences in naïve T cell signaling and the response to G-1
within the local environment of the mucosal immune system.
Another possible explanation for the observed discrepancy in G-1
modulation of IL17A expression is that more than one CD4

+

population is

responsible for our observation. γδ T cells express CD4, can produce IL17A, and
are found in abundance in the lining of the gut (Xiong and Raulet, 2007). In fact,
in naïve mice it appears that the majority of IL17A producing cells are of the γδ T
cell variety. However, staining for the γδTCR demonstrated that less than 2% of
+

the cells within the MLN were in fact γδTCR
+

(Figure 35E), and no

+

γδTCR IL17A cells were detected in either the colonic lamina propria or the
MLN (Figure 35E). This is likely due to the fact that the majority of gut associated
γδ T cells are part of the intraepithelial lymphocyte population which reside within
and immediately underneath the ICE population lining the gut lumen (see Section
1.2). These cells are lost during the process of purifying lamina propria cells
+

(Ostanin et al., 2009). NKT T cells are also CD4 and are capable of producing
IL17A (Rachitskaya et al., 2008). However, similar to our results for γδ T cells,
staining for NK1.1 and IL17A demonstrated that this population did not vary
between treatment groups, and was likely too small to account for our
+

observations (Figure 35D/E). Another CD4 population known to produce an
abundance of IL17A are the lymphoid tissue inducer-like (LTi) cells (Takatori et
al., 2009). However, these cells are distinguished from T cell populations based
on their lack of the TCR co-receptor CD3. However, we were unable to detect
-

+

any CD3 CD4 cells in any tissue tested (Figure 35E and data not shown). It is
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also worth noting that we did not observe any changes in the relative number of
any of the major immune populations (Figure 35E). Collectively, these data show
+

+

that the CD4 IL17A

population shown in Figure 33 are TH17 cells and not

another IL17A producing cell line.
One final possibility we investigated was the hypothesis that the
differential effects of G-1 in Figure 33 were in fact secondary to effects on other
critical immune populations within the gut, most notably dendritic cells (DCs) and
macrophages. Work from Bali Pulendranʼs lab has shown that by using surface
expression of CD11b and CD11c as markers, one can identify populations of
APCs within the gut lamina propria that promote either TH17 or TREG
differentiation (Denning et al., 2007). If G-1 was reducing the number of TH17+

+

promoting DCs (CD11b CD11c ), it may account for the reduction in TH17 cells
observed in diseased mice following treatment with G-1. Cells from the MLN and
lamina propria from G-1 and control treated mice were stained for CD11b and
CD11c, and their relative numbers analyzed. We noted a statistically significant
-

+

decrease in the number of TREG promoting CD11b CD11c DCs, which correlated
+

+

with an increase in the number of TH17-promoting CD11b CD11c DCs (Figure
35F). The increased proportion of TH17-promoting DCs suggested that the
reduction in TH17 was not due to changes in this population. However, we did not
evaluate the actual function of any APC population, and thus drawing firm
conclusions must be done with caution. In addition, the observation that G-1 may
reduce the number of TREG-promoting DCs suggests that a loss of TREGs may
underlie the inability of G-1 to protect against colitis. While we could not detect
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any IL10 expressing cells in the tissues tested (data not shown), we did not
analyze Foxp3 expression. Thus it remains a possibility that alteration of TREG
number or function play a critical role in our observations.

Section 6.4 : Discussion
In this chapter we attempted to build on our findings from Chapter 4 and
Chapter 5 by investigating the utility of G-1 in the treatment of T cell-mediated
colitis, an established animal model of IBD. It was interesting that cells cultured
ex vivo with TGFβ and IL6 were capable of eliciting a similar disease pattern as
compared to cells that were injected immediately after collection. In Chapter 5 we
demonstrated that cells stimulated in this fashion expressed IL10 and produced
IL10 upon re-stimulation (Figure 19 and Figure 21), in agreement with previous
studies using peptide-specific T cells from EAE mice (McGeachy et al., 2007).
We also confirmed the ability of the specific naïve T cell population used to
induce TCMC also showed the ability to up-regulate IL10 (data not shown). The
unabridged ability of these cells to drive colitis following transfer may be due to
changes in their effector properties as the undergo homeostatic proliferation. The
studies by McGeachy et al, which initially identified the IL10-producing capacity
of TGFβ and IL6 treated cells and their IL10-dependent bystander suppressive
activity, were conducted using the EAE model in which the recipient mice have
an intact immune system, and thus transferred cells were not subject to
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homeostatic proliferation following transfer. Thus this could account for the
differences between our data and their findings.
Given that the G-1 treated cells induced the same disease pattern as the
DMSO treated cells, another possibility was that we were no longer observing
IL10 induction due to subtle changes in our culture protocol, for example the new
operator of the MoFlo sorter used to collect the naïve T cell population or a
different lot of one of the key cytokines. This was partly based on the fact that a
+

few of the ex vivo culture experiments with CD4 CD62L

hi

cells that we ran

around that same time had also shown no induction of IL10. Subsequent analysis
+

hi

of IL10 induction in CD4 CD45RB

cells demonstrated a loss of G-1-mediated

effects in this population as well (data not shown). The issue with our
+

CD4 CD62L

hi

cells was resolved by changing the batch of G-1 being used.
+

However, even after restoring G-1-driven IL10 induction within the CD4 CD62L
+

hi

hi

population, we continued to get variable results with the CD4 CD45RB cells. As
of yet, it is unclear why. Thus the possibility remains that this particular
population of T cells simply do not produce sufficient IL10 to resolve any G-1mediated effects.
Another possible scenario is that G-1 treatment effects the function of
IECs in the setting of colonic inflammation, affecting barrier integrity or the
production of other immunomodulatory factors from this population. Additionally,
while we observed a reduction in the ratio of TREG to TH17 promoting DCs in
Figure 34F, we didnʼt actually check the function of any of the APC populations
within the gut. Future experiments comparing the ability of CD11c+ populations
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from the MLN and lamina propria of diseased mice treated with either vehicle of
G-1. The reduction in TREG-promoting DCs also warrants further investigation. It
may be that in addition to reducing the number of TH17 cells, G-1 treatment of
diseased mice leads to a reduction in the number of TREG cells within the MLN or
the gut wall, further exacerbating the chronic inflammation associated with the
disease. Experiments looking at Foxp3 expression in G-1 treated mice will help
answer this question.
Finally, the pharmacodynamics and pharmacokinetics of G-1 are at this
point unknown, so it is unclear how G-1 is metabolized in vivo, and where it tends
to accumulate. It is possible that rapid metabolization of G-1 yields products that
lack the functions that we delineated ex vivo in tissue culture dishes. There is
also the possibility that G-1 itself does not efficiently accumulate in the mucosa.
Along those lines, it would be interesting to test whether oral G-1 or perhaps oral
ethinyl estradiol (EE), which has been used to effectively attenuate the
development of EAE, would be prophylactically or therapeutically effective in the
T cell-mediated colitis paradigm.
There were some insightful results that came out of this study as well. The
fact that we observed a reversal of G-1 effects in terms of IL17A induction in the
MLN of diseased mice (relative to ILN within the same mice and the bulk of our
ex vivo data) does suggest that G-1 can behave differently in different contexts.
We attempted to determine if there was a detectable difference in naïve T cells
from the MLN relative to cells collected from other secondary lymphoid tissue,
utilizing the ex vivo T cell differentiation paradigm employed widely in Chapter 5,
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however there were no apparent differences in G-1-mediated induction of IL10
+

+

and IL10 IL17A

+

cells from this population. Moving forward, it would be

instructive to collect T cells from the draining lymph nodes and lamina propria of
mice with fulminate colitis and see if the same pattern of IL10 and IL17A
induction occurs following ex vivo stimulation. In this case, both naïve T cells and
activated/memory T cells would need to be evaluated. While we did note that
+

cultured CD4 CD44

hi

memory cells also respond to G-1 treatment with an
+

increase in the number of IL10 cells (data not shown), it is unclear that such
cells would behave similarly when extracted from the setting of ongoing colonic
inflammation.
There is also the possibility that rather than affecting the differentiation of
IL17A producing cells, systemic G-1 treatment affects the expression of different
chemokine receptors on a subset of T cell populations, altering their trafficking.
Blasko et al noted decreased production of the chemokines CCL4 and CCL5
following antigen-specific stimulation of cells from the draining lymph nodes of
EAE mice (Blasko et al., 2009). This provides evidence that G-1 can alter
chemokine secretion. It is possible that the reason we saw increased
+

+

CD4 IL17A

cells systemically while at the same time noting fewer in the

mucosa was due to altered trafficking of this population, perhaps via down
regulation of CCR6 or CD103 (see Section 1.3). Further studies looking at G-1mediated effects on trafficking molecules in vivo will be instructive to addressing
these questions.
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In summary, these data show that systemic treatment with G-1 cannot
treat fulminate colitis, prevent the onset of disease, or imprint a stable
suppressive phenotype on colitogenic T cell populations following ex vivo
treatment.

Section 6.5 : Conclusions
Despite the compelling evidence that G-1 can drive IL10 production from
+

+

CD4 T cell populations and expand the number of Foxp3 cells, we were unable
+

to delineate any conditions in which this drug could effectively suppress CD4 T
cell-mediated colitis. Cells treated with G-1 ex vivo failed to demonstrate
restrained disease development, let alone be protective in this model, as was
predicted. It is possible that the variable induction of IL10 within the colitogenic
+

hi

CD4 CD45RB cells was partly to blame for the failure (data not shown), or that
G-1-mediated IL10 expression is not stable during the homeostatic proliferation
that follows adoptive transfer of the cells. In addition, systemic treatment with G-1
immediately following adoptive transfer of colitogenic T cells conferred no
appreciable protection from disease, even when 60 day release pellets were
utilized. There is a distinct possibility that G-1 or its metabolites do not
accumulate within the colonic lamina propria, rendering blood-borne delivery
useless. It would be interesting to see if oral delivery would yield different results.
Collectively, these data suggest that G-1 is ineffective in this model, and another
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approach is warranted to investigate the ability of G-1-treated T cells to function
therapeutically in vivo.
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Section 6.6 : Figures

Figure 31 : T cell-mediated colitis: Ex vivo treatment of T cells with G-1.
+

hi

CD4 CD45RB naïve CD4+ T cells were collected by FACS and stimulated in culture for 4 days in the presence of TGFβ
+ IL6 and either DMSO (grey filled boxes) or G-1 (red filled triangles). Cells were then injected into Rag1KO mice, with
animals receiving vehicle alone (open boxes) serving as the control. N = number of animals. Error bars = 95% C.I.

Figure 32 : T cell-mediated colitis: G-1 pellet experiments.
+

hi

CD4 CD45RB naïve CD4+ T cells were collected by FACS and injected into Rag1KO mice that were implanted with
either a sham pellet (grey filled boxes) or G-1 pellet (red filled triangles). Rag1KO mice implanted with either a sham pellet
(grey open boxes) or G-1 pellet (red open triangles) which received saline injections served as the control. Pellets were
implanted 7 days prior to adoptive transfer. N = number of animals. Error bars = S.D.
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Figure 33 : T cell-mediated colitis: G-1 injections starting at day 1.
+

hi

CD4 CD45RB naïve CD4+ T cells were collected by FACS and injected into Rag1KO mice. Mice received either vehicle
(black filled boxes) or 5µg G-1 (red filled triangles) subcutaneously for 21 consecutive days starting the day after adoptive
transfer. Non-diseased mice receiving vehicle injections served as controls (black open boxes). N = number of animals.
Error bars = S.D.

Figure 34 : T cell-mediated colitis: G-1 treatment during fulminate colitis.
+

hi

CD4 CD45RB naïve CD4+ T cells were collected by FACS and injected into Rag1KO mice. Mice received either vehicle
(grey open boxes) or 5µg G-1 (red filled boxes) subcutaneously for 7 consecutive days starting 35 days after adoptive
transfer. Non-diseased mice receiving vehicle injections (grey open triangles) or G-1 (red filled triangles) as controls (black
open boxes). N = number of animals. Error bars = S.E.M.
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Figure 35 : T cell-mediated colitis: G-1 effects on cytokine production.
Tissue samples were collected from the mice in Figure 34 and stained as described in the methods found in Chapter 3 . P
values determined by students t-test. Error bars = S.E.M.
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Chapter 7 : Overall Conclusions

Section 7.1 : Summary and Significance

Introduction
Several concepts about estrogen-mediated immune regulation have been
established. They first emerged when epidemiological data demonstrated that the
prevalence of autoimmune diseases was heavily skewed toward females
(Whitacre et al., 1999). However, while it is clear that estrogen imparts a direct
effect on immune physiology, many questions remain. Studies of patients with
systemic lupus erythematosus (SLE) (Clowse, 2007) and rheumatoid arthritis
(RA) (Da Silva and Spector, 1992) demonstrated estrogenʼs role in autoimmune
pathogenesis. Interestingly, TH17 cells have been implicated in both diseases as
well (Pernis, 2009). Conversely, work with animal models have shown that
+

estrogen can illicit IL10 expression in CD4 T cells and protect animals from
Experimental Autoimmune Encephalomyelitis (EAE), a widely accepted animal
model of multiple sclerosis (Ito et al., 2001; McClain et al., 2007; Offner and
Polanczyk, 2006; Polanczyk et al., 2004a; Polanczyk et al., 2004b; Polanczyk et
al., 2005). In addition, estrogen has been linked to several important mediators
within TH17 and TREG populations, including decreasing IRF1 expression in
murine splenocytes (Lengi et al., 2006), increasing IRF4 expression in dendritic
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cells (Carreras et al., 2010), inducing Foxp3 expression in CD4

+

T

cells(Polanczyk et al., 2004b), and enhancing TREG function (Polanczyk et al.,
2006, 2007). Thus, evidence for both pro-inflammatory and immunosuppressive
properties of estrogen exists. Despite a few isolated studies looking at Foxp3
expression (Polanczyk et al., 2004b) and EAE suppression (Polanczyk et al.,
2004a), little evidence exists for specific functions of distinct estrogen receptors
+

in CD4 T cell differentiation. Recent findings demonstrating a regulatory role in
thymic atrophy (Wang et al., 2008), TGFβ signaling (Kleuser et al., 2008), and
suppression of EAE (Blasko et al., 2009; Wang et al., 2009a) suggest that GPER
is important in estrogen-induced immune regulation. Consistent with this notion,
our preliminary results showed that the treatment with the GPER-directed agonist
+

G-1 enhanced IL10 and IL17A production from CD4 T cells in several settings,
+

+

+

including the induction of a CD4 IL10 IL17A population. These data suggested
that GPER signaling may modulate balance along the TREG-TH17 axis.
Given the attractive pharmacological properties of the GPER-directed
compounds, and the historical success in targeting GPCRʼs therapeutically, the
importance of the TREG-TH17 axis to immunopathology, the functional plasticity of
TREG and TH17 cells, and previous successes using G-1 to treat EAE, we decided
to ask the following questions: (i) What is the role of GPER signaling in regulating
+

CD4 T cell differentiation, in particular the TREG and TH17 populations? (ii) Does
G-1 exhibit any T cell-modulatory properties that can be developed for clinical
use?
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Results
In Chapter 4 we showed that naïve T cells and nTREG cells express GPER
mRNA, while G-1 treatment of unpolarized, polyclonally stimulated naïve T cells
selectively increased expression of the TREG-associated transcription factor
Foxp3 without eliciting changes in the other lineage specific transcription factors
T-bet, GATA-3, or RORγt. Flow cytometry based studies demonstrated that the
+

increased Foxp3 expression reflected an increase in the number of Foxp3 cells
+

in vivo and in culture. G-1 was also able to drive expansion of a Foxp3 RORγt

+

T cell population in cells cultured under TH17-polarizing conditions. TH17polarized cells treated with G-1 showed increased suppressive function in a T cell
suppression assay. Interestingly, we did not note any changes to PD-1
expression following in vivo treatment with G-1, which stands in contrast to
previous studies demonstrating G-1-mediated inhibition of EAE is dependent on
PD-1, which correlated with increased PD-1 expression on Foxp3

+

T cells.

However, this may reflect differences in experimental conditions (see Section 4.5,
5.5, 7.2 and 7.3). Similar trends were observed for CTLA-4.
In Chapter 5, we built upon our preliminary findings by exploring
alterations in cytokine secretion, focusing on IL10, IL17A, and IFNγ. We
demonstrated that G-1 was able to drive IL10 expression and secretion under
TH17-polarizing conditions. This effect was specific as secretion of IL6, IL17A,
TNFα, and IFNγ were unaffected by G-1 treatment. We also began the work of
delineating the signaling mechanisms responsible for the G-1-mediated effects.
We noted that G-1-mediated induction of IL10 was ERK-dependent, and did not
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+

appear to result from proliferation of IL10 cells as G-1 was able to drive IL10
expression in non-dividing cells. This finding fits well with the known mechanisms
of IL10 induction in helper T cell populations, which are dependent on the STAT
and ERK signaling pathways. One important note is that we did observe
increased IL17A expression in a few conditions, including some of our
preliminary findings. These findings translated in vivo as subcutaneous injection
of G-1 resulted in increased IL10/IL17A secretion and decreased IFNγ secretion
from harvested splenocytes stimulated in culture.
Our data demonstrating in vivo and ex vivo treatment with G-1 drives
+

Foxp3 expression and IL10 secretion in CD4 T cells gave us confidence moving
forward testing G-1 in the setting of T cell-based chronic inflammation. Therefore
in Chapter 6 we evaluated G-1 as a prophylactic and therapeutic treatment in the
setting of T cell-mediated colitis. To our surprise, G-1 treatment of donor cells
prior to adoptive transfer was ineffective in altering the course of disease, while
systemic treatment of G-1 also elicited no detectable protection. Interestingly,
treatment of diseased mice with G-1 led to an acute exacerbation of the wasting
+

disease that correlated with a decrease in the percentage of IL17A

cells

specifically within gut mucosal tissues and mesenteric lymph nodes. Consistent
with preliminary data and a subset of experiments from Chapter 5, G-1 treatment
+

led to an increase in the percentage of IL17A cells within the systemic immune
system, as measured in the inguinal lymph nodes.
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Discussion and future directions
These findings will prove critical to the development of T cell-targeted
therapies aimed at exploiting GPER, or in the pharmacological development of
the G compounds. Despite the great promise of therapies tailored to direct the
immune system toward a specific response, few such regimens have made it to
the clinic. Cytokine targeted biologics such as Ustekinumab (human mAb
directed against IL12/IL23) and Etanercept (anti-TNFα therapy) can elicit robust
reductions in disease severity, but they are associated with a number of
disadvantages, including severe side-effects and immense cost (Uhlenhake and
Feldman, 2010). These issues are compounded by the need for repeated dosing.
Other drugs such as Methotrexate and Cytoxin are associated with even more
severe side-effect profiles. Dosing can be a challenge, often leading to significant
detriment to quality of life despite limited efficacy in resolving symptoms and
controlling disease. Orally available treatments that elicit refined changes to T
cell populations will profoundly change how we treat immunological and
neoplastic disease and revolutionize medicine. Such immunomodulatory
therapies will require identifying signaling targets amenable to disruption and
highly specific in their function. This work demonstrates that G-1 can serve in this
capacity, and that GPER may be one such target.
This study provides several lines of evidence that the context of G-1
treatment is important to its ability to modulate T cell activity. First, we present
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clear evidence that systemic treatment of G-1 does not alter the expression of
+

PD-1 on the Foxp3 T cell population in naïve (non-diseased) male mice. We
+

also have data which shows an increase in the number of Foxp3 T cells. This
finding is clearly distinct from data showing systemic G-1 treatment in female
+

EAE mice greatly enhances PD-1 expression on Foxp3 T cells, without altering
cell number. Whether these reflect gender-based differences or result from
environmental differences a naïve mouse and the setting of encephalomyelitis
+

+

+

are not clear. Second, G-1 increased the number of CD3 CD4 IL17A

cells

within the systemic immune system when delivered via subcutaneous injection in
+

+

+

diseased TCMC mice (Figure 35), yet led to a reduction in the CD3 CD4 IL17A

population within the mucosa of the same mice. This suggests that G-1 can elicit
distinct responses in a context-specific manner within the same animals,
although other possibilities are discussed in Section 6.4 and 6.5. Our data
demonstrating that G-1 is ineffective in the setting of colitis should not undermine
future attempts to investigate this compound in the context of disease.
Furthermore, our study does not include an analysis of G-1 in the setting of TH1
or TH2 polarizing conditions. The fact that G-1-mediated IL10 induction was
mediated through the ERK signaling pathway suggests that similar findings will
be observed in TH1 and TH2 polarized cells as ERK signaling is a common factor
in the induction of IL10 for all three effector lineages (Saraiva et al., 2009). This
+

hi

hypothesis is supported by our observation that CD4 CD44 memory T cells can
also be driven to express IL10 following G-1 treatment in culture (data not
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shown). Thus, the effects of G-1 in various in vivo settings, disease models, and
in TH1 and TH2 polarizing conditions warrant further study.
If G-1 is to be developed for therapeutic use with the purpose of
addressing immunological conditions, several paths of investigation need to be
pursued. One factor that has recently received more attention is the mechanisms
by which T cell populations (and other immune populations) are targeted to
specific tissue sites or inflammatory settings. Undoubtedly, the site where
manipulated populations accumulate within the body will have far-reaching
implications in determining therapeutic success. Our observation in Chapter 4
+

+

that G-1 can elicit what appear to be Foxp3 RORγt hybrid T cells suggests that
G-1 treatment can alter the trafficking of TREG populations. For example, one of
the pivotal studies discussed previously that substantiated the concept of hybrid
T cell populations looked at the importance of TREG trafficking. They showed that
+

T-bet induced CXCR3 expression in Foxp3 cells was critical for targeting TREGs
to sites of TH1-type inflammation during chronic infection with M. tuberculosis,
+

and adoptive transfer of Foxp3 cells from T-betKO mice were unable to rescue
Foxp3KO (scurfy) mice from their fatal TH1-mediated lymphoproliferative
+

disorder, while Foxp3 from wildtype mice completely abrogated disease (Stock
et al., 2004). Along these same lines, future work aimed at delineating G-1mediated effects in inducing hybrid T cell populations, and any resultant changes
in pertinent trafficking molecules, will be vital to any therapeutic development of
this compound.
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Other therapeutic paradigms are also worth considering. If there is a
sufficient pool of target cells available at the site where an intervention is needed,
G-1 may serve to act on the local populations in situ to modulate disease. For
example, if the large number of TH17 cells within the inflammed mucosal wall of
Crohnʼs disease (CD) patients (Kleinschek et al., 2009) can be converted to
produce IL10, there may be a sufficiently large target population available at the
site of inflammation to elicit an therapeutic effect without the need to recruit
peripherally induced populations. Indeed there is promising evidence that
conversion of T cell populations in situ can reverse the course of autoimmunity.
In an elegant study from the Santamaria group, nanoparticles coated with
peptide-loaded MHC complexes were able to drive endogenous low-avidity CD8

+

T cells into an autoregulatory population that blunted disease progression and
reversed hyperglycemia in a non-obese diabetic (NOD) mice (Anderson et al.,
1999). There are certain to be instances where site-specific recruitment
determines treatment success and side effect profiles, and conditions where local
alteration of T cell function play a predominant role in therapeutic viability. Thus
both topics will be of great interest as therapies aimed at T cell populations
increase in sophistication.
The fact that we observed such a large amount of variability in the
+

hi

induction of IL10 within the CD4 CD45RB

population made it difficult to draw

any firm conclusions from this data. Attempts to determine the difference
+

hi

+

hi

between the CD4 CD45RB population and the CD4 CD62L population will be
needed to better characterize the nature of the problem, and help guide future
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studies. One of the major differences between these two populations is the
+

number of Foxp3 cells (See Appendix B), thus it may be that the presence of
Foxp3

+

TREGs is necessary for G-1 induced IL10 production. Future work

delineating the precise cellular populations wherein G-1 elicits it effects are
needed. This will be important in guiding development in that appropriate
pathologies can be targeted. This will also prove seminal to attempts to utilize
this compounds for adoptive therapies in that purification of appropriate target
populations will be critical to therapeutic success.
What of the other G compounds? The striking effects of G-1 on T cell
activity and cytokine secretion beg the question; can G15 or G36 drive a
proinflammatory phenotype in T cell populations? These complex questions may
best be delineated in models from the field of tumor immunology. Work by the
Restifo group at the NIH has shown that polarization of naïve T cell populations
toward a TH17 phenotype ex vivo enhances tumor killing in a mouse xenograft
model of melanoma. Strangely, this effect was lost in mice housed in a sterile
environment which lack commensal flora in the gut. Reintroduction of the flora
restored the effect. The plasticity of TH17 cells arises from these studies as well,
as the benefit of TH17-polariztion ex vivo effect is dependent on in vivo
production of IFNγ (Muranski et al., 2008). When molded into a single picture, it
appears that the benefit of TH17 polarization is to induce surface receptors that
target these cells to the gut, where they acquire enhanced tumor killing by a
mechanism dependent on the commensal gut flora. Conversely, in a xenograft
+

model of melanoma, Foxp3 cells suppress immunity by destroying DC within
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tumor draining LNs in an IDO and perforin dependent manner (Boissonnas et al.,
2010). Thus animal models of tumorigenesis should prove to be an appropriate
venue to investigate the G compounds.
Finally, this work offers some interesting estrogen-related questions that
warrant further investigation. A major point that needs to be addressed by future
+

studies is gender-based differences in estrogen-driven effects within the CD4 T
cell compartment. A 2007 study showed that regulatory T cell-derived IL10
participates in the development of tolerance to paternal antigens during
pregnancy (Schumacher et al., 2007; Thuere et al., 2007). It has also been
shown that GPER is responsible for the protective effects of orally delivered
ethinyl estradiol in EAE (Yates et al., 2010) in female mice. These data along
with our findings, wherein G-1 induced IL10 in cells collected from male mice,
appear to indicate that there are some similarities between systemic G-1
treatment in female and male mice. Furthermore, our findings may be helpful
reconciling the predominantly anti-inflammatory properties of estrogen that have
been described empirically with the irrefutable evidence that women suffer from a
high prevalence of autoimmunity. Estrogen protects animals from EAE, yet
women suffer from a four-fold higher prevalence of MS than men. Why is that?
One can imagine that during high-estrogen periods of estrous cycle there is an
expansion of these TH17-like TREG populations via GPER signaling, likely under
conditions where some low-level TH17-like inflammation is already present. Upon
shifting to a low estrogen state, these cells lose their IL10 and/or Foxp3
expression, reverting to a more proinflammatory phenotype in response to
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another unknown factor or simply in response to the local milieu. This could lead
to sequential amplification of an ongoing inflammatory process. A hint that his
might indeed be the case comes from the clinic, where MS patients experience a
decease in flare-ups during pregnancy but, conversely, a dramatic increase in
symptomology postpartum (Vukusic et al., 2004). Might this increase in disease
severity postpartum reflect reversion of E2-induced hybrid T cells to a more
pathogenic phenotype? If so, why then does this effect disappear over time
(patients will generally revert to their prepartum disease status over time)? As
more and more examples of T cell plasticity are described along the TREG-TH17
axis, more explicit hypotheses are likely to be developed. Further studies will be
required to explore these possibilities. As these questions relate to the stability of
these induced populations, answers to these questions will also be instructive in
guiding how drugs aimed at targeting these properties are designed and utilized,
and in what context they are most appropriately used.

Overall conclusions
In conclusion, this work may prove seminal in understanding the complex
interactions of estrogen signaling and the T cell differentiation by linking G1/GPER with two critical T cell populations; TREG and TH17 cells. Thus these
findings will help to provide further understanding in the complex story of
estrogen-immune interactions. Moreover, these data lay the groundwork for
analyzing the G compounds, and G-1 in particular, as T cell-targeted therapies.
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The surprising findings that G-1 cannot protect in the animal model of colitis
should not dissuade from future studies aimed at addressing itʼs therapeutic
potential in other disease settings. Furthermore, the unexpected results in
GPERKO mice must be addressed, and the molecular target of G-1 responsible
for our findings clearly delineated, be it GPER or another unknown protein.
Collectively, our findings highlight the need to further understand the intricacies of
T cell biology and estrogen physiology if we are to intelligently manipulate their
function for medical purposes.

Section 7.2 : List of major limitations and caveats

Detailed discussions about the various limitations and caveats has been
presented throughout the manuscript, and are intertwined with various
discussions, conclusions, the preceding summary section of this chapter (Section
7.1). This next section offers a neat summary of the major points that have been
discussed, and offers some guidance as to where they are discussed.

Molecular target of G-1 is not clear
The true target of G-1 that is responsible for these observations remains
unclear. While testing against ERα/ERβ and small panel of receptors suggest
that it does indeed specifically target GPER, our findings that the G-1-mediated
effects were lost in GPER(+/-) mice and returned in GPER(-/-) mice strongly
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suggest that G-1 can exhibit off-target activity that is relevant to the work
presented here. Given the role of GPER in estrogen-induced thymic atrophy and
apoptosis of maturing thymocytes, future experiments utilizing conditional
knockout strategies will be needed to adequately address the role of GPER in E2
and G-1-mediated T cell effects. (See Section 5.4).

Limited data in the in vivo disease setting
In this work our goal was to analyze a multitude of cytokines, chemokines,
and surface markers in the setting of colitis. We were able to achieve a small part
of that goal with the data presented in Figures 34 and 35. However, future work
will be needed to address whether our findings of G-1-mediated Foxp3, IL10, or
IL17A expression are of therapeutic interest. (See Section 6.4, 6.5, and 7.1)

Male versus female mice
The entirety of this work was done using male mice and cells from male
mice. The reasoning behind this was discussed previously, but centered on the
desire to avoiding the confounding effects of the cyclical nature of endogenous
estrogen in female, and the potentially inflammatory effects of surgical
intervention that would be required to mitigate the problem via ovariectomy.
While this gave us clean results, the veracity of these findings in sexually mature
females is unclear, and nothing that we presented addresses this concern. There
+

are differences (PD-1 expression on Foxp3 TREGs) and similarities (induction of
IL10) to previous work carried out in female animals. How these findings translate
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to female mice (and people) should be a focus of future work. (See Section 4.4,
5.4, and 7.1)

G-1-mediated Foxp3 induction may be the result of apoptosis/proliferation
The majority of the effects that we observed throughout Chapter 4 were
modest, generally in the neighborhood of 50% increases or less. While in general
the results did achieve statistical significance, there is the possibility that G-1 was
exhibiting selective apoptosis in the non-Foxp3

+

populations. In fact we did

detect significantly higher levels of apoptosis following ex vivo treatment with G-1
(Figure 42, Appendix D). While we did not detect any significant changes in the
+

number of CD4 T cell following systemic treatment of G-1, given the modest
increases that we observed, more work needs to be done to corroborate our
findings. Additionally, it is possible that the increased apoptosis observed in G-1
treated cultures was the result of increased TREG activity, as one of the
mechanisms employed by regulatory T cells in suppressing immunity is cytotoxic
lysis of other immune populations (see Section 1.3).

Section 7.3 : List of future directions
Like the limitations and caveats, discussions about the various future
directions were presented throughout the manuscript, and are intertwined with
various discussions, conclusions, and the preceding summary section of this
chapter (Section 7.1). Like Section 7.2, this next section offers a neat summary of
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the most pertinent future directions, and offers some guidance as to where they
are discussed, though not all topics have been discussed in depth.

What is the effect of G-1 on T cell under TH1 or TH2 polarizing conditions?
As discussed in Section 7.1, the finding that G-1-mediated IL10 induction
requires ERK signaling strongly suggests that a similar effect would be observed
in the other effector lineages. Therefore, repeating our findings form Chapter 5
under TH1 and TH2-polarizing conditions is an obvious next step to take.

What is the mechanism of ERK activation?
We show that G-1 drives IL10 secretion by activation of ERK, however,
the mechanism of the activation remains unclear. Studies of GPER signaling
have led to a model wherein GPER activation drives activation of epidermal
growth factor receptor (EGFR) activation and subsequent transactivation of MAP
kinase cascades (such as ERK) and the PI3 kinase pathway (See Figure 6). In
order to further address the signaling mechanisms responsible for G-1-mediated
IL10 secretion, we attempted to treat cultured T cells with the EGFP inhibitor
AG1478. However, this led to near complete blockade of T cell proliferation and
widespread cell death. This may be due to the unique culture conditions that we
use, which lack phenol red and utilize charcoal stripped FBS (See Chapter 3), but
that remains a hypothesis at this point. Thus future studies determining EGFR
expression on T cell populations, and more sophisticated attempts at disrupting
the activity of EGFR are warranted. One example might be to try retroviral
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expression of a kinase dead EGFR. Experiments looking at EGFR activation,
either by western blot or using Luminex arrays, are needed as well. Experiments
designed to investigate downstream transcriptional profiles are described below.

What is the effect of G-1 on other key TREG and TH17 molecules?
Numerous other proteins, including Helios (Getnet, 2010; Getnet et al.,
2010), AhR (Ramirez et al., 2010), IRF1 (Kano et al., 2008), IRF4 (Brustle et al.,
2007; Chen et al., 2008), RORα (Yang et al., 2008), and IL23 (Volpe et al., 2008)
are also involved in TH17 development (Iwakura and Ishigame, 2006), and
warrant further investigation. Understanding how these proteins are affected by
G-1 treatment will have important implications in designing experiments to test G1 therapeutically. For example, CCR4 has been shown to play a role in TREGmediated suppression of colitis, and other receptors such as CD103 (Leithauser
et al., 2006) and CCR6 are also important in targeting cells to the mucosa (Wang
et al., 2009b). Thus delineating G-1 effects on trafficking receptor expression
profiles would be of immense value, and may help explain why our studies with
the T cell-mediated colitis model failed. (See Section 7.1).
Future studies could include simple approaches like qRT-PCR and flow
cytometry-based techniques, as well as more technically refined approaches like
microarray analysis. Perhaps the best approach would be to conduct microarray
analysis following ex vivo G-1 treatment if highly enriched (>99%) naïve T cells
under non-polarizing and TH17-polarizing conditions, as well as following
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systemic G-1 treatment in a relevant animal model. The obvious choice here
might be EAE.

Why did the colitis model fail, what about other models?
One obvious approach would be to go back to the model where G-1 is
known to exert a protective effect, namely EAE, and see if G-1 effects are lost in
IL10KO mice. A second option would be to attempt to being work using a mouse
tumor model. As described in Section 7.1, this would allow investigation of all 3 G
compounds in T cell based immunotherapies.

Do these findings translate into female mice?
All of our work was done in male mice and cells from male mice. As
discussed in Section 4.5, 5.5, and 7.1, this may underlie differences between our
data and other published reports. Thus repeating experiments where disparate
results were obtained from those in the literature in ovariectomized female mice
will be needed to address whether these reflect gender based differences in the
effects of G-1. Moreover, it is important to understand the properties of these
compounds in the female setting as they make up over half of all autoimmune
disease patients, aside from the obvious ethical implications.

Do these findings translate into human samples?
Since the ultimate goal outlined in the summary is to focus on therapeutic
development of these compounds, future studies addressing how these
169

molecules function within human T cell populations are pivotal to our stated
goals. As was discussed in the introductory discussion about regulatory T cells
(Section 1.3), these appear to be some differences in the form and function of
human versus murine TREG populations. Thus studies utilizing T cell populations
derived from preparations of human PBMCs are a critical future direction. In
addition, given the recent data demonstrating that the transcription factor Helios
is important in human TREG function and stabilization of Foxp3 expression
(Getnet, 2010; Getnet et al., 2010), carrying out the studies described above to
investigate Helios expression may prove pivotal in determining the ability of G-1
to stably affect TREG activity clinically.
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Appendices

Appendix A : Determining GPER protein expression
In Chapter 4 it was shown by qRT-PCR that GPER mRNA is expressed in
murine naïve T cells and in nTREG cells (see Figure 12, Chapter 4). This was
consistent with previous published reports which demonstrated GPER expression
in Foxp3

+

T cells from human PBMC preparations using IHC (Blasko et al.,

2009). In this work, they also demonstrated GPER staining in primary human
macrophages and the mouse monocyte/macrophage cell line RAW 264.7. To
corroborate that the mRNA we detected was being translated into protein, we
attempted to detect GPER using western blots and immunofluorescence. Our
own custom-made rabbit sera were used for these experiments. The first, serum
8073, was raised against a peptide sequence from the C-terminus of human
GPER, although all but one or two residues are identical in mice (there are two
published sequences), and both are highly conserved. It is worth noting that the
published findings discussed above utilized our 8073 rabbit serum as well. The
second, serum 9368, was raised against a peptide derived from extra cellular
loop 2 (ECL2) of murine GPER.
We started our analysis with western blots. Blotting with 8073 yielded
expected results for African green monkey derived Cos7 cells (which express
very low levels of GPER) and human SkBR3 cells (which express high levels of
GPER) (Figure 36A). However, despite data suggesting the GPER is expressed
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in the murine spleen (Wang et al., 2008) and our qRT-PCR data, we detected
very little cross-reaction with murine whole spleen, FACS sorted naïve T cells, or
RAW cells (Figure 36A). This discrepancy was not due to loading, as indicated
by Coomassie staining of the membrane post-transfer (data not shown). It is
possible that, despite the substantial similarity between the relevant peptide
sequences in human and mouse, the single residue difference abrogates
antibody binding to murine GPER. Notably, the authors of the previous report
demonstrating 8037 staining in RAW 264.7 cells were able to eliminated antibody
binding by the addition of excess target peptide (Blasko et al., 2009). However,
we conducted several in silico blast searches within the NCBI protein databank
using our target peptide as bait. We found no similar sequences within any
known human or mouse protein or putative ORF, with the exception of being able
to identify the expected target sequence in hGPER and mGPER (data not
shown).
We next tested whether we could detect GPER using the 9368 serum.
While we were able to detect a signal at the appropriate MW (42/44 kDa, Figure
36A) in nearly all lysates tested, we also detected a band in Cos7 cells which
largely lack GPER mRNA. These findings were further confounded by the
detection of a band of roughly 44kDa in whole spleen lysate from GPERKO mice
(Figure 36E), which lack detectable GPER mRNA (See Figure 12, Chapter 4).
+

Finally, we analyzed primary CD4 T cells, RAW 264.7 cells, and tissue
sections from mouse spleen for GPER expression using immunofluorescence. In
all three samples, we detected staining with the 8073 serum while staining with
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Prebleed control serum yielded no detectable signal (Figure 36B-D) and data not
shown). Of note, the staining was largely nuclear, suggesting one of the
following; (A) the GPCR GPER is expressed in the nucleus, or (B) that these
antibodies recognize additional target(s) distinct from GPER. Overall, given the
inconsistency of our findings, it was not possible to draw any concrete
conclusions from these data.

Figure 36 : Protein expression of GPER.
The expression of GPER was analyzed using western blots and immunofluorescence assay (IFA). (A) Western blots of
various cell lysates using two distinct rabbit sera, 8073 (raised against human C-terminal peptide) and 9368 (raised
against mouse peptide from ECL2). (B) IFA showing GPER (Red, serum 8073) in a paraffin embedded section,
demonstrating the border between the red and white pulp of the spleen from a C57BL/6 mouse (C) AutoMACS sorted
CD4+ T cell (purity >90%) stained for GPER (Red, serum 8073) and Foxp3 (Green), with DAPI counterstain to identify
nuclei. (D) Murine macrophage cell line RAW 264.7 stained for GPER (Red, serum 8073) and actin (Green). (E) Western
blot probing for GPER (9368) on total spleen protein lysate from wild-type (Left lane), GPER heterozygote (Middle lane),
and GPERKO (Right lane) mice.
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Appendix B : FACS sorting strategies
+

hi

CD4 CD62L naïve T cells
The collection of naïve T cells was based on surface expression of the
CD4 co-receptor, which distinguishes the CD4+ helper T cell populations from
the CD8+ cytotoxic T cell population, and the expression of L-selectin (CD62L),
which is used by T cell and other immune populations to enter secondary
lymphoid organs such as the lymph nodes through high endothelial venules
(HEVs) by binding to sialylated carbohydrate groups like those found on GlyCam1. While other immune populations like macrophages have been known to
express CD4, they are usually observed to express lower levels than naïve T
cells and can be easily sorted out (see Figure 37).

CD4+Foxp3+ natural TREG cells
As is discussed in the intro and in Chapter 4, Foxp3 expression within the
CD4+ T cell compartment can be driven during thymic development or induced
peripherally. When induced during thymic T cell development, Foxp3 expression
tends to be more stable. In the unchallenged (naïve) mice that we are using for
our donors, the majority of the Foxp3 populations should fall into the category of
natural regulatory T cell. This is an oversimplification as the mice are not raised
in a germ-free environment, and hence have developed immunity to commensal
flora in the alimentary tract and the lungs. The intestinal tract in particular is a
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known site for robust generation of inducible regulatory T cells. None-the-less,
cells expressing Foxp3 in naïve mice should predominantly fall into the natural
TREG category. Thus to collect natural TREGs, cells from Foxp3egfp mice were
stained with CD4, and CD4+GFP+ cells were sorted out. (see Figure 37)

+

hi

CD4 CD45RB naïve T cells for T cell-mediated colitis
The induction of T cell-mediated colitis is exquisitely sensitive to the
+

+

presence of regulatory T cells, in particular Foxp3 TREGs. Thus the CD4 CD62L

hi

populations sorted above are not colitogenic because of the presence of a small
population of Foxp3

+

cells. In order to induce disease, the surface marker

CD45RB must be used in place of CD62L. In this case the population is collected
+

by taking the 40% of the total CD4 population which express the highest amount
of CD45RB, as determined by flow. (see Figure 37)

+

lo

hi

CD4 CD44 CD45RB GFP(Foxp3)

+/-

naïve T cells

As mentioned above, the naïve mice that we use are not, in fact, truly
naïve because they are not housed in a germ-free environment. Thus there are
some memory T cells that have developed in these mice. Interestingly, there are
two main types of memory T cells, effector memory cells and central memory
cells. While generally thought to be a smaller portion of the total memory T cell
repertoire, central memory cells can express CD62L, and hence can be found in
the same secondary lymphoid organs we use to collect our T cell populations. To
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eliminate these cells, co-staining with the memory cell marker CD44 allows us to
hi

sort out any CD44 cells from our naïve T cell preps. We can also gate out any
+

GFP cells to eliminate TREG cells. As you can see in the figure below, the
hi

hi

population of CD44 CD62L cells in generally very small. In this case 2.69% of
all CD4

+

lo

cells fall into that category, as compared to the CD44 CD62L

hi

+

population which comprises 76.3% of CD4 cells. (see Figure 37)

CD4+CD44hi memory T cells
The sorting logic of memory T cell is similar to naïve T cells, only
+

hi

CD4 CD44 are collected in this case. CD44 is a surface protein that has a wide
range of functions and appears to play a role in T cell activation, aside from being
the classical marker for memory T cells. It can bind to several ligands, including
many of the canonical proteins of the extracellular matrix, and in some cases
even L- and P-selectin. (see Figure 37)
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Figure 37 : FACS sorting strategies
The gating logic for different populations of cells that were collected sorting on the MoFlo system here at the UNM Shared
Flow Facility. The various antibodies used for staining and the reasoning for the markers chosen is described in the figure
and the text above, respectively. These data were collected on the Beckton Dickenson FACScalibur, also in the UNM
Shared Flow Facility. It is important to note that the MoFlo system is not a proficient at detection as the FACScalibur, and
therefore one should anticipate some differences in the appearance of various populations when actually sorting, in
particular with the PerCP stains.
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Appendix C : Other data from in vivo treatments

+

Figure 38 : Ratio of CD4 cells in the spleen following in vivo treatments.
Spleens from the mouse indicated were collected following treatment with 500ng/day of E2 or 5µ/day of G-1, as indicated.
See Methods chapter for details. Collected tissue was homogenized by mechanical disruption into a single cells
suspension, treated with PBC lysis buffer and stained with anti-CD4-PE antibody, and in some cases others as described
elsewhere, and analyzed by flow cytometry on a BD FACScalibur. The graphs depicts the percent of the total cell
+

population that was CD4 . GPER(+/+), mice have minimum 3 mice per group, GPER (+/-) mice have minimum 2 mice per
group, and GPER (-/-) mice have minimum 3 mice per group. These results are considered preliminary.

178

Figure 39 : In vivo treatment with G-1 drives Foxp3 expression in GPERKO mice.
Seven to eleven week old male Foxp3

egfp

Foxp3

egfp

xGPERhet, or Foxp3

egfp

xGPERKO mice were injected with 17β-

estradiol (E2 - 0.5µg/day) , G-1 (5µg/day) or vehicle for 7 consecutive days. One day following the last injection, single cell
suspensions were made from spleen. Cell were then stained for CD4 and analyzed by flow cytometry. GPER(+/+) ,mice
have minimum 3 mice per group, GPER (+/-) mice have minimum 2 mice per group, and GPER (-/-) mice have minimum 3
mice per group. These results are considered preliminary.
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Figure 40 : Spleen weights following in vivo treatments.
Spleens from the mouse indicated were collected following treatment with 500ng/day of E2 or 5µ/day of G-1, as indicated.
See Methods chapter for details. Wet weight of collected tissues was determined after dabbing on cellulose paper to
remove any residual fluid from the surface.
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Appendix D : Other data from ex vivo T cell stimulation assays

Figure 41 : G-1-mediated Foxp3 expression is independent of MAPK signaling.
+

lo

hi

egfp

CD4 CD44 CD62L naive CD4+ T cells were collected by FACS from Foxp3

mice and cultured for 4 days ex vivo with

anti-CD3/28 + IL6 + TGFβ in the presence of 100nM G-1 (black bars) or DMSO (white bars). Cultures were supplemented
with inhibitors of the ERK (PD98059), JNK (JNK II inhibitor), or p38 (SB203580) signaling cascades. Following culture,
cells were collected analyzed by flow cytometry for GFP expression. Summary of data from three independent
experiments. Statistical analysis done by studentʼs t-test. *** = P <0.0005. Error bars = S.E.M. NS = Not significant.
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Figure 42 : G-1-treated cultures exhibit elevated apoptosis.
+

hi

+

lo

hi

egfp

CD4 CD62L or CD4 CD44 CD62L naive T cells from Foxp3

or wild-type mice were collected by FACS and cultured

for 4 days with TGFβ + IL6, supplemented with either 100nM G-1 or DMSO, as indicated. Cells were then stained for
Annexin V (+/- 7-AAD). (A) A representative dot plots showing Annexin V and 7-AAD staining for both the Foxp3+ and
FOxp3- populations following treatment with DMSO or G-1. (B) Summary of data from three experiments showing the
relative percent of apoptotic cells in the total population. (C) P values determined by studentʼs t-test. Error bars = S.D.
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Appendix E : Other data from Luminex multiplex assays

Figure 43 : Other data: cytokine secretion from GPERKO splenocytes.
Seven to eleven week old male wild-type or GPERKO C57BL/6 mice were injected with estrogen (E2 – 500ng/day) or
vehicle for 7 consecutive days. One day following the last injection, splenocytes were collected and cultured in the
presence of antiCD3ε (1.0 µg/mL) and antiCD28 (2.5 µg/mL) Ab. Culture medium was collected after 48 hours and
analyzed for the presence of secreted cytokines by Luminex multiplex assay.. Graphs are mean data with three mice per
group. Errors bars = S.E.M.
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Appendix E : The T cell-mediated colitis model

Figure 44 : The T cell-mediated colitis model
The T cell-mediated colitis model is induced by the injection of CD4+CD45RBhi cells into Rag1KO mice. (A) Growth curve
egfp

from an experiment carried out in our lab. (B) Cryosections from the distal colon of Foxp3

mice from experiment in A,

stained with H&E (top & middle) or imaged by IF (bottom). (C) Examples of intracllular cytokine staining, in this case for
IL17A and IFNγ, from single cell suspensions of various tissues from the animals in A. (D) Staining for lineage markers
relevant to study, from MLN cells of diseased animals in A.
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Figure 45 : Sample sections from colon from TCMC mice
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